WO2010072338A1 - Alkaloid aminoester derivatives and medicinal composition thereof - Google Patents

Alkaloid aminoester derivatives and medicinal composition thereof Download PDF

Info

Publication number
WO2010072338A1
WO2010072338A1 PCT/EP2009/008870 EP2009008870W WO2010072338A1 WO 2010072338 A1 WO2010072338 A1 WO 2010072338A1 EP 2009008870 W EP2009008870 W EP 2009008870W WO 2010072338 A1 WO2010072338 A1 WO 2010072338A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
bicyclo
phenylamino
azonia
acetoxy
Prior art date
Application number
PCT/EP2009/008870
Other languages
French (fr)
Inventor
Antonio Caligiuri
Mauro Riccaboni
Gabriele Amari
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010072338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN200980152004.9A priority Critical patent/CN102264734B/en
Priority to NZ593695A priority patent/NZ593695A/en
Priority to JP2011542695A priority patent/JP2012513420A/en
Priority to CA2748100A priority patent/CA2748100A1/en
Priority to MX2011006642A priority patent/MX2011006642A/en
Priority to KR1020117014392A priority patent/KR101414333B1/en
Priority to BRPI0918206A priority patent/BRPI0918206A2/en
Priority to SG2011045689A priority patent/SG172316A1/en
Priority to MEP-2011-114A priority patent/ME01185B/en
Priority to EA201190017A priority patent/EA020974B1/en
Priority to EP20090778904 priority patent/EP2376489B1/en
Priority to MA34030A priority patent/MA32979B1/en
Priority to UAA201106921A priority patent/UA107334C2/en
Priority to AU2009331945A priority patent/AU2009331945A1/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of WO2010072338A1 publication Critical patent/WO2010072338A1/en
Priority to TN2011000282A priority patent/TN2011000282A1/en
Priority to IL213712A priority patent/IL213712A0/en
Priority to HK12102580.8A priority patent/HK1162174A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Definitions

  • the present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for the preparation thereof, compositions comprising them and the therapeutic use thereof.
  • Quaternary ammonium salts acting as muscarinic (M) receptor antagonist drugs are currently used in therapy to induce bronchodilation for the treatment of respiratory diseases.
  • M receptor antagonists are represented by ipratropium bromide and tiotropium bromide.
  • Several chemical classes acting as selective M3 receptor antagonist drugs have been developed for the treatment of inflammatory or obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Said M and M3 receptor antagonists are currently administered through inhalation in order to deliver the drug directly at the site of action and hence limiting the systemic exposure.
  • M3 receptor antagonists able to act locally, while having high potency and long duration of action. Said drugs, once adsorbed, are degraded to inactive compounds which are deprived of any systemic side effects typical of muscarinic antagonists.
  • the present invention provides alkaloid aminoester derivatives with these therapeutically desirable characteristics.
  • the compounds of general formula (I) behave as soft-drugs, since they are able to produce a persistent bronchodilating effect in the lung but are consistently and rapidly transformed into inactive metabolites after passing into human plasma.
  • US2824106 discloses quaternary alkyl derivatives of the tropeine series with increased spasmolytic activity and in particular N-phenyl amino acetyl derivatives.
  • J.Med.Chem. 1994, 37, 1712- 1719 refers to presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs and in particular to N-phenyl amino acetyl derivatives.
  • US 2856407 discloses aminoacid esters of hydroxypiperidines; among them are N-methyl-3-piperidyl-2'-N'-dimethylaminoacetate and N-methyl-4- piperidyl-2 ' -N' -dimethy laminoacetate.
  • WO 99/20612 describes compounds that inhibit the farnesylation of mutant ras gene products and in particular 4-(methylsulfanyl) butanoate derivatives.
  • WO 2008/053158 refers to inhibitors of p38 MAP kinase activity, useful in the treatment of inflammatory and autoimmune disease and in particular to methylpiperidin-4-yl L-leucinate derivatives.
  • Khimiko-Farmatsevticheskii Zhurnal (1977), 1 1(7), 30-5 refers to tropine ester of phenylglyoxylic acid and in particular to phenylalanine ester derivatives.
  • the invention concerns alkaloid aminoester derivatives of general formula (I)
  • (C 3 -C 8 )-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo ( 0), SH, NO 2 , CN, CON(R5) 2 , COOH, CO 2 R5, CF 3 , (C r C 10 )-alkoxycarbonyl, (C 1 -C 10 )-alkylsulfinyl, (Ci-Cio)-alkylsulfonyl, (C,-Cio)-alkyl and (C r C 10 )-alkoxyl;
  • R6 represents a group of formula (i) or (ii) or (iii) or (iv)
  • a " is a physiologically acceptable anion; R4 is a group of formula (Y)
  • W is selected from the group consisting of H, (C r C 6 )-alkyl,
  • (C 3 -C 8 )-cycloalkyl, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo ( 0), SH, NO 2 , CN, CON(R5) 2 , COOH, NH 2 , NHCOR5, CO 2 R5, (C 1 -C 10 )- alkoxycarbonyl, (C r C 10 )-alkylsulfanyl, (C t -Cio)-alkylsulfinyl, (C 1 -Ci 0 )- alkylsulfonyl, (C r Ci 0 )-alkyl and (Ci-Cio)-alkoxyl;
  • R5 is selected from the group consisting of H, (C r Ci 0 )alkyl, (C r C 6 )alkylhalo, (C 2 -C 6 )alkynyl, (C 2 -C 6 )alkenyl, (C 3 -C 7 )cycloalkyl,
  • the invention also refers to compounds of general formula (VI):
  • Rl , R2 and R3 are as described above
  • R7 represents a group of formula (vi) or (vii) or (viii) or (ix)
  • R6 is not a group of formula (viii) and
  • the compounds of general formula (VI) are not N-methyl-3- piperidy 1-2 ' -N' dimethy laminoacetate and N-methyl-4-piperidyl-2 ' - N'-dimethylaminoacetate.
  • the invention also refers to a process for the preparation of a compound of formula (I) as reported in Scheme 1, which comprises the alkylation of compounds of general formula (VI)
  • the invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises the alkylation of amine compounds of general formula (II)
  • LG is a suitable leaving group and K may be either a hydroxyl group or a suitably protected hydroxyl group, to yield a compound of formula
  • the invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises coupling an amine of general formula (II) R1 - ,R2
  • the invention also concerns a process for the preparation of a compound of formula (I) as reported in scheme 1 , which comprises reacting compound (IX) with an alkylating agent of general formula (VIII),
  • the invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises coupling compounds of general formula (III) to compound of general formula (V)
  • the invention also provides pharmaceutical compositions of compounds of general formula (I) or of general formula (VI) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients.
  • the invention also provides compounds of general formula (I) and (VI) for use as a medicament.
  • the invention provides the use of compounds of formula (I) or of general formula (VI) for the manufacture of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
  • broncho-obstructive or inflammatory diseases preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • (C 3 -C 8 )-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo ( 0), SH, NO 2 , CN, CON(R5) 2 , COOH, CO 2 R5, CF 3 , (C r Ci 0 )-alkoxycarbonyl, (C r C 10 )-alkylsulfinyl, (C r C 10 )-alkylsulfonyl, (C,-Ci O )-alkyl and (C r Ci 0 )-alkoxyl; R8 represents a group of formula (i) or (ii) or (iii) or (iv) or (vi) or (vii) or (viii) or (ix) "
  • a " is a physiologically acceptable anion; R4 is a group of formula (Y)
  • W is selected from the group consisting of H, (C r C 6 )-alkyl,
  • (C 3 -C 8 )-cycloalkyl, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo ( 0), SH, NO 2 , CN, CON(R5) 2 , COOH, NH 2 , NHCOR5, CO 2 R5, (C 1 -C 10 )- alkoxycarbonyl, (CrC ⁇ -alkylsulfanyl, (CrC 10 )-alkylsulfinyl, (C 1 -C 10 )- alkylsulfonyl, (Cj-C 1 o)-alkyl and (C 1 -C 1 o)-alkoxyl;
  • the invention also provides a method for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD), which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of general formula (I), (VI) or (XIX).
  • broncho-obstructive or inflammatory diseases preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • the invention also provides pharmaceutical preparations suitable for administration by inhalation, such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
  • the invention also refers to a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a soft mist nebulizer comprising the compounds of general formula (I) or (VI).
  • the invention also refers to a kit comprising the pharmaceutical compositions of compounds of general formula (I) or (VI) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a soft mist nebulizer comprising the compounds of general formula (I) or (VI).
  • halogen atoms includes fluorine, chlorine, bromine, and iodine.
  • (C 1 -C] O ) alkyl refers to straight or branched chain alkyl groups wherein the number of carbon atoms is from 1 to 10. Examples of said groups are methyl, ethyl, n-propyl, isopropyl, t-butyl, pentyl, hexyl, heptyl, octanyl, nonenyl and decenyl.
  • one or more hydrogen atoms can be replaced by halogen atoms in alkyl groups.
  • the derived expressions "(C]-C 1O )- alkoxycarbonyl", (C r C 10 )-alkylsulfanyl”, “(C r Ci 0 )-alkylsulfinyl", “(C 1 -C 10 )- alkylsulfonyl” and "(C]-C 10 )-alkoxyl” should be construed in an analogous manner.
  • aryl refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15 and wherein at least one ring is aromatic. In said rings one or more hydrogen atoms may be replaced by one or more halogen atoms.
  • heteroaryl refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom or heteroaromatic group (e.g. N, NH, S or O). In said rings one or more hydrogen atoms may be replaced by one or more halogen atoms.
  • arylalkyl refers to a "(C]-C 4 ) alkyl” optionally substituted by aryl as above defined.
  • Suitable arylalkyl groups include benzyl and diphenylmethyl.
  • heteroarylalkyl refers to a "(C 1 -C 4 ) alkyl” optionally substituted by a heteroaryl group as above defined.
  • heteroarylalkyl groups examples include thiophenylmethyl.
  • Suitable monocyclic systems include thiophene, cyclopentadiene, benzene, pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, imidazolidine, piperidine and furan radicals.
  • bicyclic systems examples include naphthalene, biphenyl, purine, pteridine, benzotriazole, quinoline, isoquinoline, indole, isoindole and benzothiophene radicals.
  • Suitable tricyclic systems include fluorene radicals. DETAILED DESCRIPTION OF THE INVENTION
  • the invention refers to alkaloid aminoester derivatives of formula (I) and (VI) acting as muscarinic receptor antagonists, and to the salts thereof, said derivatives preferably acting on the M3 receptors.
  • physiologically acceptable anions A include those selected from chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, and p-toluenesulfonate, preferably chloride, bromide and iodide.
  • Rl is hydrogen
  • R2 is arylalkyl or (Ci-Cio)-alkyl or aryl or (Cs-Cg)-CyClOaIlCyI or heteroaryl
  • R3 is (C r Cio)-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R6 is as defined above.
  • Rl is H
  • R2 is arylalkyl or (Ci-C ! o)-alkyl or aryl or (C 3 -Cg)-cycloalkyl or heteroaryl
  • R3 is (C J -C JO )- alkyl or aryl or (C 3 -C 8 )-cycloalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vi)
  • Rl is H
  • R2 is arylalkyl or (C 1 -C] 0 )-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or heteroaryl
  • R3 is (C r Cio)-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R6 is a group of formula (i)
  • R2 and R3 are phenyl.
  • R2 and R3 are phenyl.
  • R4 is a group of formula (Y)
  • R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is an optionally phenyl.
  • R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is thienyl or thiazolyl.
  • R4 is a group of formula (Y), wherein p is 2, P is O, q is 0 and W is phenyl.
  • R4 is a group of formula (Y), wherein p is 3, P is O, q is 0 and W is phenyl.
  • Rl is H
  • R2 is arylalkyl or (C r C 10 )-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or heteroaryl and
  • R3 is (C r C 10 )-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii)
  • R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
  • Rl is H
  • R2 is arylalkyl or (C r C 10 )-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or heteroaryl and
  • R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
  • Rl is H
  • R2 is arylalkyl or (C]-C ⁇ ))-alkyl or aryl or (C 3 -Cg)-cycloalkyl or heteroaryl and
  • R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
  • Rl is H
  • R2 is arylalkyl or (Ci-C ⁇ ))-alkyl or aryl or (C 3 -Cg)-cycloalkyl or heteroaryl and
  • R3 is (C r C 10 )-alkyl or aryl or (C 3 -C 8 )-cycloalkyl or arylalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein
  • R7 is a group of formula (viii)
  • R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
  • Rl is H
  • R2 is arylalkyl or (C 1 -Cio)-alkyl or aryl or (C 3 -Cg)-cycloalkyl or heteroaryl
  • R3 is (Ci-C ⁇ ))-alkyl or aryl or (C 3 -Cg)-cycloalkyl or arylalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (ix)
  • R2 and R3 are phenyl.
  • a preferred group of compounds are the corresponding quaternary ammonium salts of compounds of general formula (XII), (XIV), (XV), (XVII) and (XVIII).
  • the compounds of general formula (I) and (VI) may contain asymmetric centers. Therefore the invention also includes the optical stereoisomers and mixtures thereof. Where the compounds according to the invention have at least one asymmetric center, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • Compounds of general formula (XII), (XIII), (XV) and (XVI) wherein R3 is different from H can be obtained in S- R, R-R, R-S, S-S configuration or as a mixture of diastereoisomers (R-R and S-R configuration or R-S and S-S configuration).
  • compounds of general formula (VI) and in particular compounds of general formula (XII), (XIII), (XV) and (XVI) wherein R3 is different from H, show at least two chiral centers, which are respectively represented by the alkaloid carbon atom bearing the aminoester group and the carbon atom bearing H, R3 and NHR2.
  • the active compounds of formula (I) and (VI) show at least one chiral center, which is represented by the alkaloid carbon atom bearing the aminoester group.
  • compound (I) is in the form of (S)-enantiomer when R6 is a group of formula (i).
  • compound (I) is in the form of (R)-enantiomer when R6 is a group of formula (i).
  • the present invention provides the compounds reported below:
  • Route A - Alkylation of amine compounds of general formula (II), wherein Rl and R2 are as described above, with compounds of general formula (III), in which LG is a suitable leaving group (e.g. an halide such as bromine) and K may be either a hydroxyl group or a suitably protected hydroxyl group (e.g. K OAlkyl such as OMe).
  • the reaction may be promoted by a base selected from the group consisting of triethylamine, pyridine and 4-dimethylaminopyridine, either neat or in a suitable solvent (e.g. acetonitrile). This reaction is usually performed in a temperature range from 0 0 C to 130 0 C over a period of 1 hour up to 74 hours.
  • the reaction may be conducted under conventional heating (using an oil bath) or under microwave heating.
  • the reaction may be carried out in an open vessel or in a sealed tube.
  • Reagents of general formula (III) are commercially available or may be conveniently prepared according to standard procedures extensively reported in literature.
  • compounds of general formula (III) in which LG is a halogen such as a bromine may be prepared by halogenation of the opportunely substituted phenyl acetic ester (for example following the procedure reported by Epstein, J. W. in J.Med. Chem., 1981, 24/5, 481).
  • compounds of general formula (III) may be prepared starting from the appropriately substituted mandelic derivative, using procedures readily apparent to those skilled in the art (a survey of the suitable reactions is given by Larock, L. C, Comprehensive Organic Transformation, Second edition (1999), John Wiley & Son Inc, pg 689-700).
  • ketones (VII) can be most conveniently converted into compounds of general formula (III) (Route F) using conditions well known to those skilled in the art.
  • ketones (VII) are treated with a reducing agent such as sodium borohydride and the like, in a suitable solvent (e.g. ethanol and methanol) to smoothly provide the corresponding alcohol intermediate.
  • a suitable solvent e.g. ethanol and methanol
  • LG leaving group
  • a base such as triethylamine, pyridine, 4-dimethylaminopyridine and the like, either neat or in aprotic solvent (e.g. dichloromethane).
  • a base such as triethylamine, pyridine, 4-dimethylaminopyridine and the like
  • aprotic solvent e.g. dichloromethane
  • Route C - Compound (IX) may be reacted with an alkylating agent of general formula (VIII), in which z is a suitable leaving group such as a carbonyl group or an halide (i.e. bromine, iodine, chlorine) or sulfonate ester (i.e. tosylate, triflates, mesylate), according to procedures readily available to those skilled in the art (e.g. Huang, Tetrahedron, 1997, 53/37, 12391).
  • an alkylating agent of general formula (VIII) in which z is a suitable leaving group such as a carbonyl group or an halide (i.e. bromine, iodine, chlorine) or sulfonate ester (i.e. tosylate, triflates, mesylate), according to procedures readily available to those skilled in the art (e.g. Huang, Tetrahedron, 1997, 53/37, 12391).
  • the coupling between compounds of general formula (VIII) and (IX) may be promoted by a suitable catalyst.
  • the catalyst is a copper catalyst (e.g. copper iodide), and the reaction is performed in the presence of a suitable base selected from the group consisting of potassium and cesium carbonate or amines such as triethylamine, in solvents selected from the group consisting of dimethyl sulfoxide (DMSO) and DMF, at a temperature ranging from ambient to 1 10 0 C, over a period ranging from one to 48 hours.
  • DMSO dimethyl sulfoxide
  • the reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation.
  • the reaction may be conducted either in an open vessel or in a sealed tube (Ma, D., Tetrahedron Asymmetry 1996, 7/1 1, 3075 or Kurokawa, M., Heterocycles, 2007, 71/4, 847).
  • compound of general formula (VIII) and (IX) may react under the typical conditions of the aromatic nucleophilic substitution to afford compound (IV).
  • Route D Compounds of formula (VI) may be prepared by coupling alcohols of formula (V) with compounds of formula (IV).
  • the method for the preparation of compounds of formula (VI) from alcohols (V) and compounds (IV) is chosen on the basis of the reactivity of the alcohol (V), the commercial availability of reagents such as (IV) and the compatibility with the groups present in both the starting materials.
  • K may be either a hydroxyl group or a halide such as chlorine
  • K is a protected hydroxyl group
  • the protecting group has to be removed before performing the coupling with (V).
  • a suitable aqueous base selected from the group consisting of sodium, lithium and potassium hydroxide in the opportune solvents (e.g. tetrahydrofuran, dioxane etc).
  • RT room temperature
  • a commercially available condensing agent such as a carbodiimide (e.g. l-(3-dimethylamino)propyl)-3- ethylcarbodiimide hydrochloride (EDC) and the like) for example in the presence of N-hydroxybenzotriazole (HOBt) followed by reaction of the activated intermediate with alcohol (V), results in the formation of compounds (VI).
  • An organic base such as triethylamine may be also present in the reaction mixture.
  • the activated intermediate may be either isolated, or pre-formed or generated in situ.
  • Suitable solvents for the coupling include, but are not limited to, halocarbon solvents (e.g. dichloromethane), tetrahydrofuran, dioxane and acetonitrile.
  • the reaction proceeds at temperature range from 0 0 C up to 170 0 C, for a time in the range of about 1 hour up to 72 hours.
  • the reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation.
  • the reaction may be conducted either in an open vessel or in a sealed tube.
  • the alcohol (V) is reacted with the suitable acyl halide (IV), using methods that are readily apparent to those skilled in the art.
  • the reaction may be promoted by a base such as triethylamine, pyridine and 4-dimethylaminopyridine, in a suitable solvent (e.g. dichloromethane). This reaction is performed in a temperature range from 0 0 C to 130 0 C over a period of 1 hour up to 74 hours.
  • the reaction may be conducted under conventional heating (using an oil bath) or under microwave heating.
  • the reaction may be carried out in an open vessel or in a sealed tube.
  • DMF dimethylformamide
  • suitable aprotic solvent e.g. dichloromethane, tetrahydrofuran
  • reaction of the activated intermediate with alcohol (V) provides the desired compound of formula (VI).
  • the reaction may also require the use of an organic base such as diisopropylethylamine and usually proceeds at about RT.
  • acids (IV) and alcohol (V) are reacted in presence of a phosphine (e.g. triphenylphosphine) and an azadicarboxylate ester (e.g. diethyl azodicarboxylate or diisopropyl azodicarboxylate) in an aprotic solvent such as tetrahydrofuran.
  • a phosphine e.g. triphenylphosphine
  • an azadicarboxylate ester e.g. diethyl azodicarboxylate or diisopropyl azodicarboxylate
  • aprotic solvent such as tetrahydrofuran.
  • compounds of formula (VI) may be prepared according to route E. W may be LG or hydroxy.
  • Compounds of general formula (III) may be coupled to compound of general formula (V) to yield compound (X), applying one of the procedures readily apparent to those skilled in the art. For instance, the conditions used to perform the coupling may be selected among those described to produce the coupling between compound (IV) and (V) in Scheme 1.
  • the resulting intermediate (X) may then be used as the alkylating agent of amines of general formula (II) to furnish the desired intermediate (VI).
  • This reaction may be performed under the typical conditions extensively reported in literature, such as those described to obtain compound (IV) by coupling (II) and (III) (Scheme 1).
  • Compound of general formula (VI), in which R3 and R7 are defined hereinbefore, can be achieved either as single diastereoisomer or as a mixture of diastereoisomers.
  • R7 is a group of formula (vi)
  • the alcohol can feature either a R or a S configuration. If R-enantiomer is used, compound VI can be obtained in S-R configuration, in R-R configuration or as a mixture of diastereoisomers (R-R and S-R configuration).
  • the mixture of diastereoisomers may be converted to compounds of formula (I) of Scheme 1 or can be most conveniently resolved to give the two single diastereoisomers, which in turn may be converted to compounds of formula (I) of Scheme 1.
  • This separation can be accomplished using procedures well known to those skilled in the art. These procedures include, but are not limited to, chromatography purification, preparative HPLC purification and crystallization.
  • the two diastereoisomers can be separated by flash chromatography on silica gel eluting with suitable solvents or mixture of solvents such as DCM and Methanol and the like.
  • separation of diastereoisomers may be obtained using a column filled with a chiral stationary phase, for example Chiralpack AY or Chiralcel OD or Chiralcel OZ, and eluting, for example, with acetonitrile and/or with mixtures of acetonitrile and an alcohol.
  • a chiral stationary phase for example Chiralpack AY or Chiralcel OD or Chiralcel OZ
  • the separation of diastereoisomers may be most conveniently achieved by crystallization from an opportune solvent (e.g. ethyl ether), as a free base or after the formation of a suitable salt (e.g. (+)-tartaric acid)).
  • an opportune solvent e.g. ethyl ether
  • a suitable salt e.g. (+)-tartaric acid
  • A is a suitable leaving group selected from the group consisting of halide (i.e. bromine, iodine, chlorine) and sulfonate ester
  • reaction i.e. tosylate, triflates, mesylate
  • a suitable solvent selected from the group consisting of acetonitrile, DMF,
  • reaction typically proceeds at temperature range from 0 0 C up to 170 0 C, for a time in the range of few minutes up to
  • the reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation.
  • the reaction may be conducted either in an open vessel or in a sealed tube.
  • the present invention also provides pharmaceutical compositions of compounds of general formula (I) and (VI) in admixture with one or more pharmaceutically acceptable carriers, for example those described in
  • Administration of the compounds of the present invention may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
  • solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
  • the compounds of the invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
  • Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
  • liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
  • dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
  • the compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
  • Formulations for vaginal administration can be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose.
  • Topical administration may also involve transdermal administration via means such as transdermal patches.
  • the compounds according to the invention are preferably administered by inhalation.
  • Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
  • inhalable powders for administration as a dry powder, single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir.
  • a diluent or carrier generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
  • Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form.
  • the propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
  • the propellant-free inhalable formulations comprising the compounds of the invention may be in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers or by soft-mist nebulizers.
  • the compounds of the invention may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, corticosteroids and anticholinergic or antimuscarinic agents.
  • the dosages of the compounds of the invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound.
  • the compounds of formula (I) can be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day.
  • the compounds of formula (I) are administered by inhalation route, they are -preferably given at a dosage comprised between 0.001 and 500 mg/day, preferably between 0.1 and 200 mg/day.
  • the compounds of formula (I) may be administered for the prevention and/or treatment of any disease wherein M3 antagonists are active.
  • Said disease include: diseases involving inflammation such as asthma and COPD, acute rhinitis; diseases involving the gastrointestinal tract such as peptic ulcer; diseases involving the cardiovascular system such as acute myocardial infarction; diseases involving the genitourinary tract such as renal colic; anticholinesterase and mushroom poisoning; uses in anesthesia; uses in ophthalmology.
  • Neurode disorders such as Parkinsonism and motion sickness.
  • the compounds of formula (I) may be administered for the prevention and/or treatment of respiratory diseases such as from mild to acute severe conditions of asthma and COPD.
  • respiratory diseases include bronchitis, bronchiolitis, bronchiectasis, acute nasopharyngitis, acute and chronic sinusitis, maxillary sinusitis, pharyngitis, tonsillitis, laryngitis, tracheitis, epiglottitis, croup, chronic disease of tonsils and adenoids, hypertrophy of tonsils and adenoids, peritonsillar abscess, rhinitis, abscess or ulcer and nose, pneumonia, viral and bacterial pneumonia, bronchopneumonia, influenza, extrinsic allergic alveolitis, coal workers' pneumoconiosis, asbestosis, pneumoconiosis, pneumonopathy, respiratory conditions due to chemical fumes, vapors and other external agents, emphysema, pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis, postinflammatory pulmonary fibrosis, other al
  • Diastereoisomer 2 of C2 (65 mg) is further purified by preparative LC-MS to obtain 28.3 mg of a pale yellow oil (TFA salt).
  • Diastereoisomer 1 of C2 1H NMR (300 MHz, DMSO-d 6 ) ppm: 9.38 (br. s., IH), 7.50 - 7.72 (m,
  • Diastereoisomer 1 of C 12 (80 mg) is further purified by preparative LC-MS to obtain 53.0 mg of a pale yellow oil (TFA salt). Diastereoisomer 1 of C 12
  • Diastereoisomer 1 of C 14 7.46 - 7.57 (m, 2 H), 7.29 - 7.45 (m, 3 H), 7.08 - 7.21 (m, 2 H), 6.67 - 6.81 (m, 1 H), 6.50 - 6.67 (m, 2 H), 5.20 - 5.37 (m, 1 H), 5.12 (d, 1 H), 4.84 - 5.05 (m, 1 H), 2.46 - 3.04 (m, 4 H), 2.44 (s, 3 H), 2.10 - 2.26 (m, 1 H), 1.63 - 1.82 (m, 1 H).
  • Diastereoisomer 2 of C14 7.46 - 7.57 (m, 2 H), 7.29 - 7.45 (m, 3 H), 7.08 - 7.21 (m, 2 H), 6.67 - 6.81 (m, 1 H), 6.50 - 6.67 (m, 2 H), 5.20 - 5.37 (m, 1 H), 5.12 (d, 1 H), 4.84 - 5.05 (m, 1 H), 2.46 - 3.04 (m, 4 H), 2.33 (s, 3 H), 2.26 - 2.40 (m, 1 H), 1.86 - 2.05 (m, 1 H);
  • Diastereoisomer 2 of C20 listed in Table 4 is prepared as previously described for diastereoisomer 1 of C20, starting from the commercially available (R)-2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid. Table 4
  • PS-DCC (2.05 g, 2.57 mmol, loading: 1.25 mmol/g) is suspended in THF (15 mL) and shaken for few minutes. Then (2-methoxy-phenylamino)- phenyl-acetic acid hydrochloride (136) (377 mg, 1.28 mmol) and HOBT (393 mg, 2.57 mmol) are added. After 10 minutes, (R)-quinuclidin-3-ol (490 mg, 3.85 mmol) is added and the mixture is shaken at RT for 16 hours (Conversion complete by UPLC/MS-UV). PS-DCC is filtered off and the filtrate is evaporated to dryness. The residue is dissolved in EtOAc and washed with sat. NaHCO 3 , water and brine. The organic layer is recovered, dried over Na 2 SO 4 , filtered and evaporated to afford the title compound as a yellow oil (548 mg, quantitative yield, mixture of diastereoisomers).
  • PS-DCC (1.15 g, 1.44 mmol, loading: 1.25 mmol/g) is suspended in
  • PS-DCC (920 mg, 1.15 mmol, loading: 1.25 mmol/g) is suspended in THF (15 mL). Phenyl-(3-trifluoromethoxy-phenylamino)-acetic acid hydrochloride (140) (200 mg, 0.57 mmol) and HOBT (176 mg, 1.15 mmol) are added, followed by (R)-quinuclidin-3-ol (219 mg, 1.73 mmol) and the mixture is shaken for 16 hours at RT. PS-DCC is filtered off and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with water, sat. NaHCO ⁇ , water and brine. The organic phase is dried over
  • PS-DCC is filtered off and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with water, sat. NaHCO3, water and brine.
  • N-(3-Aminophenyl)acetamide (371 mg, 2.47 mmol), ethyl 2-bromo-2- phenylacetate (0.29 mL, 1.64 mmol), and DIPEA (0.43 mL, 2.47 mmol) are dissolved in acetonitrile (5 mL). The reaction is heated under MW irradiation at 100 0 C for 30 minutes. Conversion complete by UPLC/MS-UV. Acetonitrile is evaporated and the crude residue is purified by flash chromatography
  • PS-DCC (798 mg, 0.10 mmol, loading: 1.25 mmol/g) is suspended in dry THF (10 mL).
  • PS-DCC (602 mg, 0.80 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (3-Methylsulfanyl-phenylamino)-phenyl-acetic acid hydrochloride (151) (124 mg, 0.40 mmol), HOBT (123 mg, 0.80 mmol), and (R)-quinuclidin-3-ol (153 mg, 1.20 mmol) are added and the suspension is shaken at RT overnight (16h). PS-DCC is filtered off, washed with THF and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated to afford the title compound as a brown oil (153 mg, quantitative yield, mixture of diastereoisomers).
  • PS-DCC (715 mg, 0.951 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL). (2,5-Dimethoxy-phenylamino)-phenyl-acetic acid hydrochloride (154) (154 mg, 0.48 mmol), HOBT (146 mg, 0.95 mmol) and (R)-quinuclidin-3-ol (181 mg, 1.43 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off and the filtrate is evaporated. The residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine.
  • PS-DCC (914 mg, 1.301 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (2,5-Difluoro-phenylamino)-phenyl-acetic acid hydrochloride (157) (195 mg, 0.65 mmol), HOBT (199 mg, 1.30 mmol), and
  • PS-DCC is filtered off and washed with THF and the filtrate is evaporated under reduced pressure.
  • the resulting residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine.
  • the organic layer is separated, dried over Na2SO4, filtered and evaporated.
  • PS-DCC (890 mg, 1.184 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL).
  • Diastereoisomer 1 7.48 - 7.64 (m, 2 H), 7.22 - 7.47 (m, 3 H), 6.95 (t, 1 H), 6.23 - 6.38 (m, 3 H), 6.09 - 6.19 (m, 1 H), 5.25 (d, 1 H), 4.50 - 4.79 (m, 1 H), 3.64 (s, 3 H), 2.97 (ddd, 1 H), 2.20 - 2.71 (m, 4 H), 2.03 - 2.13 (m, 1 H), 1.83 - 1.95 (m, 1 H), 1.19 - 1.67 (m, 4 H); Diastereoisomer 2: 7.48 - 7.64 (m, 2 H), 7.22 - 7.47 (m, 3 H), 6.95 (t, 1
  • N-methylaniline (299 ul, 2.76 mmol) is added to a solution of (S)- methyl 2-(methylsulfonyloxy)-2-phenylacetate (15) (450 mg, 1.84 mmol) in acetonitrile (10 mL). The reaction is heated at 120 0 C for 15 minutes
  • Diastereoisomer 1 of C84 7.41 - 7.65 (m, 2 H), 7.15 - 7.33 (m, 2 H), 6.96 - 7.14 (m, 1 H), 6.67 (d, 1 H), 6.43 - 6.59 (m, 2 H), 6.20 - 6.42 (m, 1 H), 5.36 (d, 1 H), 4.46 - 4.88 (m, 1 H), 2.97 (ddd, 1 H), 2.53 - 2.72 (m, 3 H), 2.18 - 2.39 (m, 1 H), 2.01 - 2.16 (m, 1 H), 1.80 - 1.96 (m, 1 H), 1.21 - 1.66 (m, 4 H).
  • Diastereoisomer 2 of C84 7.41 - 7.65 (m, 2 H), 7.15 - 7.33 (m, 2 H), 6.96 - 7.14 (m, 1 H), 6.67 (d, 1 H), 6.43 - 6.59 (m, 2 H), 6.20 - 6.42 (m, 1 H), 5.35 (d, 1 H), 4.46 - 4.88 (m, 1 H), 3.08 (ddd, 1 H), 2.53 - 2.72 (m, 5 H), 1.66 - 1.76 (m, 1 H), 1.21 - 1.66 (m, 4 H);
  • C85 listed in Table 13 is prepared as previously described for C84, using 2-fluoroaniline instead of 3-fluoroaniline.
  • PS-DCC (982 mg, 1.31 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (3-Fluoro-phenyl)-phenylamino-acetic acid hydrochloride (198) (184 mg, 0.65 mmol), HOBT (200 mg, 1.31 mmol), and (R)-quinuclidin-3-ol (249 mg, 1.96 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off and the filtrate is evaporated. The residue is dissolved in EtOAc and washed with NaHCO3, water and brine. The organic layer is dried over Na2SO4, filtered and evaporated to dryness.
  • the title compound is obtained as a colorless oil (129 mg, 56% yield, mixture of diastereoisomers) .
  • ClOO listed in Table 14 is alternatively prepared as previously described for C99, using methyl 2-(4-fluorophenyl)acetate instead of methyl 2-(3-fluorophenyl)acetate.
  • Phenylamino-(4-trifluoromethyl-phenyl)-acetic acid ethyl ester (1103) (195 mg, 0.60 mmol) and lithium hydroxide hydrate (50.6 mg, 1.21 mmol) are dissolved in THF/water (9 mL/3mL) and stirred at RT for 4h and then at 40 0 C for Ih. THF is evaporated and the remaining aqueous solution is acidified with IM HCl till pH 1. The resulting precipitate is recovered by suction filtration, washed with IM HCl and dried under vacuum at 40 0 C overnight to obtain intermediate 1152 as a white solid (200 mg, quantitative yield).
  • PS-DCC (907 mg, 1.21 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL). Phenylamino-(4-trifluoromethyl-phenyl)-acetic acid hydrochloride (1104) (200 mg, 0.60 mmol), HOBT (185 mg, 1.21 mmol), and (R)-quinuclidin-3-ol (230 mg, 1.81 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off, the filtrate is evaporated and the residue is dissolved in EtOAc and washed with NaHCO3, water and brine.
  • the title compound is obtained as a colorless oil (110 mg, 45% yield, mixture of diastereoisomers).
  • Diastereoisomer 1 of C106 7.48 - 7.62 (m, 2 H), 7.24 - 7.45 (m, 3 H), 6.98 - 7.11 (m, 2 H), 6.66 - 6.75 (m, 2 H), 6.51 - 6.62 (m, 1 H), 6.27 (d, 1 H), 5.25 (d, 1 H), 4.58 - 4.82 (m, 1 H), 3.08 (dd, 1 H), 2.54 - 2.70 (m, 5 H), 1.62 - 1.75 (m, 1 H), 0.97 - 1.60 (m, 4 H);
  • Diastereoisomer 2 of C106 7.48 - 7.62 (m, 2 H), 7.24 - 7.45 (m, 3 H), 6.98 - 7.11 (m, 2 H), 6.66 - 6.75 (m, 2 H), 6.51 - 6.62 (m, 1 H), 6.27 (d, 1 H), 5.26 (d, 1 H), 4.58 - 4.82 (m, 1 H), 2.95 (m, 1 H), 2.54 - 2.70 (m, 4 H), 2.02 - 2.14 (m, 1 H), 1.86 - 1.95 (m, 1 H), 0.97 - 1.60 (m, 4 H);
  • the purified compound is partitioned between sat. NaHCO 3 and DCM, the organic phase is dried over Na 2 SO 4 , filtered and evaporated under vacuum to give 53 mg of the title compound as brown oil (20% yield, mixture of diastereoisomers).
  • Diastereoisomer 1 H 6.34 (d, 1 H), 5.35 (d, 1 l of C143 H), 5.03 - 5.25 (m, 1 H), 4.02
  • Diastereoisomer 6.66 (m, 1 H), 6.35 (d, 1 H), l of C144 5.37 (d, 1 H), 5.06 - 5.27 (m,
  • Diastereoisomer 2 of C 154 listed in Table 19 is prepared as previously described for C 153, by reaction of 170 with 2-chloroacetylthiophene
  • Diasteroisomer 1 of C2 Diasteroisomer 1 of C 155
  • Diastereoisomer 1 of C220 and C221 listed in Table 23 are obtained as previously described for diastereoisomer 1 of Cl 13, using bromo-acetonitrile and bromo-acetic acid tert-butyl ester instead of 2-chloroacetophenone.
  • Diastereoisomer 1 of C227 listed in Table 25 is obtained as previously described for diastereoisomer 1 of C226, using 2-bromo- l-pyridin-2-yl- ethanone hydrobromide instead of 2-bromomethyl-pyridine hydrobromide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, to methods of preparing such derivatives, to compositions comprising them and therapeutic use thereof.

Description

ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
FIELD OF THE INVENTION
The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for the preparation thereof, compositions comprising them and the therapeutic use thereof. BACKGROUND OF THE INVENTION
Quaternary ammonium salts acting as muscarinic (M) receptor antagonist drugs are currently used in therapy to induce bronchodilation for the treatment of respiratory diseases. Examples of well known M receptor antagonists are represented by ipratropium bromide and tiotropium bromide. Several chemical classes acting as selective M3 receptor antagonist drugs have been developed for the treatment of inflammatory or obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Quinuclidine carbamate derivatives and their use as M3 antagonists are disclosed in WO 02051841, WO 03053966 and WO 2008012290.
Said M and M3 receptor antagonists are currently administered through inhalation in order to deliver the drug directly at the site of action and hence limiting the systemic exposure.
However, even though the systemic exposure may be reduced through the inhalatory route, the compounds of the prior art may still exhibit undesired side effects due to systemic absorption.
It is hence highly desirable to provide M3 receptor antagonists able to act locally, while having high potency and long duration of action. Said drugs, once adsorbed, are degraded to inactive compounds which are deprived of any systemic side effects typical of muscarinic antagonists. The present invention provides alkaloid aminoester derivatives with these therapeutically desirable characteristics.
The compounds of general formula (I) behave as soft-drugs, since they are able to produce a persistent bronchodilating effect in the lung but are consistently and rapidly transformed into inactive metabolites after passing into human plasma.
This behaviour gives great advantages in terms of safety.
US2824106 discloses quaternary alkyl derivatives of the tropeine series with increased spasmolytic activity and in particular N-phenyl amino acetyl derivatives.
J.Med.Chem. 1994, 37, 1712- 1719 refers to presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs and in particular to N-phenyl amino acetyl derivatives.
US 2856407 discloses aminoacid esters of hydroxypiperidines; among them are N-methyl-3-piperidyl-2'-N'-dimethylaminoacetate and N-methyl-4- piperidyl-2 ' -N' -dimethy laminoacetate.
WO 99/20612 describes compounds that inhibit the farnesylation of mutant ras gene products and in particular 4-(methylsulfanyl) butanoate derivatives. WO 2008/053158 refers to inhibitors of p38 MAP kinase activity, useful in the treatment of inflammatory and autoimmune disease and in particular to methylpiperidin-4-yl L-leucinate derivatives.
Khimiko-Farmatsevticheskii Zhurnal (1977), 1 1(7), 30-5 refers to tropine ester of phenylglyoxylic acid and in particular to phenylalanine ester derivatives.
Chemical & Pharmaceutical Bulletin (1971 ), 19(12), 2603-8 describes the one-step synthesis of atropine and other related alkaloids from dl-phenylalanine 3.alpha.-tropanyl ester and in particular to phenylalanine ester derivatives.
SUMMARY OF THE INVENTION
The invention concerns alkaloid aminoester derivatives of general formula (I)
Figure imgf000004_0001
(I) wherein:
Rl is selected from the group consisting of H, (Ci-C-io)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, NHCOR5, COR5, CO2R5, CF3, (C1-C1o)-alkoxycarbonyl, (C1-Cio)-alkylsulfanyl, (C1-C1o)-alkylsulfinyl, (Ci-Cio)-alkylsulfonyl, (CrC10)-alkyl and (CrC10)-alkoxyl;
R2 is selected from the group consisting of (C1-C1o)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, NHCOR5, COR5, CO2R5, CF3, (Ci-C10)-alkoxycarbonyl, (C]-C10)-alkylsulfanyl, (C1-C10)-alkylsulfinyl, (CrCio)-alkylsulfonyl, (CrC10)-alkyl and (CrC10)-alkoxyl; R3 is selected from the group consisting of H, (CrC10)-alkyl, aryl,
(C3-C8)-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, CO2R5, CF3, (CrC10)-alkoxycarbonyl, (C1-C10)-alkylsulfinyl, (Ci-Cio)-alkylsulfonyl, (C,-Cio)-alkyl and (CrC10)-alkoxyl; R6 represents a group of formula (i) or (ii) or (iii) or (iv)
Figure imgf000005_0001
(i) (ϋ)
Figure imgf000005_0002
(iii) iv) wherein m = 1 , 2 or 3; n =1, 2 or 3 ;
A" is a physiologically acceptable anion; R4 is a group of formula (Y)
-(CH2)P-P- (CH2)q-W (Y) wherein p is 0 or an integer from 1 to 4; q is 0 or an integer from 1 to 4;
P is absent or is selected from the group consisting of O, S, SO, SO2, CO, NR5 CH=CH, N(R5)SO2, N(R5)COO, N(R5)C(O), SO2N(R5), CO(O)N(R5) and C(O)N(R5);
W is selected from the group consisting of H, (CrC6)-alkyl,
(C3-C8)-cycloalkyl, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, NH2, NHCOR5, CO2R5, (C1-C10)- alkoxycarbonyl, (CrC10)-alkylsulfanyl, (Ct-Cio)-alkylsulfinyl, (C1-Ci0)- alkylsulfonyl, (CrCi0)-alkyl and (Ci-Cio)-alkoxyl;
R5 is selected from the group consisting of H, (CrCi0)alkyl, (CrC6)alkylhalo, (C2-C6)alkynyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl,
(C3-C7)cycloalkyl-(CrC6)alkyl, heteroaryl, (Ci-C6)alkyl-heteroaryl and aryl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CONH2, COOH,
(Ci-C1o)-alkoxycarbonyl, (C1-C1o)-alkylsulfanyl, (C1-C1o)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (CrC10)-alkyl and (CrC10)-alkoxyl; and pharmaceutically acceptable salts thereof, with the proviso that when Rl is H, R2 is phenyl, R3 is H, then R6 is not a group of formula (iii).
The invention also refers to compounds of general formula (VI):
Figure imgf000006_0001
(Vl) wherein:
Rl , R2 and R3 are as described above
R7 represents a group of formula (vi) or (vii) or (viii) or (ix)
Figure imgf000007_0001
(viii) (ix) wherein m and n are as described above; and pharmaceutically acceptable salts thereof, with the provisos that:
- when Rl is H or CH3, R2 is phenyl, R3 is H or CH3, then R6 is not a group of formula (viii) and
- the compounds of general formula (VI) are not N-methyl-3- piperidy 1-2 ' -N' dimethy laminoacetate and N-methyl-4-piperidyl-2 ' - N'-dimethylaminoacetate.
The invention also refers to a process for the preparation of a compound of formula (I) as reported in Scheme 1, which comprises the alkylation of compounds of general formula (VI)
Figure imgf000007_0002
by alkylating agents of general formula (XI)
A— R6
(Xl) in which A is a suitable leaving group selected from the group consisting of halide and sulfonate, and R6 has the above reported meanings.
The invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises the alkylation of amine compounds of general formula (II)
Figure imgf000008_0001
(II)
with compounds of general formula (III),
Figure imgf000008_0002
in which LG is a suitable leaving group and K may be either a hydroxyl group or a suitably protected hydroxyl group, to yield a compound of formula
Figure imgf000008_0003
which is condensed with a compound of formula (V)
(V)
to obtain compound (VI), and converting the compound to a further compound of formula (I). The invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises coupling an amine of general formula (II) R1 - ,R2
'N H
("I)
with ketones of formula (VII),
Figure imgf000009_0001
(VIl)
to yield a compound of formula (IV),
Figure imgf000009_0002
which is condensed with a compound of formula (V)
HO. R7
(V)
to obtain compound (VI)
Figure imgf000009_0003
and converting the compound to a further compound of formula (I).
The invention also concerns a process for the preparation of a compound of formula (I) as reported in scheme 1 , which comprises reacting compound (IX)
Figure imgf000010_0001
with an alkylating agent of general formula (VIII),
(VlIl)
in which z is a carbonyl group or a suitable leaving group such as a an halide, to yield a compound of formula (IV) in which R2 is hydrogen,
Figure imgf000010_0002
which is condensed with a compound of formula (V)
HO. R7
(V)
to obtain compound (VI)
Figure imgf000010_0003
and converting the compound to a further compound of formula (I). The invention also concerns a process for the preparation of a compound of formula (I) as reported in Scheme 1 , which comprises coupling compounds of general formula (III)
Figure imgf000011_0001
to compound of general formula (V)
H%7 (V)
to yield compound (X),
Figure imgf000011_0002
(X)
which is reacted with an amine of formula (II),
R-K ,R2
H
(II)
to obtain compound (VI)
Figure imgf000011_0003
and converting the compound into a further compound of formula (I). The invention also provides pharmaceutical compositions of compounds of general formula (I) or of general formula (VI) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients. The invention also provides compounds of general formula (I) and (VI) for use as a medicament.
In a further aspect, the invention provides the use of compounds of formula (I) or of general formula (VI) for the manufacture of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
In a further aspect the invention provides the use of the compounds of general formula (XIX)
Figure imgf000012_0001
(XIX) wherein:
Rl and R2 is independently selected from the group consisting of H, (C1-C10)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), SH, NO2, CN, CON(R5)2, COOH, NHCOR5, COR5, CO2R5, CF3, (C1-C10)- alkoxycarbonyl, (Ci-C10)-alkylsulfanyl, (CrCio)-alkylsulfinyl, (C1-C10)- alkylsulfonyl, (Ci-C10)-alkyl and (CrC10)-alkoxyl; R3 is selected from the group consisting of H, (C1-C10)-alkyl, aryl,
(C3-C8)-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, CO2R5, CF3, (CrCi0)-alkoxycarbonyl, (CrC10)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (C,-CiO)-alkyl and (CrCi0)-alkoxyl; R8 represents a group of formula (i) or (ii) or (iii) or (iv) or (vi) or (vii) or (viii) or (ix) "
Figure imgf000013_0001
(i) (ϋ)
Figure imgf000013_0002
(iii) (iv)
Figure imgf000013_0003
(vi) (vii)
Figure imgf000013_0004
(viii) (ix) wherein m = 1, 2 or 3; n =1, 2 or 3;
A" is a physiologically acceptable anion; R4 is a group of formula (Y)
-(CH2)P-P- (CH2)q-W (Y) wherein p is 0 or an integer from 1 to 4; q is 0 or an integer from 1 to 4;
P is absent or is selected from the group consisting of O, S, SO, SO2, CO, NR5 CH=CH, N(R5)SO2, N(R5)COO, N(R5)C(0), SO2N(R5), CO(O)N(R5) and C(0)N(R5);
W is selected from the group consisting of H, (CrC6)-alkyl,
(C3-C8)-cycloalkyl, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, NH2, NHCOR5, CO2R5, (C1-C10)- alkoxycarbonyl, (CrC^-alkylsulfanyl, (CrC10)-alkylsulfinyl, (C1-C10)- alkylsulfonyl, (Cj-C1o)-alkyl and (C1-C1o)-alkoxyl;
R5 is selected from the group consisting of H, (C1-C10)alkyl, (CrC6)alkylhalo, (C2-C6)alkynyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(CrC6)alkyl, heteroaryl, (CrC6)alkyl-heteroaryl and aryl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CONH2, COOH, (Ci-C1o)-alkoxycarbonyl, (C1-Ci0)-alkylsulfanyl, (C1-C1o)-alkylsulfinyl, (CrCio)-alkylsulfonyl, (CrC10)-alkyl and (CrC10)-alkoxyl, for the preparation of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
The invention also provides a method for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD), which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of general formula (I), (VI) or (XIX).
The invention also provides pharmaceutical preparations suitable for administration by inhalation, such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
The invention also refers to a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a soft mist nebulizer comprising the compounds of general formula (I) or (VI).
The invention also refers to a kit comprising the pharmaceutical compositions of compounds of general formula (I) or (VI) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler and a soft mist nebulizer comprising the compounds of general formula (I) or (VI).
DEFINITIONS
The term "halogen atoms" includes fluorine, chlorine, bromine, and iodine.
The expression "(C1-C]O) alkyl", refers to straight or branched chain alkyl groups wherein the number of carbon atoms is from 1 to 10. Examples of said groups are methyl, ethyl, n-propyl, isopropyl, t-butyl, pentyl, hexyl, heptyl, octanyl, nonenyl and decenyl.
Optionally, as reported above, one or more hydrogen atoms can be replaced by halogen atoms in alkyl groups. The derived expressions "(C]-C1O)- alkoxycarbonyl", (CrC10)-alkylsulfanyl", "(CrCi0)-alkylsulfinyl", "(C1-C10)- alkylsulfonyl" and "(C]-C10)-alkoxyl" should be construed in an analogous manner.
The derived expressions "(C2-C1O) alkenyl" and "(C2-Cio) alkynyl", should be construed in an analogous manner, as referring to groups at least comprising one double or triple bond.
The expression "aryl" refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15 and wherein at least one ring is aromatic. In said rings one or more hydrogen atoms may be replaced by one or more halogen atoms.
The expression "heteroaryl" refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom or heteroaromatic group (e.g. N, NH, S or O). In said rings one or more hydrogen atoms may be replaced by one or more halogen atoms.
The expression "arylalkyl" refers to a "(C]-C4) alkyl" optionally substituted by aryl as above defined.
Examples of suitable arylalkyl groups include benzyl and diphenylmethyl. The expression "heteroarylalkyl" refers to a "(C1-C4) alkyl" optionally substituted by a heteroaryl group as above defined.
Examples of suitable heteroarylalkyl groups include thiophenylmethyl.
Examples of suitable monocyclic systems include thiophene, cyclopentadiene, benzene, pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, imidazolidine, piperidine and furan radicals.
Examples of suitable bicyclic systems include naphthalene, biphenyl, purine, pteridine, benzotriazole, quinoline, isoquinoline, indole, isoindole and benzothiophene radicals.
Examples of suitable tricyclic systems include fluorene radicals. DETAILED DESCRIPTION OF THE INVENTION
The invention refers to alkaloid aminoester derivatives of formula (I) and (VI) acting as muscarinic receptor antagonists, and to the salts thereof, said derivatives preferably acting on the M3 receptors.
Advantageously, physiologically acceptable anions A" include those selected from chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, and p-toluenesulfonate, preferably chloride, bromide and iodide. In preferred compounds of general formula (I) Rl is hydrogen, R2 is arylalkyl or (Ci-Cio)-alkyl or aryl or (Cs-Cg)-CyClOaIlCyI or heteroaryl and R3 is (CrCio)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R6 is as defined above.
In preferred compounds of general formula (VI) Rl is H, R2 is arylalkyl or (Ci-C!o)-alkyl or aryl or (C3-Cg)-cycloalkyl or heteroaryl and R3 is (CJ-CJO)- alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vi)
Figure imgf000017_0001
(vi) according to the general formula (XII):
Figure imgf000017_0002
(XII) In a preferred group of compounds of general formula (I) Rl is H, R2 is arylalkyl or (C1-C]0)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (CrCio)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R6 is a group of formula (i)
Figure imgf000017_0003
(0 according to the general formula (XIII):
Figure imgf000018_0001
In a preferred group of compounds of general formula (XII) R2 and R3 are phenyl. In a preferred group of compounds of general formula (XIII) R2 and R3 are phenyl.
In a preferred group of compounds of general formula (XIII) R4 is a group of formula (Y)
-(CH2)P-P- (CH2)q-W (Y) wherein p is 1, P is CO, q is 0 and W is aryl or heteroaryl. In a preferred group of compounds of general formula (XIII) R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is an optionally phenyl. In a preferred group of compounds of general formula (XIII) R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is thienyl or thiazolyl.
In a preferred group of compounds of general formula (XIII) R4 is a group of formula (Y), wherein p is 2, P is O, q is 0 and W is phenyl. In a preferred group of compounds of general formula (XIII) R4 is a group of formula (Y), wherein p is 3, P is O, q is 0 and W is phenyl.
In a preferred group of compounds of general formula (VI) Rl is H, R2 is arylalkyl or (CrC10)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and
R3 is (CrC10)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii)
Figure imgf000019_0001
(vϋ) wherein m=2 and n=l, according to the general formula (XIV):
Figure imgf000019_0002
(XIV)
In a preferred group of compounds of general formula (XIV) R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
In a preferred group of compounds of general formula (VI) Rl is H, R2 is arylalkyl or (CrC10)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and
R3 is (C1-C1o)-alkyl or aryl or (C3-Cg)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii), wherein m=l and n=l, according to the general formula (XV):
Figure imgf000019_0003
(XV)
In a preferred group of compounds of general formula (XV) R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
In a preferred group of compounds of general formula (VI) Rl is H, R2 is arylalkyl or (C]-Cκ))-alkyl or aryl or (C3-Cg)-cycloalkyl or heteroaryl and
R3 is (CrCio)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii), wherein m=l and n=2, according to the general formula (XVI):
Figure imgf000020_0001
In a preferred group of compounds of general formula (XVI) R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
In a preferred group of compounds of general formula (VI) Rl is H, R2 is arylalkyl or (Ci-Cκ))-alkyl or aryl or (C3-Cg)-cycloalkyl or heteroaryl and
R3 is (CrC10)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein
R7 is a group of formula (viii)
Figure imgf000020_0002
(viii) according to the general formula (XVII):
Figure imgf000020_0003
(XVII)
In a preferred group of compounds of general formula (XVII) R2 and R3 are phenyl, preferably substituted with one or more halogen atoms.
In a preferred group of compounds of general formula (VI) Rl is H, R2 is arylalkyl or (C1-Cio)-alkyl or aryl or (C3-Cg)-cycloalkyl or heteroaryl and R3 is (Ci-Cκ))-alkyl or aryl or (C3-Cg)-cycloalkyl or arylalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (ix)
Figure imgf000021_0001
(ix) according to the general formula (XVIII):
Figure imgf000021_0002
(XVIII)
In a preferred group of compounds of general formula (XVIII) R2 and R3 are phenyl.
A preferred group of compounds are the corresponding quaternary ammonium salts of compounds of general formula (XII), (XIV), (XV), (XVII) and (XVIII).
It will be apparent that the compounds of general formula (I) and (VI) may contain asymmetric centers. Therefore the invention also includes the optical stereoisomers and mixtures thereof. Where the compounds according to the invention have at least one asymmetric center, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
The active compounds of general formula (VI) and in particular compounds of general formula (XII), (XIII), (XV) and (XVI) wherein R3 is different from H, show at least two chiral centers, which are respectively represented by the alkaloid carbon atom bearing the aminoester group and the carbon atom bearing H, R3 and NHR2. Compounds of general formula (XII), (XIII), (XV) and (XVI) wherein R3 is different from H can be obtained in S- R, R-R, R-S, S-S configuration or as a mixture of diastereoisomers (R-R and S-R configuration or R-S and S-S configuration). According to a preferred embodiment, compounds of general formula
(XII), (XIII), (XV) and (XVI) wherein R3 is different from H, show a (R,R) configuration.
The active compounds of formula (I) and (VI) show at least one chiral center, which is represented by the alkaloid carbon atom bearing the aminoester group.
According to a further embodiment, compound (I) is in the form of (S)-enantiomer when R6 is a group of formula (i).
According to a preferred embodiment, compound (I) is in the form of (R)-enantiomer when R6 is a group of formula (i). According to specific embodiments, the present invention provides the compounds reported below:
Figure imgf000022_0001
(continue)
Figure imgf000023_0001
(continue)
Figure imgf000024_0001
(continue)
Figure imgf000025_0001
(continue)
Figure imgf000026_0001
(continue)
Figure imgf000027_0001
(continue)
Figure imgf000028_0001
(continue)
Figure imgf000029_0001
(continue)
Figure imgf000030_0001
(continue)
Figure imgf000031_0001
(continue)
Figure imgf000032_0001
(continue)
Figure imgf000033_0001
(continue)
Figure imgf000034_0001
(continue)
Figure imgf000035_0001
(continue)
Figure imgf000036_0001
(continue)
Figure imgf000037_0001
The compounds of general formula (I) and (VI) may be prepared according to methods known or evident to a person skilled in the art. Some of the processes which may be used are described below and reported in Scheme 1.
Figure imgf000038_0001
Figure imgf000038_0002
R3 Y (VIII) (IX) °
Scheme 1 Procedure for the preparation of compounds of formula (I) Compounds of general formula (IV) may be prepared according to three different routes: A, B and C.
Route A - Alkylation of amine compounds of general formula (II), wherein Rl and R2 are as described above, with compounds of general formula (III), in which LG is a suitable leaving group (e.g. an halide such as bromine) and K may be either a hydroxyl group or a suitably protected hydroxyl group (e.g. K=OAlkyl such as OMe). The reaction may be promoted by a base selected from the group consisting of triethylamine, pyridine and 4-dimethylaminopyridine, either neat or in a suitable solvent (e.g. acetonitrile). This reaction is usually performed in a temperature range from 00C to 1300C over a period of 1 hour up to 74 hours. The reaction may be conducted under conventional heating (using an oil bath) or under microwave heating. The reaction may be carried out in an open vessel or in a sealed tube.
Reagents of general formula (III) are commercially available or may be conveniently prepared according to standard procedures extensively reported in literature. For instance compounds of general formula (III) in which LG is a halogen such as a bromine, may be prepared by halogenation of the opportunely substituted phenyl acetic ester (for example following the procedure reported by Epstein, J. W. in J.Med. Chem., 1981, 24/5, 481). Alternatively, compounds of general formula (III) may be prepared starting from the appropriately substituted mandelic derivative, using procedures readily apparent to those skilled in the art (a survey of the suitable reactions is given by Larock, L. C, Comprehensive Organic Transformation, Second edition (1999), John Wiley & Son Inc, pg 689-700).
Route B -. The coupling of amine of general formula (II) and ketones of general formula (VII) may be carried out using a reductive amination reaction, following one of the different procedures reported in literature (e.g.: Suwa T., Synthesis, 2000, 6, 789 or Fache, F. Tetrahedron, 1996, 52/29, 9777 or Quiang, K., Adv.Synth. Catal. 2007, 349, 1657).
Alternatively, compounds of general formula (VII) can be most conveniently converted into compounds of general formula (III) (Route F) using conditions well known to those skilled in the art. In a typical procedure, ketones (VII) are treated with a reducing agent such as sodium borohydride and the like, in a suitable solvent (e.g. ethanol and methanol) to smoothly provide the corresponding alcohol intermediate. The subsequent conversion of the alcohol moiety in a leaving group (LG) affords compounds of general formula (III). This activation can be effected according to one of the standard procedures broadly reported in the literature (a survey of the suitable reactions is given by Carey, F.A. and Sundeberg, R.J. Advanced Organic Chemistry, Third Edition (1990), Plenum Press, New York and London, pg 121). For instance, the alcohol intermediate could be treated with methanesulphonyl chloride (LG=Ms) in presence of a base such as triethylamine, pyridine, 4-dimethylaminopyridine and the like, either neat or in aprotic solvent (e.g. dichloromethane). This reaction is usually performed in a temperature range from 00C to 1300C over a period of 1 hour up to 74 hours.
Route C - Compound (IX) may be reacted with an alkylating agent of general formula (VIII), in which z is a suitable leaving group such as a carbonyl group or an halide (i.e. bromine, iodine, chlorine) or sulfonate ester (i.e. tosylate, triflates, mesylate), according to procedures readily available to those skilled in the art (e.g. Huang, Tetrahedron, 1997, 53/37, 12391).
In case z=O, compounds (IX) are reacted with aldehydes or ketones of general formula (VIII) to achieve the corresponding imines that are reduced to compound (IV) by treatment with a suitable reducing agent, following one of the procedures reported in literature (a survey of the suitable reactions is given by Carey, F. A. and Sundeberg, R.J. Advanced Organic Chemistry, Third Edition (1990), Plenum Press, New York and London, chapter 5, 219 or Ando, A., Tetrahedron, 1989, 45/16, 4969).
In case Rl is an aryl or heteroaryl and z is a halogen (typically a iodine or bromine), the coupling between compounds of general formula (VIII) and (IX) may be promoted by a suitable catalyst. In a typical procedure the catalyst is a copper catalyst (e.g. copper iodide), and the reaction is performed in the presence of a suitable base selected from the group consisting of potassium and cesium carbonate or amines such as triethylamine, in solvents selected from the group consisting of dimethyl sulfoxide (DMSO) and DMF, at a temperature ranging from ambient to 1 100C, over a period ranging from one to 48 hours. The reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation. The reaction may be conducted either in an open vessel or in a sealed tube (Ma, D., Tetrahedron Asymmetry 1996, 7/1 1, 3075 or Kurokawa, M., Heterocycles, 2007, 71/4, 847).
In case Rl is an aryl or heteroaryl and z is a halogen (typically fluorine or chlorine), compound of general formula (VIII) and (IX) may react under the typical conditions of the aromatic nucleophilic substitution to afford compound (IV).
Compounds of general formula (VI) may then be prepared according to two different routes. Route D - Compounds of formula (VI) may be prepared by coupling alcohols of formula (V) with compounds of formula (IV).
The method for the preparation of compounds of formula (VI) from alcohols (V) and compounds (IV) is chosen on the basis of the reactivity of the alcohol (V), the commercial availability of reagents such as (IV) and the compatibility with the groups present in both the starting materials.
The coupling between (IV) and (V) may be conducted in several ways, in which K may be either a hydroxyl group or a halide such as chlorine
(a survey of the suitable reactions is given by Carey, F. A. and Sundeberg, R.J.
Advanced Organic Chemistry, Third Edition (1990), Plenum Press, New York and London, pg 145 and Montalbetti, C, Tetrahedron, 2005, 61, 10827).
In particular, in the case K is a protected hydroxyl group, the protecting group has to be removed before performing the coupling with (V). For instance, if K=OMe, hydrolysis of ester moiety may be performed treating the compound (IV; K=OMe) with a suitable aqueous base selected from the group consisting of sodium, lithium and potassium hydroxide in the opportune solvents (e.g. tetrahydrofuran, dioxane etc). The reaction proceeds at room temperature (RT), over a period of 1 hour up to 36 hours.
Alternative one - In a typical procedure compounds (VI) may be prepared by condensation between (V) and acid (IV) (K=OH) under standard amidation and peptide coupling conditions. For instance, treatment of the acid (IV) (K=OH) with one or more equivalents of a commercially available condensing agent such as a carbodiimide (e.g. l-(3-dimethylamino)propyl)-3- ethylcarbodiimide hydrochloride (EDC) and the like) for example in the presence of N-hydroxybenzotriazole (HOBt) followed by reaction of the activated intermediate with alcohol (V), results in the formation of compounds (VI). An organic base such as triethylamine may be also present in the reaction mixture. The activated intermediate may be either isolated, or pre-formed or generated in situ. Suitable solvents for the coupling include, but are not limited to, halocarbon solvents (e.g. dichloromethane), tetrahydrofuran, dioxane and acetonitrile. The reaction proceeds at temperature range from 00C up to 1700C, for a time in the range of about 1 hour up to 72 hours. The reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation. The reaction may be conducted either in an open vessel or in a sealed tube.
Alternative two - In the case where K is halogen such as chlorine, the alcohol (V) is reacted with the suitable acyl halide (IV), using methods that are readily apparent to those skilled in the art. The reaction may be promoted by a base such as triethylamine, pyridine and 4-dimethylaminopyridine, in a suitable solvent (e.g. dichloromethane). This reaction is performed in a temperature range from 00C to 1300C over a period of 1 hour up to 74 hours. The reaction may be conducted under conventional heating (using an oil bath) or under microwave heating. The reaction may be carried out in an open vessel or in a sealed tube.
In some embodiments of the present invention, the needed acyl halide (IV) may be readily prepared from the corresponding acid (IV) (K=OH). This activation may be effected according to one of the standard procedures reported in the literature. For instance, treatment of acid (IV) (K=OH) with one or more equivalents of oxalyl chloride in the presence of a catalytic amount of dimethylformamide (DMF) in a halocarbon solvent, such as dichloromethane, at temperature ranging form 00C to 35°C, affords the required acyl chloride (IV) (K=Cl). Alternative three - Alternatively, acylation of alcohol (V) to give compounds of general formula (VI) may be accomplished using procedures which convert in situ the acid (IV) (K=OH) into the corresponding acyl halides. For example, alcohols (V) are reacted with acids (IV) (K=OH) in presence of triphenylphosphine and a halocarbon solvent such as carbon tetrachloride or dichloromethane, at about RT, in a maximum period of time of 16 hours (Lee, J.B. J.Am.Chem.Soc, 1966, 88, 3440).
Alternative four - In another process for the preparation of the compounds of the present invention, acid (IV) (K=OH) may be activated with other commercially available activating agents such as bromotripyrrolidinophosphonium hexafluorophosphate (PyBrOP) or carbonylimidazole, in the suitable aprotic solvent (e.g. dichloromethane, tetrahydrofuran), at about RT. Subsequent reaction of the activated intermediate with alcohol (V) provides the desired compound of formula (VI). The reaction may also require the use of an organic base such as diisopropylethylamine and usually proceeds at about RT.
Alternative five - In another process for the preparation of the compounds of the present invention, compounds (VI) can be efficiently prepared by the condensation between acids (IV) (K=OH) and alcohol (V) under typical Mitsunobu conditions (Kumara Swamy, K. C, Chem. Rev. 2009, 109, 2551-2651). For example, acids (IV) and alcohol (V) are reacted in presence of a phosphine (e.g. triphenylphosphine) and an azadicarboxylate ester (e.g. diethyl azodicarboxylate or diisopropyl azodicarboxylate) in an aprotic solvent such as tetrahydrofuran. The reaction typically proceeds at temperature range from 00C up to 1000C, for a time in the range of about 30 minutes up to 72 hours.
Alternatively compounds of formula (VI) may be prepared according to route E. W may be LG or hydroxy. Compounds of general formula (III) may be coupled to compound of general formula (V) to yield compound (X), applying one of the procedures readily apparent to those skilled in the art. For instance, the conditions used to perform the coupling may be selected among those described to produce the coupling between compound (IV) and (V) in Scheme 1.
In case W is a halide, the resulting intermediate (X) may then be used as the alkylating agent of amines of general formula (II) to furnish the desired intermediate (VI). This reaction may be performed under the typical conditions extensively reported in literature, such as those described to obtain compound (IV) by coupling (II) and (III) (Scheme 1).
In case W in compound (III) is hydroxy, it must be converted into a opportune leaving group selected from the group consisting of halide
(i.e. bromine, iodine, chlorine) and sulfonate ester (i.e. tosylate, triflates, mesylate), according to procedures available to those skilled in the art
(a general overview is given by Carey, F. A. and Sundeberg, R.J. Advanced
Organic Chemistry, Third Edition (1990), Plenum Press, New York and
London, chapter 3, 121), before performing the coupling with amines (II). In case W is a suitably protected hydroxyl group, it must be deprotected and activated as above before performing the coupling with amines (II).
Compound of general formula (VI), in which R3 and R7 are defined hereinbefore, can be achieved either as single diastereoisomer or as a mixture of diastereoisomers. For instance, in the case R7 is a group of formula (vi), the alcohol can feature either a R or a S configuration. If R-enantiomer is used, compound VI can be obtained in S-R configuration, in R-R configuration or as a mixture of diastereoisomers (R-R and S-R configuration).
The mixture of diastereoisomers may be converted to compounds of formula (I) of Scheme 1 or can be most conveniently resolved to give the two single diastereoisomers, which in turn may be converted to compounds of formula (I) of Scheme 1. This separation can be accomplished using procedures well known to those skilled in the art. These procedures include, but are not limited to, chromatography purification, preparative HPLC purification and crystallization. For example, the two diastereoisomers can be separated by flash chromatography on silica gel eluting with suitable solvents or mixture of solvents such as DCM and Methanol and the like. In another process of the present invention separation of diastereoisomers may be obtained using a column filled with a chiral stationary phase, for example Chiralpack AY or Chiralcel OD or Chiralcel OZ, and eluting, for example, with acetonitrile and/or with mixtures of acetonitrile and an alcohol. Alternatively the separation of diastereoisomers may be most conveniently achieved by crystallization from an opportune solvent (e.g. ethyl ether), as a free base or after the formation of a suitable salt (e.g. (+)-tartaric acid)). The alkylation of compounds of general formula (VI)
Figure imgf000045_0001
by alkylating agents of general formula (XI)
A~ R6
(Xl)
in which A is a suitable leaving group selected from the group consisting of halide (i.e. bromine, iodine, chlorine) and sulfonate ester
(i.e. tosylate, triflates, mesylate) provides compounds of general formula (I). This kind of reaction is largely described in literature under several different conditions, for instance, the reaction may be performed neat or in a suitable solvent selected from the group consisting of acetonitrile, DMF,
DMSO and tetrahydrofuran. The reaction typically proceeds at temperature range from 00C up to 1700C, for a time in the range of few minutes up to
72 hours. The reaction may be carried out under conventional heating (using an oil bath) or under microwave irradiation. The reaction may be conducted either in an open vessel or in a sealed tube.
Compounds of general formula (I) in Scheme 1 can be either considered as final products or can be further reacted to prepare other compounds of general formula (I). Thus, a moiety of Rl, R2, R3 or R6 group in general formula (I) could undergo reactions of oxidation, reduction or cleavage (e.g to remove a needed protecting group) to afford other final compounds of general formula (I).
The present invention also provides pharmaceutical compositions of compounds of general formula (I) and (VI) in admixture with one or more pharmaceutically acceptable carriers, for example those described in
Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N. Y.,
U.S.A.
Administration of the compounds of the present invention may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
Various solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention. Various liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
Formulations for vaginal administration can be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art. For topical administration the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches. For the treatment of the diseases of the respiratory tract, the compounds according to the invention are preferably administered by inhalation.
Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations. For administration as a dry powder, single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir. A diluent or carrier, generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form. The propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
The propellant-free inhalable formulations comprising the compounds of the invention may be in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers or by soft-mist nebulizers.
The compounds of the invention may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, corticosteroids and anticholinergic or antimuscarinic agents.
The dosages of the compounds of the invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound.
Advantageously, the compounds of formula (I) can be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day. When the compounds of formula (I) are administered by inhalation route, they are -preferably given at a dosage comprised between 0.001 and 500 mg/day, preferably between 0.1 and 200 mg/day.
The compounds of formula (I) may be administered for the prevention and/or treatment of any disease wherein M3 antagonists are active. Said disease include: diseases involving inflammation such as asthma and COPD, acute rhinitis; diseases involving the gastrointestinal tract such as peptic ulcer; diseases involving the cardiovascular system such as acute myocardial infarction; diseases involving the genitourinary tract such as renal colic; anticholinesterase and mushroom poisoning; uses in anesthesia; uses in ophthalmology.
They also include neurological and psychiatric disorders such as Parkinsonism and motion sickness.
Preferably, the compounds of formula (I) may be administered for the prevention and/or treatment of respiratory diseases such as from mild to acute severe conditions of asthma and COPD.
Other respiratory diseases include bronchitis, bronchiolitis, bronchiectasis, acute nasopharyngitis, acute and chronic sinusitis, maxillary sinusitis, pharyngitis, tonsillitis, laryngitis, tracheitis, epiglottitis, croup, chronic disease of tonsils and adenoids, hypertrophy of tonsils and adenoids, peritonsillar abscess, rhinitis, abscess or ulcer and nose, pneumonia, viral and bacterial pneumonia, bronchopneumonia, influenza, extrinsic allergic alveolitis, coal workers' pneumoconiosis, asbestosis, pneumoconiosis, pneumonopathy, respiratory conditions due to chemical fumes, vapors and other external agents, emphysema, pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis, postinflammatory pulmonary fibrosis, other alveolar and parietoalveolar pneumonopathy, idiopathic fibrosing alveolitis, Hamman-Rich syndrome, atelectasis, ARDS, acute respiratory failure, mediastinitis. The present invention will now be further described by the following examples.
I = intermediates
C = compounds
EXAMPLE 1
Preparation of (R)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)- acetate (Diastereoisomers 1 and 2 of C2)
of C2
Figure imgf000050_0002
Figure imgf000050_0001
Figure imgf000050_0003
diasteroisomer 2 of C2 Scheme 2
Preparation of 2-phenyl-2-(phenylamino)acetic acid (II): α-Bromophenylacetic acid (5.01 g, 23.2 mmol.) is dissolved in aniline (25 mL, 274 mmol) and the mixture reacted in a closed vessel under MW irradiation at 1200C for 5 min (LC-MS monitoring: complete conversion). Dichloromethane (DCM) (100 mL) is added to the reaction mixture and the resulting solid is filtered; 2M Na2CO3 (50 mL) is added to the solution, and the aqueous layer is washed with DCM (3x100 mL). The aqueous layer is acidified with 12N HCl (36 mL) and the title compound is recovered as racemic mixture by filtration (5.1 g, 97% yield, white solid). Preparation of (R)-quinuclidin-3-yI 2-phenyl-2-(phenylamino)- acetate (Diastereoisomers 1 and 2 of C2)
A solution of 2-phenyl-2-(phenylamino)acetic acid (II) (1.90 g, 8.41 mmol) in dioxane, is added with with a 4M solution of HCl in dioxane (5 mL) and the reaction is stirred at RT for 1 h; the solvent is evaporated under reduced pressure to obtain a white solid which is dissolved in dry THF (40 mL). DCC (2.12 g, 10.0 mmol), HOBt (1.33 g, 10.0 mmol) and 3(R)-quinuclidinol (3.10 g, 25.1 mmol) are added to the resulting solution and the mixture is stirred for 96 h at RT under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated, IN HCl (50 mL) is added to the resulting crude and the aqueous layer is washed with EtOAc (2x100 mL); a saturated solution Of NaHCO3 is added to the aqueous layer (pH=7- 8) and the desired compound is extracted with DCM. The resulting crude is purified by flash chromatography (DCM/MeOH=95/5, 0.1% NH3 (aq.)) recovering diastereoisomer 1 of C2 as a white solid (0.8 g; 28% yield, single diastereoisomer), and subsequently diastereoisomer 2 of C2 as a white solid (0.4 g, 14% yield, single diastereoisomer). Diastereoisomer 1 of C2 (80 mg) is further purified by preparative
LC-MS to obtain 55.3 mg of a pale yellow oil (TFA salt).
Diastereoisomer 2 of C2 (65 mg) is further purified by preparative LC-MS to obtain 28.3 mg of a pale yellow oil (TFA salt).
Diastereoisomer 1 of C2: 1H NMR (300 MHz, DMSO-d6) ppm: 9.38 (br. s., IH), 7.50 - 7.72 (m,
2H), 7.26 - 7.50 (m, 3H), 6.98 - 7.25 (m, 2H), 6.68 - 6.83 (m, 2H), 6.52 - 6.68 (m, IH), 5.34 (s, IH), 4.92 - 5.18 (m, IH), 3.57 - 3.67 (m, IH), 3.05 - 3.33 (m, 3H), 2.57 - 2.81 (m, 2H), 2.08 - 2.30 (m, IH), 1.63 - 1.94 (m, 4H);
LC-MS (ESI POS): 337.3 (MH+); [α]D= -32.0° (c=0.5, MeOH).
Diastereoisomer 2 of C2:
1H NMR (300 MHz, DMSO-d6) ppm: 9.49 (br. s., IH), 7.48 - 7.64 (m, 2H), 7.25 - 7.48 (m, 3H), 7.00 - 7.15 (m, 2H), 6.66 - 6.78 (m, 2H), 6.52 - 6.65 (m, IH), 5.30 (s, IH), 4.94 - 5.16 (m, IH), 3.54 - 3.76 (m, IH), 3.03 - 3.28 (m, 5H), 2.03 (br. s., IH), 1.65 - 1.93 (m, 2H), 1.33 - 1.65 (m, 2H);
LC-MS (ESI POS): 337.3 (MH+);
[α]D= 2.4° (c=0.5, MeOH).
The compounds listed in Table 1 are obtained by LC-MS purification as previously described for C2, starting from the suitable commercially available 2-bromo-phenylacetic acid derivatives and anilines.
Table 1
Figure imgf000052_0001
Figure imgf000053_0001
EXAMPLE 2
Alternative preparation of (R)-quinuclidin-3-yl 2-phenyl-2- (phenylamino)-acetate (Diastereoisomers 1 and 2 bf C2):
A solution of 2-phenyl-2-(phenylamino)acetic acid (II) (3.40 g, 14.9 mmol) in THF (600 mL), is added with with DCC (4.02 g, 19.4 mmol),
HOBt (3.06 g, 19.44 mmol) and 3(R)-quinuclidinol (3.80 g, 29.9 mmol). The resulting mixture is stirred for 16 h at RT (LC-MS monitoring: complete conversion). The solvent is evaporated, the residue is taken up with EtOAc and the insoluble is filtered off. The clear solution is washed with IM K2CO3 and then with brine, dried over Na2SO4, filtered and evaporated to dryness.
The resulting crude is purified by flash chromatography (DCM/MeOH=95/5,
0.1% NH3 (aq.)) recovering first diastereoisomer 1 of C2 as a white solid
(1.13 g, 22.5% yield, single diastereoisomer), and subsequently diastereoisomer 2 of C2 as a white solid (0.69 g, 13.7% yield, single diastereoisomer).
Diastereoisomer 1 of C2:
1H NMR (300 MHz, DMSO-J6) ppm: 7.48 - 7.59 (m, 2 H), 7.26 - 7.46 (m,
3 H), 7.02 - 7.14 (m, 2 H), 6.67 - 6.79 (m, 2 H), 6.51 - 6.64 (m, 1 H), 6.27 (d, 1 H),
5.26 (d, 1 H), 4.61 - 4.78 (m, 1 H), 2.96 (ddd, 1 H), 2.55 - 2.67 (m, 3 H), 2.16 - 2.37 (m, 1 H), 2.06 (d, 1 H), 1.79 - 1.94 (m, 1 H), 1.59 - 1.76 (m, 1 H), 1.35 - 1.59 (m, 2 H), 1.20 - 1.34 (m, I H);
LC-MS (ESI POS): 337.04 (MH+);
[α]D= -44.6 (c=0.25 MeOH).
Diastereoisomer 2 of C2:
1H NMR (300 MHz, DMSO-^6) ppm: 7.48 - 7.60 (m, 2 H), 7.24 - 7.43 (m, 3 H), 6.97 - 7.14 (m, 2 H), 6.66 - 6.78 (m, 2 H), 6.51 - 6.66 (m, 1 H), 6.26 (d, 1 H), 5.24 (d, 1 H), 4.62 - 4.81 (m, 1 H), 3.08 (ddd, 1 H), 2.54 - 2.70 (m, 5 H), 1.64 - 1.79 (m, 1 H), 1.32 - 1.64 (m, 2 H), 1.16 - 1.32 (m, 1 H), 0.93 - 1.16 (m, 1 H);
LC-MS (ESI POS): 337.04 (MH+);
[α]D= +27.6 (c= 0.25 MeOH)
EXAMPLE 3
Alternative preparation of (R)-phenyl-phenylamino-acetic acid (R)- (l-aza-bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomers 1 of C2)
Figure imgf000054_0001
HCI dioxane
Figure imgf000054_0002
Figure imgf000054_0003
diasteroisomers 1 of C2 I7
Scheme 3 Preparation of (S)-methyl 2-(methyIsuIfonyloxy)-2-phenyIacetate (15):
A solution of (S)-methyl 2-hydroxy-2-phenylacetate (20.0 g, 120 mmol) in DCM (240 mL) maintained at 00C under N2 flowstream, is added with mesylchloride ( 1 1.2 mL, 144 mmol) and TEA (20.1 mL, 144 mmol) and the mixture is stirred at RT for 1 h (UPLC-MS monitoring: complete conversion). The mixture is cooled to 00C, 0.1N HCl (240 mL) is added and the desired compound is extracted with DCM (2x200 mL). The combined DCM phases are dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is purified by filtration through a silica bed eluting with DCM, obtaining 22.4 g of the title compound as white solid (76% yield).
Preparation of (R)-methyl 2-phenyI-2-(phenylamino)acetate (16): Aniline (16.8 mL, 184 mmol) is added to a solution of (S)-methyl 2- (methylsulfonyloxy)-2-phenylacetate (15) (22.4 g, 92.0 mmol) in CH3CN (50 mL). The mixture is heated under MW irradiation at 1200C for 5 min (UPLC- MS monitoring: complete conversion). The resulting crude is partitioned between EtOAc (200 mL) and IN HCl (200 mL) and the aqueous phase is extracted with EtOAc (3x200 mL). The combined organic layers are dried over Na2SO4, filtered and evaporated under vacuum to obtain 20.3 g of a pale yellow solid (92% yield), which is used in the next step without further purification. Preparation of (R)-2-phenyl-2-(phenylamino)acetic acid (17): 12N HCl (85 mL) is added to a solution of (R)-methyl 2-phenyl-2- (phenylamino)acetate (16) (20.3 g, 84.0 mmol), in dioxane (85 mL) and the mixture is heated at 700C for 18 h (UPLC-MS monitoring: complete conversion). The dioxane is evaporated, the mixture is cooled to O0C and the resulting solid is collected by filtration to obtain 19. Ig of intermediate 17 as a white solid (99% yield).
Preparation of (R)-((R)-quinuclidin-3-yl) 2-phenyl-2-
(phenylamino)acetate) (Diastereoisomers 1 of C2): (R)-2-Phenyl-2-(phenylamino)acetic acid (17) (6.50 g, 28.7 mmol), is dissolved in dry THF (140 mL) under inert atmosphere. 3S-Quinuclidinol (4.0 g, 31.6 mmol), triphenylphosphine (8.90 g, 43.0 mmol) and diethyl azodicarboxylate (6.8 mL, 43.0 mmol) are added and the resulting mixture is refluxed for 30 min (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between water (100 mL) and EtOAc (100 mL). The aqueous phase is further extracted with EtOAc (3x100 mL). The combined organic layers are dried over Na2SO4, filtered and evaporated under vacuum. The resulting crude is purified by flash chromatography (DCM/MeOH=95/5) recovering 8.7 g of diastereoisomer 1 of compound C2 as a pale yellow solid (90% yield, single diastereoisomer).
Diastereoisomer 1 of C2:
1H NMR (300 MHz, DMSO-J6) ppm: 7.49 - 7.58 (m, 2 H) 7.25 - 7.47 (m, 3 H)
7.00 - 7.12 (m, 2 H) 6.66 - 6.78 (m, 2 H) 6.51 - 6.63 (m, 1 H) 6.27 (d, 1 H) 5.20 - 5.31 (m, 1 H) 4.62 - 4.73 (m, 1 H) 2.95 (ddd, 1 H) 2.53 - 2.68 (m, 3 H) 2.17 - 2.34 (m, 1 H)
2.01 - 2.13 (m, 1 H) 1.83 - 1.93 (m, 1 H) 1.38 - 1.71 (m, 3 H) 1.17 - 1.34 (m, 1 H)
LC-MS (ESI POS): 337.2 (MH+). EXAMPLE 4
Preparation of (R)-quinuclidin-3-yl 2-(3-fluorophenyl)-2-(3- fluorophenylamino)acetate (Diastereoisomer 1 and 2 of C12)
Figure imgf000056_0001
18 19
,NH,
Figure imgf000056_0002
diastereoisomer 1 and 2 of C12 111 110
Scheme 4 Preparation of ethyl 2-(3-fluorophenyl)acetate (18):
A solution of 3 -fluorophenyl acetic acid (10.0 g, 64.9 mmol) in ethanol (300 mL), is added with a catalytic amount of H2SO4 (98%, 1 mL) and the mixture reacted for 12 h at 1000C (LC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between EtOAc and water; the organic layer is separated and dried over Na2SO4 to obtain 10.1 g of (18) as a white solid (85% yield).
Preparation of ethyl 2-bromo-2-(3-fIuorophenyI)acetate (19):
A solution of ethyl 2-(3-fluorophenyl)acetate (18) (10.1 g, 55.0 mmol) in
CCl4 (250 mL), is added with NBS (9.70 g, 55.0 mmol) and the mixture refluxed for 2 h at 800C (LC-MS monitoring: complete conversion). The solvent is evaporated and the resulting crude is dissolved in DCM and purified by filtration on a silica bed to obtain 7.80 g of (19) as a colorless oil (54% yield).
Preparation of ethyl 2-(3-fluorophenyI)-2-(3-fluorophenylamino)- acetate (110):
A solution of ethyl 2-bromo-2-(3-fluorophenyl)acetate (19) (1.80 g, 6.84 mmol) in 3-fluoroaniline (6.50 mL, 68.0 mmol) is heated at 1000C for 5 min under MW irradiation (LC-MS monitoring: complete conversion). The solvent is evaporated and the resulting crude is purified by flash chromatography
(Hexane/EtOAc=9/l) to obtain 2.00 g of 110 as a yellow oil (99% yield).
Preparation of 2-(3-fluorophenyI)-2-(3-fluorophenylamino)acetic acid (111):
A solution of ethyl 2-(3-fluorophenyl)-2-(3-fluorophenylamino)-acetate (2.00 g, 6.81 mmol) in THF/H2O (1 : 1 mixture, 10 mL), is added with LiOH (816 mg, 34.0 mmol) and the mixture is reacted for 2 h at RT (LC-MS monitoring: complete conversion). IN HCl (15 mL) is added and the desired compound is extracted with EtOAc. The resulting crude is purified by flash chromatography (Hexane/EtOAc=l/l) to obtain 1.79 g of Il 1 as a pale yellow solid (99% yield).
Preparation of (R)-quinuclidin-3-yl 2-(3-fluorophenyl)-2-(3- fluorophenylamino)acetate (Diastereoisomer 1 and 2 of C12):
A solution of 2-(3-fluorophenyl)-2-(3-fluorophenylamino)acetic acid
(11 1) (1.79 g, 6.80 mmol) in dioxane (70 mL), is added with a 4M solution of
HCl in dioxane (5 mL). The reaction is stirred at RT for 1 h, then the solvent is evaporated under reduced pressure to obtain a white solid. The compound is dissolved in dry THF (70 mL) and DCC (1.71 g, 8.20 mmol), HOBt (1.10 g,
8.20 mmol) and 3(R)-quinuclidinol (2.60 g, 20.4 mmol) are added. The reaction is stirred at RT for 96h under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between EtOAc and water; the organic layer is separated, dried over Na2SO4, filtered and evaporated to dryness. The crude is purified by flash chromatography (DCM/MeOH=97/3) recovering first 150 mg of diastereoisomer 1 of C51 as pale yellow solid (6% yield, single diastereoisomer) and subsequently 830 mg of mixture of diastereoisomers 1 and 2 of C12 as a pale yellow oil (32% yield, mixture of diastereoisomers).
Diastereoisomer 1 of C 12 (80 mg) is further purified by preparative LC-MS to obtain 53.0 mg of a pale yellow oil (TFA salt). Diastereoisomer 1 of C 12
1H NMR (300 MHz, DMSO-d6) ppm: 9.48 (br. s., 1 H), 7.31 - 7.58 (m, 3 H), 7.15 - 7.26 (m, 1 H), 7.10 (td, 1 H), 6.77 (d, 1 H), 6.47 - 6.65 (m, 2 H), 6.27 - 6.47 (m, 1 H), 5.48 (d, 1 H), 4.95 - 5.20 (m, 1 H), 3.63 (ddd, 1 H), 3.07 - 3.31 (m, 3 H), 2.74 - 2.91 (m, 2 H), 2.16 - 2.33 (m, 1 H), 1.65 - 1.95 (m, 4 H); LC-MS (ESI POS): 373.2 (MH+); [α]D= -37.80° (c=0.2, MeOH). Mixture of diastereoisomers 1 and 2 of C 12
IH NMR (300 MHz, DMSO-d6) ppm: 9.58 (br. s., 1 H), 7.31 - 7.58 (m, 3 H), 7.15 - 7.26 (m, 1 H), 7.10 (td, 1 H), 6.77 (d, 1 H), 6.47 - 6.65 (m, 2 H), 6.27 - 6.47 (m, 1 H)5 5.44 (d, 1 H), 4.95 - 5.20 (m, 1 H), 3.67 (ddd, 1 H), 3.07 - 3.31 (m, 3 H), 2.74 - 2.91 (m, 2 H), 2.05 (m, 1 H), 1.65 - 1.95 (m, 4 H); LC-MS (ESI POS): 373.2 (MH+). EXAMPLE 5
Preparation of (R)-l-methylpiperidin-4-yI-2-phenyl-2- (phenylamino)-acetate (C13)
Figure imgf000059_0001
11 C13
Scheme 5 A solution of 2-phenyl-2-(phenylamino)acetic acid (II) (234 mg, 0.91 mmol) in dioxane, is added with a 4M solution of HCl in dioxane (5 mL) and the reaction is stirred at RT for 1 h; the solvent is evaporated under reduced pressure to obtain a white solid which is dissolved in dry THF (10 mL). DCC (222 mg, 1.12 mmol), HOBt (144 mg, 1.14 mmol) and N-methyl-4-piperidinol (307 mg, 2.71 mmol) are added and the mixture is stirred for 96h at RT under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between DCM and water; the organic layer is separated and dried over Na2SO4. The crude compound is purified by preparative LC-MS and the collected fractions are portioned between 2M K2CO3 and EtOAc. The 'organic phase is dried over Na2SO4, filtered and evaporated to dryness to obtain 20.6 mg of the title compound as a white solid (7% yield, racemic mixture).
1H NMR (300 MHz, DMSO-d6) ppm: 7.45 - 7.60 (m, 2H), 7.20 - 7.45 (m, 3H), 6.95 - 7.17 (m, 2H), 6.69 (d, 2H), 6.47 - 6.63 (m, IH), 6.23 (d, IH), 5.20 (d, IH), 4.71 (tt, IH), 2.34 - 2.48 (m, IH), 2.11 - 2.25 (m, 2H), 2.09 (s, 3H), 1.94 - 2.08 (m, IH), 1.71 - 1.90 (m, IH), 1.51 - 1.71 (m, 2H), 1.29 - 1.51 (m, IH); LC-MS (ESI POS): 325.2 (MH+). EXAMPLE 6
Preparation of (R)-l-methyIpyrrolidin-4-yl-2-phenyI-2-
(phenylamino)acetate (C14)
Figure imgf000060_0001
Scheme 6
A mixture of 2-phenyl-2-(phenylamino)acetic acid (II) (200 mg, 0.88 mmol), DCC (218 mg, 1.05 mmol), HOBt (142 mg, 1.05 mmol) and (R)- I- methylpyrrolidin-3-ol (289 uL, 2.64 mmol) in dry THF (10 mL) is stirred at room temperature overnight under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated and the residue is taken up with aq. HCl (pH about 2) and washed with DCM. The aqueous phase is basified with NaHCO3 and extracted with DCM (three times). The organic layers are combined, dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is first purified by flash chromatography (DCM to DCM/MeOH=95/5) and then by preparative LC-MS. The purified compound is partitioned between sat. NaHCO3 and DCM, the organic phase is dried over Na2SO4, filtered and evaporated under vacuum to give 90.8 mg of the title compound as brown oil (33% yield, mixture of diastereoisomers).
1H NMR (300 MHz, CHLOROFORM-d) ppm
Diastereoisomer 1 of C 14: 7.46 - 7.57 (m, 2 H), 7.29 - 7.45 (m, 3 H), 7.08 - 7.21 (m, 2 H), 6.67 - 6.81 (m, 1 H), 6.50 - 6.67 (m, 2 H), 5.20 - 5.37 (m, 1 H), 5.12 (d, 1 H), 4.84 - 5.05 (m, 1 H), 2.46 - 3.04 (m, 4 H), 2.44 (s, 3 H), 2.10 - 2.26 (m, 1 H), 1.63 - 1.82 (m, 1 H). Diastereoisomer 2 of C14: 7.46 - 7.57 (m, 2 H), 7.29 - 7.45 (m, 3 H), 7.08 - 7.21 (m, 2 H), 6.67 - 6.81 (m, 1 H), 6.50 - 6.67 (m, 2 H), 5.20 - 5.37 (m, 1 H), 5.12 (d, 1 H), 4.84 - 5.05 (m, 1 H), 2.46 - 3.04 (m, 4 H), 2.33 (s, 3 H), 2.26 - 2.40 (m, 1 H), 1.86 - 2.05 (m, 1 H);
LC-MS (ESI POS): 31 1.3 (MH+).
The compounds listed in Table 2 are prepared as previously described for diastereoisomers 1 and 2 of C 14, coupling acid Il with the commercially available (S)-l-methylpyrrolidin-3-ol and (R)-l-methylpiperidin-3-ol respectively.
Table 2
Figure imgf000061_0001
(continue)
Figure imgf000062_0001
EXAMPLE 7
Preparation of 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenyl-2- (phenylamino)acetate (CIl)
Figure imgf000062_0002
11 C17
Scheme 7
A mixture of 2-phenyl-2-(phenylamino)acetic acid Il (250 mg, 0.90 mmol), EDC (255 mg, 1.35 mmol), HOBt (245 mg, 1.80 mmol) and 8-methyl-8-azabicyclo[3.2.1]octan-3-ol (380 mg, 2.71 mmol) in dry DMF (10 mL) is heated under microwave irradiation at 1000C for 1 h (LC-MS monitoring: complete conversion). The reaction is concentrated under reduced pressure and the residue is partitioned between EtOAc and water. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is purified by preparative HPLC. The collected compound is partitioned between IN NaHCO3 and DCM, the organic phase is separated dried over Na2SO4, filtered and evaporated under vacuum to give 20.1 mg of the title compound as a colorless oil (7% yield, mixture of diastereoisomers). II1iiH NMR (300 MHz, CHLOROFORM-d) ppm: 7.45 - 7.57 (m, 2 H), 7.29 - 7.45 (m, 3 H), 7.04 - 7.21 (m, 2 H), 6.65 - 6.77 (m, 1 H), 6.51 - 6.65 (m, 2 H), 5.02 - 5.13 (m, 2 H), 5.00 (d, 1 H), 3.07 - 3.30 (m, 1 H), 2.81 - 3.07 (m, 1 H), 2.28 (s, 3 H), 2.19 - 2.27 (m, 1 H), 1.84 - 2.18 (m, 3 H), 1.70 - 1.82 (m, 2 H), 1.45 (d, I H), 1.17 (ddd, 1 H);
LC-MS (ESI POS): 351.3 (MH+).
Cl 8 listed in Table 3 is prepared as previously described for C 17.
Table 3
Figure imgf000063_0002
EXAMPLE 8
Preparation of (S)-((R)-quinuclidin-3-yl) 2-amino-3- phenylpropanoate di-trifluoroacetate (Diastereoisomer 1 of C20)
Figure imgf000063_0001
119 Diasteroisomers 1 of C20
Scheme 8
Preparation of (S)-((R)-quinuclidin-3-yl) 2-(tert- butoxycarbonylamino)-3-phenylpropanoate (119)
A solution of (S)-2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid
(1.03 g, 3.81 mmol) in THF (70 mL), is added with DCC (1.03 g, 4.91 mmol),
HOBt (660 mg, 4.90 mmol) and 3(R)-quinuclidinol (1.18 g, 9.48 mmol) and the resulting mixture is stirred for 12hr at RT under nitrogen flowstream (LC-
MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between EtOAc (100 mL) and 2M K2CO3 (50 mL); the organic layer is separated, washed with brine and dried over Na2SO4. The resulting crude is purified by flash chromatography (DCM/MeOH=95/5, 0.1% NH3 (aq.)) to obtain 1.12 g of 119 (80% yield).
Preparation of (S)-(R)-quinuclidin-3-yI) 2-amino-3- phenylpropanoate di-trifluoroacetate (Diastereoisomer 1 of C20)
A solution of 119 (220 mg, 0.58 mmol) in DCM (5 mL), is added with trifluoroacetic acid (0.50 mL, 4.41 mmol) and the mixture stirred at RT overnight. The solvent is evaporated and the resulting crude is purified by preparative LC-MS to obtain 59.4 mg of diastereoisomer 1 of C20 as a brown gummy solid (56% yield, di-trifluoroacetate salt, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6) ppm: 9.81 (br. s., IH), 8.52 (br. s., 3H), 7.24 - 7.41 (m, 5H), 5.02 - 5.09 (m, IH), 4.20 - 4.46 (m, IH), 3.60 - 3.73 (m, IH), 3.00 - 3.33 (m, 7H), 2.01 (br. s., IH), 1.79 - 1.95 (m, IH), 1.76 (br. s., IH), 1.60 (br. s., 2H);
LC-MS (ESI POS): 275.3 (MH+).
Diastereoisomer 2 of C20 listed in Table 4 is prepared as previously described for diastereoisomer 1 of C20, starting from the commercially available (R)-2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid. Table 4
Figure imgf000065_0002
EXAMPLE 9
Preparation of (S)-3-phenyl-2-phenylamino-propionic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (Diastereoisomers 1 of C22)
Figure imgf000065_0001
121 Diasteroisomer 1 of C22
Scheme 9 Preparation of 3-phenyl-2-(phenylamino)propanoic acid (121) A solution of (S)-2-amino-3-phenylpropanoic acid (1.52 g, 9.12 mmol) in a DMF/H2O mixture (10/1, 16.5 mL) maintained under nitrogen flowstream, is added with iodobenzene (1.00 mL, 9.12 mmol), dichlorobis(tri-o- tolylphosphine)palladium(II) (357 mg, 0.42 mmol) CuI (86.4 mg, 0.42 mmol), K2CO3 (1.21 g, 9.12 mmol), trimethylbenzylammonium chloride (286 mg, 1.51 mmol) and triethylamine (TEA) (2.50 mL, 18.0 mmol) and the mixture stirred for 24hr at 1000C under nitrogen flowstream (LC-MS monitoring: complete conversion). The reaction mixture is partitioned between EtOAc and water; IN HCl is added until pH =1 and the organic layer is separated, washed with brine and dried over Na2SO4. The resulting crude is purified by flash chromatography (DCM/MeOH=99/l) and 1.21 g of 121 is obtained (56% yield). Preparation of (S)-3-phenyl-2-phenylamino-propionic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomers 1 of C22)
A solution of 3-phenyl-2-(phenylamino)propanoic acid (121) (1.21 g, 5.01 mmol) in dioxane, is added with a 4M solution of HCl in dioxane (5 mL) and the reaction is stirred at RT for 1 hr; the solvent is evaporated under reduced pressure to obtain a white solid which is dissolved in dry THF (70 mL). DCC (1.22 g, 6.01 mmol), HOBt (0.8 g, 6.0 mmol) and 3(R)-quinuclidinol (1.31 g, 10.1 mmol) are added to the resulting solution and the mixture stirred for 24hr at RT under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated. IN HCl (20 mL) is added to the resulting crude and the aqueous layer is washed with EtOAc (2x50 mL); NaHCO3 is added to the aqueous layer (pH=7-8) and the product is extracted with DCM and dried over Na2SO4, to obtain 530 mg (35% yield) of diastereoisomer 1 of C22, which is further purified by preparative LC-MS to obtain the title product as a brown oil (mixture of diastereoisomers that contains 20% of diastereoisomer 2 of C22, TFA salt).
1H NMR (300 MHz, DMSO-d6) ppm: 9.58 (br. s., IH), 7.19 - 7.38 (m, 5H), 6.91 - 7.15 (m, 2H), 6.55 - 6.68 (m, 3H), 4.94 (ddd, IH), 4.34 (t, IH), 3.62 (ddd, IH), 2.92 - 3.25 (m, 7H), 1.63 - 1.95 (m, 3H), 1.36 - 1.63 (m, 2H); LC-MS (ESI POS): 351.3 (MH+). Diastereoisomer 2 of C22 listed in Table 5 is obtained as previously described for diastereoisomer 1 of C22, starting from the commercially available (R)-2-amino-3-phenylpropanoic acid. Table 5
Figure imgf000067_0001
EXAMPLE 10 Preparation of (R)-quinuclidin-3-yl 2-(benzylamino)-2- phenylacetate (C24)
Figure imgf000067_0002
123 C24
Scheme 10 Preparation of 2-(benzylamino)-2-phenylacetic acid (123): A solution of methyl 2-(benzylamino)-2-phenylacetate (1.00 g,
3.90 mmol) in THF (90 mL) and IN NaOH (10 niL) is stirred at room temperature overnight (LC-MS monitoring: complete conversion). The solvent is removed under reduced pressure and the crude is partitioned between EtOAc and water. The aqueous phase is acidified with cone. HCl (pH about 3) and then extracted with EtOAc (three times). The organic phase is dried over Na2SO4, filtered and evaporated to dryness to give the title compound as a white solid (940 mg, quantitative yield), which is used in the next step without any further purification.
Preparation of (R)-quinuclidin-3-yl 2-(benzylamino)-2- phenylacetate (Diastereoisomers 1 and 2 of C24): A mixture of 2-(benzylamino)-2-phenylacetic acid (123) (0.94 g, 3.90 mmol), DCC (0.97 g, 4.70 mmol), HOBt (0.63 g, 4.07 mmol) and 3(R)- quinuclidinol (1.51 g, 11.7 mmol) in dry THF (30 mL) is stirred at room temperature overnight under nitrogen flowstream (LC-MS monitoring: complete conversion). The solvent is evaporated and the residue is taken up with EtOAc and washed twice with water. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is purified by flash chromatography
(DCM/MeOH=98/2, 0.2%NH3(aq.) to 95/5, 0.5%NH3(aq.)) to give a mixture of diastereoisomers 1 and 2 of C24 (231 mg, 52% yield, mixture of diastereoisomers).
The mixture of diastereoisomers 1 and 2 of C24 (55 mg) is further purified by preparative HPLC.
1H NMR (300 MHz, DMSO-d6 +Na2CO3) ppm: 7.20 - 7.45 (m, 1 1 H),
4.55 - 4.79 (m, 1 H), 4.35 (s, 1 H), 3.67 (d, 2 H), 2.85 - 3.14 (m, 2 H),
2.56 - 2.71 (m, 2 H), 2.31 - 2.46 (m, 1 H), 2.07 - 2.23 (m, 1 H), 1.82 - 1.93 (m, 1 H), 1.32 - 1.79 (m, 4 H); LC-MS (ESI POS): 351.2 (MH+).
EXAMPLE 11
Preparation of (R)-quinuclidin-3-yl 2-(cyclopentyIamino)-2- phenylacetate di-trifluoroacetate (C26)
Figure imgf000068_0001
2HCl
C25 C26
Scheme 11 Preparation of (R)-quinuclidin-3-yl 2-amino-2-phenylacetate di- hydrochloride (C25):
A mixture of 2-(tert-butoxycarbonylamino)-2-phenylacetic acid (0.90 g,
4.18 mmol), HOBt (0.68 g, 12.5 mmol), DCC (1.29 g, 6.27 mmol) and 3(R)-quinuclidinol (1.59 g, 12.5 mmol) in dry THF (50 mL) is stirred at room temperature for 16 hours (LC-MS monitoring: complete conversion). The solvent is removed under reduced pressure, the residue is taken up with EtOAc and washed twice with 2M K2CO3. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The compound is triturated with hexane to give (R)-quinuclidin-3-yl 2-(tert-butoxycarbonylamino)-2-phenylacetate as a white solid (1.46 g; 97% yield, mixture of diastereoisomers). This compound is dissolved in DCM (50 mL) and 4N HCl in dioxane (5 mL) is added. The reaction is stirred at room temperature for 1 hour (LC-MS monitoring: complete conversion) and then solvent is separated. The gummy solid is triturated with hexane to give C25 as a white solid (1.26 g, 94% yield, di hydrochloride, mixture of diastereoisomers).
Preparation of (R)-quinuclidin-3-yl 2-(cyclopentylamino)-2- phenylacetate di-trifluoroacetate (C26):
(R)-Quinuclidin-3-yl 2-amino-2-phenylacetate (C25) (200 mg, 0.60 mmol) is dissolved in dry DCM (10 mL) and treated with sodium triacetoxyborohydride (508 mg, 2.40 mmol). The reaction is stirred at room temperature for 30 minutes and then cyclopentanone (106 uL, 1.20 mmol) is added and the reaction is stirred at room temperature for additional 16 hours
(LC-MS monitoring: complete conversion). The reaction is diluted with DCM and washed twice with IN NaOH, the organic layer is dried over Na2SO4, filtered and evaporated to dryness. The crude compound is purified by preparative HPLC to give C26 as a white solid (53.1 mg, 16% yield, di trifluoroacetate salt, mixture of diastereoisomers). 1H NMR (300 MHz, DMSO-d6) ppm: 10.02 (br. s., 2 H), 9.75 (br. s., 1 H), 7.43 - 7.76 (m, 5 H), 5.24 - 5.49 (m, 1 H), 5.01 - 5.24 (m, 1 H), 3.51 - 3.79 (m, 1 H), 3.12 - 3.37 (m, 4 H), 2.93 - 3.12 (m, 1 H), 2.75 - 2.94 (m, 1 H), 2.20 - 2.39 (m, 1 H), 1.78 - 2.14 (m, 4 H), 1.61 - 1.77 (m, 5 H), 1.31 - 1.57 (m, 3 H);
LC-MS (ESI POS): 329.2 (MH+).
C27 listed in Table 6 is obtained as previously described for C26, using cyclohexanone instead of cyclopentanone.
Table 6
Yield and
Compound Structure Analytical appearance
LC-MS (ESI POS): 343.2 (MH+)
1 IH NMR (300 MHz, DMSO-d6)
24% yield ppm : 9.47 - 9.79 (m, 3 H), 7.36 -
| YY [si 7.85 (m, 5 H), 5.37 - 5.54 (m, 1
C27 N 5.10 - 5.20 (m, 1 H), 3.56 -
2 TFA White solid H), 3.82 (m, 1 H), 2.68 - 3.28 (m, 5
H), 1.97 - 2.33 (m, 3 H), 1.66 -
Mixture of 1.94 (m, 5 H), 1.56 (br. s., 2 H), diastereoisomers 1.29 (br. s., 2 H), 1.12 (br. S ., 3 H)
EXAMPLE 12
Preparation of ((4-chloro-phenylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C29)
Figure imgf000070_0001
Scheme 12 Preparation of (4-chloro-phenyiamino)-phenyl-acetic acid (128):
A solution of α-bromophenylacetic acid (1.00 g, 4.65 mmol) in acetonitrile (20 mL), is added with 4-chloro-phenylamine (1.18 g, 9.30 mmol) and the mixture reacted in a closed vessel under MW irradiation at 1000C for 1 h (UPLC-MS monitoring: complete conversion). Solvent is evaporated and residue is partitioned between EtOAc and IN HCl. The organic phase is dried over Na2SO4, filtered and evaporated to dryness to get intermediate 176 as a yellow solid (0.57 g; 47% yield). Preparation of ((4-chloro-phenylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C29):
A solution of (4-chloro-phenylamino)-phenyl-acetic acid (128) (574 mg, 2.20 mmol) in dry THF (20 mL), is added with DCC (543 mg, 2.64 mmol), HOBt (359 mg, 2.64 mmol) and 3(R)-quinuclidinol (558 mg, 4.40 mmol). The resulting mixture is stirred at RT overnight (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between EtOAc and 2M K2CO3. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is purified by flash chromatography (DCM/MeOH=99/l to 85/15) to obtain the title compound as a white solid (306 mg, 37% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.46 - 7.59 (m, 2 H), 7.22 - 7.45 (m, 3 H), 6.99 - 7.18 (m, 2 H), 6.65 - 6.80 (m, 2 H), 6.52 (d, 1 H), 5.28 (d, 1 H), 4.60 - 4.82 (m, 1 H), 3.04 (ddd, 1 H), 2.54 - 2.70 (m, 4 H), 2.03 - 2.36 (m, 1 H), 1.67 - 1.97 (m, 1 H), 1.36 - 1.68 (m, 2 H), 1.05 - 1.35 (m, 2 H); LC-MS (ESI POS): 371.1 (MH+).
The compounds listed in Table 7 are obtained as previously described for C29, starting from the suitable commercially available 2-bromo- phenylacetic acid derivatives and anilines. Table 7
Figure imgf000072_0001
(continue)
Figure imgf000073_0001
Figure imgf000074_0001
EXAMPLE 13
Preparation of 2-({[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]- phenyl-methyl}-amino)-benzoic acid methyl ester (C35)
Figure imgf000074_0002
134 C35
Scheme 13
Preparation of N-ethyl-N-isopropylpropan-2-amine 2-[(carboxy- phenyl-methyl)-amino]-benzoic acid methyl ester (134):
2-Bromo-2-phenylacetic acid (400 mg, 1.86 mmol), methyl 2-aminobenzoate (0.26 mL, 2.05 mmol), and N,N-diisopropylethylamine (DIPEA) (0.65 mL, 3.72 mmol) are dissolved in acetonitrile (8 mL). The resulting solution is heated under MW irradiation in a sealed vial at 100°C for 20 minutes. The mixture is evaporated and the crude residue is purified by flash chromatography (DCM/MeOH=97/3) affording intermediate 182 as a white solid (61 1 mg, 79% yield, DIPEA salt).
Preparation of 2-({[(R)-(l-aza-bicyclo[2.2.2]oct-3-yI)oxycarbonyl]- phenyl-methyl}-amino)-benzoic acid methyl ester (C35): N-Ethyl-N-isopropylpropan-2-amine 2-(2-(methoxycarbonyl)- phenylamino)-2-phenylacetate (134) (61 1 mg, 1.47 mmol), 2-(1H- benzo[d][l ,2,3]triazol- l-yl)-l , l ,3,3-tetramethylisouronium hexafluoro- phosphate(V) (559 mg, 1.47 mmol), and HOBT (226 mg, 1.47 mmol) are dissolved in THF (7 mL) and MeCN (3 mL). (R)-Quinuclidin-3-ol (375 mg, 2.95 mmol) is added and the mixture is stirred at RT for Ih. Solvents are evaporated, the residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated. The crude is purified by preparative HPLC and the collected fractions are evaporated, the residue is dissolved in EtOAc and washed with NaHCO3 and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated to afford compound the title compound as a colorless compound (95 mg, 16% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 8.56 - 8.92 (m, 1 H), 7.80 - 7.94 (m, 1 H), 7.46 - 7.58 (m, 2 H), 7.22 - 7.45 (m, 4 H), 6.31 - 6.78 (m, 2 H), 5.53 and 5.51 (d, 1 H), 4.47 - 4.87 (m, 1 H), 3.86 (s, 3 H), 3.07 and 2.97 (ddd, 1 H), 2.54 - 2.68 (m, 4 H), 0.95 - 2.34 (m, 6 H);
LC-MS (ESI POS): 395.3 (MH+). EXAMPLE 14
Preparation of (2-methoxy-phenylaraino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C37)
Figure imgf000076_0001
l36 C37
Scheme 14
Preparation of (2-methoxy-phenyIamino)-phenyl-acetic acid hydrochloride (136):
Ethyl 2-bromo-2-phenylacetate (500 mg, 2.06 mmol), 2-methoxyaniline (0.28 mL, 2.47 mmol) and DIPEA (0.47 ml, 2.67 mmol) are dissolved in acetonitrile (10 mL). The resulting solution is heated under microwave irradiation at 1000C for 30 minutes. DIPEA (47 ul, 0.27 mmol) and 2-methoxyaniline (28 uL, 0.25 mmol) are added and microwave heating is carried out for a further 15 minutes. Water (5 mL) and lithium hydroxide hydrate (259 mg, 6.17 mmol) are directly added to the reaction solution and the resulting mixture is vigorously stirred at RT for 1 hour. Acetonitrile is evaporated, the remaining water phase is cooled at 00C and 4M HCl in 1,4-dioxane is added until pH is about 1. The solid obtained is collected by filtration and washed with water. The solid-cake is recovered and dried under vacuum to obtain intermediate 184 as a brown solid (377 mg, 62% yield).
Preparation of (2-methoxy-phenylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yI) ester (C37):
PS-DCC (2.05 g, 2.57 mmol, loading: 1.25 mmol/g) is suspended in THF (15 mL) and shaken for few minutes. Then (2-methoxy-phenylamino)- phenyl-acetic acid hydrochloride (136) (377 mg, 1.28 mmol) and HOBT (393 mg, 2.57 mmol) are added. After 10 minutes, (R)-quinuclidin-3-ol (490 mg, 3.85 mmol) is added and the mixture is shaken at RT for 16 hours (Conversion complete by UPLC/MS-UV). PS-DCC is filtered off and the filtrate is evaporated to dryness. The residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated to afford the title compound as a yellow oil (548 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.45 - 7.55 (m, 2 H), 7.13 - 7.43 (m, 3 H), 6.78 - 6.93 (m, 1 H), 6.64 (m, 2 H), 6.29 - 6.51 (m, 1 H), 5.40 (d, 1 H), 5.31 (d, 1 H), 4.58 - 4.85 (m, 1 H), 3.84 (s, 3 H), 2.91 - 3.14 (m, 1 H), 2.54 - 2.72 (m, 3 H), 1.95 - 2.47 (m, 2 H), 0.98 - 1.92 (m, 5 H);
LC-MS (ESI POS): 367.3 (MH+).
EXAMPLE 15
Preparation of phenyl-o-methylphenylamino-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C39)
Figure imgf000077_0001
Scheme 15
Preparation of phenyl-o-methyl phenylamino-acetic acid hydrochloride (138):
Ethyl 2-bromo-2-phenylacetate (0.28 mL, 1.64 mmol), orto-toluidine (0.26 mL, 2.47 mmol) and DIPEA (0.43 mL, 2.47 mmol) are dissolved in acetonitrile (5 mL) and stirred under MW irradiation at 1000C for Ih (Conversion complete by UPLC/MS-UV). Lithium hydroxide hydrate (207 mg, 4.94 mmol) and water (3 mL) are added and the mixture is stirred at RT for 16 hours. 4M HCl in dioxane is added until pH is about 1, then the solvents are evaporated, the residue is suspended in water, sonicated, cooled at 00C and the resulting solid is recovered by filtration and dried under vacuum to get intermediate 186 as a off-white solid (290 mg, 63% yield). Preparation of phenyl-o-methyl phenylamino-acetic acid (R)-(l-aza- bicyc!o[2.2.2]oct-3-yl) ester (C39):
PS-DCC (1.15 g, 1.44 mmol, loading: 1.25 mmol/g) is suspended in
THF (15 mL). Phenyl-o-methylphenylamino-acetic acid hydrochloride (138)
(200 mg, 0.72 mmol) and HOBT (221 mg, 1.44 mmol) are added, followed by (R)-quinuclidin-3-ol (275 mg, 2.16 mmol) and the mixture is shaken for 16 hours at RT. PS-DCC is filtered off and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed sequentially with water, sat. NaHCO3, water and brine. The organic layer is dried over Na2SO4, filtered and evaporated to give the title compound as a colorless oil (260 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.50 - 7.62 (m, 2 H), 7.25 - 7.46
(m, 3 H), 7.00 - 7.07 (m, 1 H), 6.82 - 6.98 (m, 1 H), 6.51 - 6.66 (m, 1 H), 6.30
- 6.49 (m, 1 H), 5.32 (d, 1 H), 5.10 (d, 1 H), 4.65 - 4.85 (m, 1 H), 2.85 - 3.16
(m, 1 H), 2.56 - 2.69 (m, 3 H), 2.23 (s, 3 H), 2.13 - 2.46 (m, 2 H), 0.95 - 1.97 (m, 5 H);
LC-MS (ESI POS): 351.2 (MH+).
EXAMPLE 16
Preparation of phenyl-(3-trifluoromethoxy-phenylamino)-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C41)
Figure imgf000079_0001
I4O C41 c heme 16
Preparation of phenyI-(3-trifluoromethoxy-phenylamino)-acetic acid hydrochloride (140):
Ethyl 2-bromo-2-phenylacetate (400 mg, 1.64 mmol), 3-(trifluoromethoxy)aniline (0.33 mL, 2.47 mmol), and DIPEA (0.43 mL, 2.47 mmol) are dissolved in acetonitrile (5 mL) and heated under MW irradiation at
1000C for Ih (Conversion complete by UPLC/MS-UV). Water (5 mL) and lithium hydroxide hydrate (207 mg, 4.94 mmol) are directly added and the resulting mixture is stirred at RT for Ih. Then 4M HCl in dioxane is added to pH 1 , the organic solvents are evaporated and the resulting crude oil is purified by filtration through a silica pad using DCM/MeOH= 9/1 as the eluent. Intermediate 188 is collected as a brown oil (569 mg, quantitative yield).
Preparation of phenyl-(3-trifluoromethoxy-phenylamino)-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C41):
PS-DCC (920 mg, 1.15 mmol, loading: 1.25 mmol/g) is suspended in THF (15 mL). Phenyl-(3-trifluoromethoxy-phenylamino)-acetic acid hydrochloride (140) (200 mg, 0.57 mmol) and HOBT (176 mg, 1.15 mmol) are added, followed by (R)-quinuclidin-3-ol (219 mg, 1.73 mmol) and the mixture is shaken for 16 hours at RT. PS-DCC is filtered off and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with water, sat. NaHCOβ, water and brine. The organic phase is dried over
Na2SO4, filtered and evaporated to give the title compound as a colorless oil
(206 mg, 85% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.26 - 7.62 (m, 5 H), 7.16 (t, 1 H), 6.79 (d, 1 H), 6.38 - 6.75 (m, 3 H), 5.34 (d, 1 H), 4.66 - 4.80 (m, 1 H), 2.91 - 3.24 (m, 1 H), 2.53 - 2.76 (m, 3 H), 1.97 - 2.39 (m, 2 H), 1.67 - 1.96 (m, 1 H), 0.99 - 1.67 (m, 4 H);
LC-MS (ESI POS): 421.2 (MH+).
EXAMPLE 17
Preparation of (3-ethyl-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicycIo[2.2.2]oct-3-yl) ester (C43)
Figure imgf000080_0001
142 C43
Scheme 17
Preparation of (3-ethyl-phenyIamino)-phenyl-acetic acid hydrochloride (142):
Ethyl 2-bromo-2-phenylacetate (0.29 mL, 1.64 mmol), 3-ethylaniline (0.31 mL, 2.47 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.43 mL,
2.47 mmol) are dissolved in acetonitrile (5 mL) and stirred under MW irradiation at 1000C for Ih (Conversion complete by UPLC/MS-UV). Lithium hydroxide hydrate (207 mg, 4.94 mmol) and water (3 mL) are added and the mixture is stirred at RT for 16 hours. 4M HCl in dioxane is added until pH 1 and the solvents are evaporated. The residue is suspended in water, sonicated, cooled at 00C and filtered under suction. The recovered white solid is dried under vacuum at 400C overnight (414 mg, 86% yield).
Preparation of (3-ethyl-phenyIaraino)-phenyI-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C43): PS-DCC (1097 mg, 1.371 mmol, loading: 1.25 mmol/g) is suspended in
THF (15 niL). HOBT (210 mg, 1.37 mmol), (3-ethyl-phenylamino)-phenyl- acetic acid hydrochloride (142) (200 mg, 0.68 mmol), and (R)-quinuclidin-3-ol (262 mg, 2.06 mmol) are added and the suspension is shaken at RT for 16h.
PS-DCC is filtered off and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with water, sat. NaHCO3, water and brine.
The organic phase is dried over Na2SO4, filtered and evaporated. The crude is purified by flash chromatography (DCM/MeOH=95/5) to obtain the title compound as a colorless oil (72 mg, 30% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.45 - 7.60 (m, 2 H), 7.21 - 7.47 (m, 3 H), 6.96 (t, 1 H), 6.56 - 6.66 (m, 1 H), 6.47 - 6.56 (m, 1 H), 6.38 - 6.47 (m, 1 H),
6.17 (d, 1 H), 5.16 - 5.39 (m, 1 H), 4.60 - 4.79 (m, 1 H), 2.89 - 3.16 (m, 1 H), 2.54
- 2.70 (m, 3 H), 2.45 (q, 2 H), 1.98 - 2.34 (m, 2 H), 1.66 - 1.96 (m, 1 H), 1.20 -
1.66 (m, 4 H), 1.11 (t, 3 H);
LC-MS (ESI POS): 365.3 (MH+).
EXAMPLE 18
Preparation of (3-acetylamino-phenylamino)-phenyI-acetic acid (R)- (l-aza-bicyclo[2.2.2]oct-3-yl) ester (C46)
Figure imgf000082_0001
Figure imgf000082_0003
Figure imgf000082_0002
Scheme 18
Preparation of (3-acetylamino-phenylamino)-phenyl-acetic acid ethyl ester (144):
N-(3-Aminophenyl)acetamide (371 mg, 2.47 mmol), ethyl 2-bromo-2- phenylacetate (0.29 mL, 1.64 mmol), and DIPEA (0.43 mL, 2.47 mmol) are dissolved in acetonitrile (5 mL). The reaction is heated under MW irradiation at 1000C for 30 minutes. Conversion complete by UPLC/MS-UV. Acetonitrile is evaporated and the crude residue is purified by flash chromatography
(DCM/EtOAc=8/2) to obtain intermediate 192 as a colorless oil (440 mg, 86% yield).
Preparation of (3-acetylamino-phenylamino)-phenyl-acetic acid hydrochloride (145):
(3-Acetylamino-phenylamino)-phenyl-acetic acid ethyl ester (144) (440 mg, 1.41 mmol) and lithium hydroxide hydrate (118 mg, 2.82 mmol) are dissolved in THF (5 mL) and water (3 mL). The reaction is stirred at RT for 2h. THF is evaporated, the resulting aqueous solution is cooled at 00C and IM HCl is added until pH is about 2. The precipitated is recovered by filtration, washed with cool water and dried under vacuum overnight to obtain intermediate 193 as a yellow solid (190 mg, 42% yield).
Preparation of (3-acetylamino-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C46):
PS-DCC (798 mg, 0.10 mmol, loading: 1.25 mmol/g) is suspended in dry THF (10 mL). (3-Acetylamino-phenylamino)-phenyl-acetic acid hydrochloride (145) (160 mg, 0.50 mmol), HOBT (153 mg, 0.10 mmol), and
(R)-quinuclidin-3-ol (190 mg, 1.50 mmol) are added and the mixture is shaken for 16 h at RT (Conversion complete by UPLC/MS-UV). PS-DCC is filtered off and washed with THF and then with EtOAc. The filtrate is evaporated, the resulting residue is taken up with EtOAc and washed with 5% NaHCO3, water and brine. The organic layer is separated, dried over Na2SO4, filtered and evaporated to afford the title compound as a yellow oil (196 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 9.62 (s, 1 H), 7.47 - 7.60 (m, 2 H), 7.25 - 7.47 (m, 3 H), 7.01 - 7.11 (m, 1 H), 6.96 (t, 1 H), 6.66 - 6.83 (m, 1 H), 6.36 - 6.46 (m, 1 H), 6.30 (d, 1 H), 5.15 (d, 1 H), 4.58 - 4.78 (m, 1 H), 2.95 and 3.06 (ddd, 1 H), 2.54 - 2.70 (m, 5 H), 1.99 (s, 3 H), 1.23 - 1.95 (m, 5 H); LC-MS (ESI POS): 394.2 (MH+).
C47 listed in Table 8 is prepared as previously described for C46, using 3-amino-N-methyl-benzamide instead of N-(3-aminophenyl)acetamide. Table 8
Figure imgf000084_0002
EXAMPLE 19
Preparation of (3-fluoro-4-methyl-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C49)
Figure imgf000084_0001
Scheme 19
Preparation of (3-fluoro-4-methyl-phenylamino)-phenyl-acetic acid hydrochloride (148):
Ethyl 2-bromo-2-phenylacetate (0.29 mL, 1.64 mmol), 3-fluoro-4- methylaniline (247 mg, 1.97 mmol) and DIPEA (0.37 mL, 2.14 mmol) are dissolved in acetonitrile (8 mL). The reaction is heated in a microwave oven at
1000C for Ih and 15 min. Then, a solution of lithium hydroxide hydrate (207 mg, 4.94 mmol) in water (5 mL) is added and the mixture is stirred at RT for 2h. Acetonitrile is evaporated under vacuum, the remaining aqueous solution is cooled at 0° and the pH is adjusted to 2 with 4M HCl in dioxane. The resulting white solid is recovered by filtration and dried at 45°C under vacuum overnight (367 mg, 75% yield). Preparation of (3-fluoro-4-methyI-phenylamino)-phenyl-acetic acid
(R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C49):
(3-Fluoro-4-methyl-phenylamino)-phenyl-acetic acid hydrochloride (148) (250 mg, 0.84 mmol), 2-(lH-benzo[d][l,2,3]triazol-l-yl)-l, 1,3,3- tetramethylisouronium hexafluorophosphate(V) (321 mg, 0.84 mmol), and HOBT (129 mg, 0.84 mmol) are dissolved in acetonitrile (6 mL). DIPEA (0.29 mL, 1.69 mmol) is added, followed by (R)-quinuclidin-3-ol (215 mg, 1.69 mmol) and the resulting yellow solution is stirred at RT overnight
(Conversion complete by UPLC/MS-UV). MeCN is evaporated, the residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated. The crude compound is purified by filtration through a pad of silica using DCM/MeOH=9/l as the eluent to obtain the title compound as a yellow oil (311 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, OMSO-d6) ppm: 7.26 - 7.65 (m, 5 H), 6.94 (td, 1 H), 6.34 - 6.61 (m, 3 H), 5.25 - 5.33 (m, 1 H), 4.78 - 5.01 (m, 1 H), 3.42 and 3.52 (ddd, 1 H), 2.82 - 3.22 (m, 4 H), 2.54 - 2.66 (m, 1 H), 1.92 - 1.99 and 2.10 - 2.21 (m, 1 H), 2.04 (s, 3 H), 1.31 - 1.87 (m, 4 H); LC-MS (ESI POS): 369.2 (MH+). EXAMPLE 20
Preparation of (3-methylsulfanyl-phenyIamino)-phenyl-acetic acid (R)-(l-aza-bicycIo[2.2.2]oct-3-yl) ester (C52)
Figure imgf000086_0001
I50
Figure imgf000086_0002
Scheme 20
Preparation of (3-methylsuIfanyl-phenylamino)-phenyl-acetic acid ethyl ester (150):
Ethyl 2-bromo-2-phenylacetate (0.22 mL, 1.23 mmol), 3-(methylthio)aniline (0.22 mL, 1.85 mmol), and DIPEA (0.32 mL, 1.85 mmol) are dissolved in acetonitrile (3 mL) and heated under microwave irradiation at 1000C for Ih. Acetonitrile is evaporated and the crude residue is purified by flash chromatography (petroleum ether/EtOAc=85/15) to obtain intermediate 198 as a colorless oil (292 mg, 79% yield). Preparation of (3-methyIsulfanyl-phenylamino)-phenyl-acetic acid hydrochloride (151):
(3-Methylsulfanyl-phenylamino)-phenyl-acetic acid ethyl ester (150) (292 mg, 0.97 mmol) and lithium hydroxide hydrate (81 mg, 1.94 mmol) are dissolved in THF (7 mL) and water (3 mL) and stirred at RT for 2h. THF is evaporated, the solution is cooled at 00C and IM HCl is added dropwise until pH 1. The resulting mixture is concentrated and extracted several times with DCM. The collected organic phases are dried over Na2SO4, filtered and evaporated to afford intermediate 199 as a brown-solid (248 mg, 83% yield). Preparation of (3-methylsulfanyl-phenylamino)-phenyl-acetic acid
(RHl-aza-bicycIofl.l.lJoct-S-yl) ester (C52):
PS-DCC (602 mg, 0.80 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (3-Methylsulfanyl-phenylamino)-phenyl-acetic acid hydrochloride (151) (124 mg, 0.40 mmol), HOBT (123 mg, 0.80 mmol), and (R)-quinuclidin-3-ol (153 mg, 1.20 mmol) are added and the suspension is shaken at RT overnight (16h). PS-DCC is filtered off, washed with THF and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is recovered, dried over Na2SO4, filtered and evaporated to afford the title compound as a brown oil (153 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.49 - 7.58 (m, 2 H), 7.28 - 7.48 (m, 3 H), 6.99 (t, 1 H), 6.58 - 6.69 (m, 1 H), 6.43 - 6.56 (m, 2 H), 6.38 (d, 1 H), 5.29 (d, 1 H), 4.59 - 4.78 (m, 1 H), 2.88 - 3.13 (m, 1 H), 2.54 - 2.69 (m, 3 H), 2.37 (s, 3 H), 1.68 - 2.24 (m, 3 H), 0.98 - 1.65 (m, 4 H); LC-MS (ESI POS): 383.2 (MH+).
C53 listed in Table 9 is prepared as previously described for C52, using l-(3-amino-phenyl)-ethanone instead of 3-(methylthio)aniline. Table 9
Figure imgf000088_0002
EXAMPLE 21
Preparation of (2,5-dimethoxy-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo [2.2.2] oct-3-yl) ester (C55)
Figure imgf000088_0001
Scheme 21
Preparation of (2,5-dimethoxy-phenylamino)-phenyl-acetic acid hydrochloride (154):
2,5-Dimethoxyaniline (284 mg, 1.85 mmol), ethyl 2-bromo-2- phenylacetate (0.22 ml, 1.23 mmol), and DIPEA (0.32 mL, 1.85 mmol) are dissolved in acetonitrile (5 mL) and stirred under MW heating at 1000C for Ih. Water (2 mL, 111 mmol) and lithium hydroxide hydrate (104 mg, 2.47 mmol) are directly added and the resulting mixture is stirred at RT overnight. Acetonitrile is evaporated, IM HCl is added and the acid aqueous phase is extracted with DCM. The collected organic phases are washed with brine, dried (Na2SO4), filtered and evaporated to obtain intermediate 1102 as a white solid (154 mg, 38% yield).
Preparation of (2,5-Dimethoxy-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C55):
PS-DCC (715 mg, 0.951 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL). (2,5-Dimethoxy-phenylamino)-phenyl-acetic acid hydrochloride (154) (154 mg, 0.48 mmol), HOBT (146 mg, 0.95 mmol) and (R)-quinuclidin-3-ol (181 mg, 1.43 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off and the filtrate is evaporated. The residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine.
The organic layer is dried over Na2SO4, filtered and evaporated to dryness.
The crude compound is purified by flash chromatography (DCM/MeOH=95/5) to afford the title compound as a colorless oil (108 mg, 57% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMS(W6) PPm: 7.23 - 7.59 (m, 5 H), 6.74 (d, 1
H), 6.09 - 6.20 (m, 1 H), 6.04 (d, 1 H), 5.42 (d, 1 H), 5.33 (d, 1 H), 4.64 - 4.83
(m, 1 H), 3.79 (s, 3 H), 3.56 (s, 3 H), 2.90 - 3.03 and 3.04 - 3.15 (m, 1 H),
2.54 - 2.67 (m, 4 H), 1.96 - 2.25 (m, 1 H), 1.65 - 1.73 and 1.89 - 1.96 (m, 1 H), 0.98 - 1.66 (m, 4 H);
LC-MS (ESI POS): 397.3 (MH+).
EXAMPLE 22
Preparation of (2,5-difluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C58)
Figure imgf000090_0001
156
LiOH
Figure imgf000090_0002
C58 157
Scheme 22
Preparation of (2,5-difIuoro-phenylamino)-phenyl-acetic acid ethyl ester (156):
2,5-Difluoroaniline (0.19 mL, 1.85 mmol), ethyl 2-bromo-2- phenylacetate (0.22 mL, 1.23 mmol), and DIPEA (0.32 mL, 1.85 mmol) are dissolved in acetonitrile (3 mL) and heated under MW irradiation at 1000C for 6h and then at 1100C for 4h. Acetonitrile is evaporated and the crude is purified by flash chromatography (Petroleum ether/EtOAc=97/3) to obtain intermediate 1104 as a white solid (240 mg, 67% yield). Preparation of (2,5-difluoro-phenylamino)-phenyl-acetic acid hydrochloride (157):
(2,5-Difluoro-phenylamino)-phenyl-acetic acid ethyl ester (156)
(240 mg, 0.82 mmol) is dissolved in THF/water (7/3 mL). Lithium hydroxide hydrate (69.1 mg, 1.65 mmol) is added and the resulting mixture is stirred at RT for 16h. THF is evaporated under reduced pressure, the solution is cooled at 00C and IM HCl is added dropwise until pH 1. The white solid is recovered by filtration, washed with cold water and dried under vacuum at 400C overnight to obtain intermediate 1105 as a white solid (198 mg, 80% yield).
Preparation of (2,5-difluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C58):
PS-DCC (914 mg, 1.301 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (2,5-Difluoro-phenylamino)-phenyl-acetic acid hydrochloride (157) (195 mg, 0.65 mmol), HOBT (199 mg, 1.30 mmol), and
(R)-quinuclidin-3-ol (248 mg, 1.95 mmol) are added and the suspension is shaken at RT for 16h (Conversion complete by UPLC/MS-UV). PS-DCC is filtered off under suction and the filtrate is evaporated. The resulting residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is separated, dried over Na2SO4, filtered and evaporated. The crude is purified by filtration through a silica-pad using DCM/MeOH=95/5 as the eluent. The title compound is collected as a colorless oil (195 mg, 80% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.49 - 7.62 (m, 2 H) 7.28 - 7.47 (m, 3
H) 7.02 - 7.15 (m, 1 H) 6.46 - 6.60 (m, 1 H) 6.32 - 6.46 (m, 1 H) 5.85 - 6.00 (m, 1
H) 5.43 and 5.45 (d, 1 H) 4.66 - 4.82 (m, 1 H) 2.99 and 3.09(ddd, 1 H) 2.54 - 2.69 (m, 4 H) 2.01 - 2.31 (m, 1 H) 1.85 - 1.96 and 1.65 - 1.75 (m, 1 H) 0.92 - 1.66 (m, 4
H);
LC-MS (ESI POS): 373.2 (MH+).
C59 listed in Table 10 is prepared as previously described for C58, using 2,6-dimethyl-phenylamineinstead of 2,5-difluoroaniline. Table 10
Figure imgf000092_0001
EXAMPLE 23
Preparation of (2-ethyl-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C61)
Figure imgf000092_0002
Scheme 23
Preparation of (2-ethyl-phenylamino)-phenyl-acetic acid hydrochloride (160):
2-Ethylaniline (0.23 mL, 1.85 mmol), ethyl 2-bromo-2-phenylacetate
(0.22 mL, 1.23 mmol), and DIPEA (0.32 mL, 1.85 mmol) are dissolved in acetonitrile (3 mL) and stirred under MW irradiation at 1000C for Ih. Water
(2 ml, 1 1 1 mmol) and lithium hydroxide hydrate (104 mg, 2.47 mmol) are added to the reaction and the resulting mixture is stirred at RT overnight (16h). Acetonitrile is evaporated and IM HCl is added until pH 1. The aqueous phase is extracted several times with DCM and the organic phases are collected and washed with water and brine, dried (Na2SO4), filtered and evaporated to give intermediate I108as an off-white solid (316 mg, 88% yield).
Preparation of (2-ethyl-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C61)
PS-DCC (962 mg, 1.37 mmol, loading: 1.33 mmol/g) is suspended in
THF (10 mL). HOBT (210 mg, 1.37 mmol), (2-ethyl-phenylamino)-phenyl- acetic acid hydrochloride (160) (200 mg, 0.68 mmol), and (R)-quinuclidin-3-ol
(262 mg, 2.06 mmol) are added and the mixture is shaken at RT overnight.
PS-DCC is filtered off and washed with THF and the filtrate is evaporated under reduced pressure. The resulting residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The organic layer is separated, dried over Na2SO4, filtered and evaporated. The residue is first purified by flash chromatography (DCM/MeOH=9/l) and then by preparative HPLC. The fractions containing the product are pooled, concentrated under vacuum, basified with sat. NaHCO3 and extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and evaporated to afford the title compound as a colorless oil (52 mg, 21% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-</6) ppm: 7.47 - 7.60 (m, 2 H), 7.23 - 7.46 (m, 3 H), 7.00 - 7.08 (m, 1 H), 6.86 - 6.96 (m, 1 H), 6.53 - 6.66 (m, 1 H), 6.34 - 6.48 (m, 1 H), 5.32 and 5.33 (d, 1 H), 5.17 and 5.18 (d, 1 H), 4.66 - 4.84 (m, 1 H), 2.96 and 3.07 (ddd, 1 H), 2.61 (q, 2 H), 2.55 - 2.69 (m, 3 H), 1.98 - 2.39 (m, 2 H), 1.65 - 1.73 and 1.85 - 1.96 (m, 1 H), 1.24 (t, 3 H), 1.02 - 1.77 (m, 4 H); LC-MS (ESI POS): 365.1 (MH+). EXAMPLE 24
Preparation of (2-acetyl-phenylamino)-phenyI-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C64)
Figure imgf000094_0001
162
LiOH H,0
Figure imgf000094_0002
Scheme 24
Preparation of (2-acetyl-phenylamino)-phenyl-acetic acid ethyl ester (162) l-(2-Aminophenyl)ethanone (250 mg, 1.85 mmol), ethyl 2-bromo-2- phenylacetate (0.22 ml, 1.23 mmol), DIPEA (0.32 mL, 1.85 mmol) and a catalytic amount of potassium iodide are dissolved in acetonitrile (4 mL) and heated under MW irradiation at 1000C for 2h and then at 1200C for 1 h.
Acetonitrile is evaporated and the crude is purified by flash chromatography
(petroleum ether/EtOAc=93/7) to obtain intermediate 1110 as a yellow oil (367 mg, quantitative yield).
Preparation of (2-acetyl-phenylamino)-phenyl-acetic acid hydrochloride (163):
(2-Acetyl-phenylamino)-phenyl-acetic acid ethyl ester (162) (367 mg, 1.23 mmol) and lithium hydroxide hydrate (104 mg, 2.47 mmol) are dissolved in water (1.7 mL) and acetonitrile (5 mL). The reaction is stirred at RT overnight and then the solvents are evaporated. The residue is dissolved in
EtOAc and washed several times with IM HCl. The organic phase is recovered, dried (Na2SO4), filtered and evaporated to afford intermediate 11 11 as a brown solid ( 181 mg, 48% yield).
Preparation of (2-acetyl-phenyIamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C64):
PS-DCC (890 mg, 1.184 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL). (2-Acetyl-phenylamino)-phenyl-acetic acid hydrochloride (163) (181 mg, 0.59 mmol), HOBt (181 mg, 1.18 mmol), and (R)-quinuclidin-
3-ol (226 mg, 1.78 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off and the filtrate is evaporated. The residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine, dried over Na2SO4, filtered and evaporated. The resulting crude oil is purified by flash chromatography (DCM/MeOH=9/l) to afford the title compound as a colorless oil (239 mg, quantitative yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 9.81 and 9.82 (d, 1 H), 7.83 - 7.94 (m,
1 H), 7.44 - 7.54 (m, 2 H), 7.22 - 7.44 (m, 4 H), 6.54 - 6.73 (m, 2 H), 5.52 and 5.53
(d, 1 H), 4.61 - 4.87 (m, 1 H), 2.99 and 3.10 (ddd, 1 H), 2.59 (s, 3 H), 2.54 - 2.69 (m, 3 H), 2.02 - 2.39 (m, 2 H), 1.69 - 1.78 and 1.87 - 1.97 (m, 1 H), 0.94 - 1.70 (m,
4 H);
LC-MS (ESI POS): 379.3 (MH+).
C65 listed in Table 1 1 is prepared as previously described for C64, using 3,5-difluoro-phenylamine instead of l-(2-aminophenyl)ethanone. Table 11
Figure imgf000096_0002
EXAMPLE 25
Preparation of 3-({[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]- phenyl-methyl}-amino)-benzoic acid ethyl ester (C67)
Figure imgf000096_0001
166 C67
Scheme 25
Preparation of 3-[(carboxy-phenyI-methyl)-amino]-benzoic acid ethyl ester hydrochloride (166):
Ethyl 3-aminobenzoate (0.52 mL, 3.49 mmol), 2-bromo-2-phenylacetic acid (250 mg, 1.16 mmol), and DIPEA (0.41 mL, 2.32 mmol) are dissolved in acetonitrile (4 mL) and heated under MW irradiation at 1000C in a sealed vial for 30 minutes. Acetonitrile is evaporated and the crude is dissolved in DCM and washed with IM HCl, water and brine. The organic layer is separated, dried (Na2SO4) and evaporated to obtain intermediate 1114 as clear-brown oil (348 mg, 89% yield).
Preparation of 3-({[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]- phenyl-methyl}-amino)-benzoic acid ethyl ester (C67):
3-[(Carboxy-phenyl-methyl)-amino]-benzoic acid ethyl ester hydrochloride (166) (161 mg, 0.48 mmol), 2-(lH-benzo[d][l,2,3]triazol-l-yl)- 1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (218 mg, 0.57 mmol), and HOBT (88 mg, 0.57 mmol) are dissolved in dry THF (10 mL). (R)-Quinuclidin-3-ol (61.0 mg, 0.48 mmol) and DIPEA (0.17 mL, 0.96 mmol) are added and the mixture is stirred under inert atmosphere overnight. THF is evaporated and the crude residue is dissolved in EtOAc and washed with sat. NaHCO3, water and brine. The recovered organic layer is dried (Na2SO4), filtered and evaporated. The crude is purified by flash chromatography (DCM/MeOH=95/5) to afford the title compound as a yellow oil (154 mg, 79% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.50 - 7.61 (m, 2 H), 7.29 - 7.48 (m, 4 H), 7.14 - 7.29 (m, 2 H), 6.92 - 7.02 (m, 1 H), 6.70 (d, 1 H), 5.35 (d, 1 H), 4.56 - 4.92 (m, 1 H), 4.26 (q, 2 H), 3.09 - 3.25 (m, 1 H), 2.65 - 2.95 (m, 4 H), 2.21 - 2.38 (m, 1 H), 1.79 - 2.10 (m, 1 H), 1.36 - 1.80 (m, 4 H), 1.30 (t, 3 H);
LC-MS (ESI POS): 409.3 (MH+).
EXAMPLE 26
Preparation of (3-methoxy-phenylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C69)
Figure imgf000097_0001
Scheme 26 Preparation of (3-methoxy-phenylamino)-phenyl-acetic acid (168):
A solution of 2-bromo-2-phenylacetic acid (0.5 g, 2.28 mmol) and 3- methoxyaniline (0.54 mL, 4.56 mmol) in THF (12 mL) is refluxed for 4 hours. Solvent is removed under vacuum, the residue is taken up with IM HCl and extracted with EtOAc. The organic phase is dried (Na2SO4), filtered and evaporated. The crude is purified by flash chromatography (DCM/MeOH=98/2 to 9/1) to obtain intermediate 1116 as a white solid (0.58 g, 99% yield).
Preparation of (3-methoxy-phenyIamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yI) ester (C69):
(3-Methoxy-phenylamino)-phenyl-acetic acid (0.58 g, 2.25 mmol), HOBT (0.45 g, 2.93 mmol) and DCC (0.60 g, 2.93 mmol) are dissolved in THF (100 mL) and stirred at RT for 20 minutes. Then, (R)-quinuclidin-3-ol (0.57 g, 4.51 mmol) is added and the resulting reaction is stirred at the same temperature for one day. The solvent is evaporated, the residue is taken up with EtOAc and the insoluble is filtered off. The organic solution is washed with IM K2CO3 and then with brine. The crude is purified by flash chromatography (DCM/MeOH= 99/1 to 80:20) to obtain the title compound as a yellow solid (0.43 g, 52% yield, mixture of diastereoisomers). 1H NMR POO MHZ5 DMSO-^6) ppm:
Diastereoisomer 1 : 7.48 - 7.64 (m, 2 H), 7.22 - 7.47 (m, 3 H), 6.95 (t, 1 H), 6.23 - 6.38 (m, 3 H), 6.09 - 6.19 (m, 1 H), 5.25 (d, 1 H), 4.50 - 4.79 (m, 1 H), 3.64 (s, 3 H), 2.97 (ddd, 1 H), 2.20 - 2.71 (m, 4 H), 2.03 - 2.13 (m, 1 H), 1.83 - 1.95 (m, 1 H), 1.19 - 1.67 (m, 4 H); Diastereoisomer 2: 7.48 - 7.64 (m, 2 H), 7.22 - 7.47 (m, 3 H), 6.95 (t, 1
H), 6.23 - 6.38 (m, 3 H), 6.09 - 6.19 (m, 1 H), 5.24 (d, 1 H), 4.50 - 4.79 (m, 1 H), 3.64 (s, 3 H), 3.04 - 3.14 (m, 1 H), 2.20 - 2.71 (m, 5 H), 1.68 - 1.74 (m, 1 H), 1.19 - 1.67 (m, 4 H); LC-MS (ESI POS): 367.1 (MH+). EXAMPLE 27
Preparation of [(4-fluoro-phenyl)-methyl-amino]-phenyI-acetic acid (R)-(l-aza-bicycIo[2.2.2]oct-3-yl) ester (C72)
DlPEA
Figure imgf000099_0002
Figure imgf000099_0001
170
LiOH H5O-THF
Figure imgf000099_0003
C72 171
Scheme 27
Preparation of [(4-fIuoro-phenyl)-methyl-amino]-phenyl-acetic acid ethyl ester (170): 4-Fluoro-N-methylaniline (0.33 g, 2.67 mmol) is added to a solution of ethyl 2-bromo-2-phenylacetate (0.36 mL, 2.06 mmol) in acetonitrile (6.86 mL) and DIPEA (0.47 ml, 2.67 mmol). The dark solution is stirred at 1000C under microwave irradiation for 1 hour. Then solvent is evaporated and the crude is purified by flash chromatography (Petroleum ether/EtOAc = 97/3) to obtain intermediate Il 18 as a yellow solid (0.59 g, 100 % yield).
Preparation of [(4-fluoro-phenyl)-methyl-amino]-phenyl-acetic acid hydrochloride (171):
A solution of [(4-fluoro-phenyl)-methyl-amino]-phenyl-acetic acid ethyl ester (170) (0.59 g, 2.05 mmol) in THF (10 mL) and water (10 mL) is added lithium hydroxide hydrate (0.26 g, 6.14 mmol) is added. The reaction is stirred at RT for 3.5h and then at 700C for 24h. 3 N HCl is added till pH is about 1 and the mixture is evaporated. Water (15 mL) is added and the residue is triturated obtaining a pale brown suspension that is filtered on a buckner funnel, washed with water and then with acetonitrile. The solid is dried under vacuum at 400C overnight to obtain intermediate 11 19 as a pale brown powder (0.44 g, 72 % yield).
Preparation of [(4-fluoro-phenyl)-methyl-amino]-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C72): PS-DCC (1.02 g, 1.35 mmol, loading: 1.33 mmol/g) is suspended in dry
THF (13.5 mL). Then HOBT (0.21 g, 1.35 mmol), [(4-fluoro-phenyl)-methyl- amino]-phenyl-acetic acid hydrochloride (171) (0.20 g, 0.68 mmol) and (R)- quinuclidin-3-ol (0.26 g, 2.03 mmol) are added. The mixture is shaken at RT overnight. PS-DCC is filtered off, washed with EtOAc and THF. The solution is evaporated and the residue is partitioned between EtOAc and water. The organic phase is washed with sat. NaHCO3, dried (Na2SO4) and evaporated.
The crude is purified by flash chromatography (DCM/MeOH = 95/5) to afford the title compound as a colorless oil (209 mg, 84 % yield, mixture of diastereoisomers). 1H NMR (300 MHz, DMSO-Uf6) ppm: 7.26 - 7.49 (m, 5 H) 6.99 - 7.13 (m, 2
H) 6.83 - 6.99 (m, 2 H) 5.78 (d, 1 H) 4.74 - 4.88 (m, 1 H) 3.02 - 3.18 (m, 2 H) 2.56 - 2.79 (m, 5 H) 2.29 - 2.46 (m, 2 H) 1.76 - 1.93 (m, 1 H) 1.41 - 1.63 (m, 3 H) 1.19 - 1.39 (m, I H);
LC-MS (ESI POS): 369.2 (MH+). EXAMPLE 28
Preparation of (methyl-phenyl-amino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C75)
Figure imgf000101_0001
Scheme 28
Preparation of (R)-(methyl-phenyl-amino)-phenyl-acetic acid methyl ester (173):
N-methylaniline (299 ul, 2.76 mmol) is added to a solution of (S)- methyl 2-(methylsulfonyloxy)-2-phenylacetate (15) (450 mg, 1.84 mmol) in acetonitrile (10 mL). The reaction is heated at 1200C for 15 minutes
(microwave irradiation). 2N HCl (5 mL) is added and the mixture is extracted with EtOAc. The organic phase is dried over sodium sulphate and the solvent is evaporated to dryness. The crude is purified by flash chromatography on silica gel (Petroleum ether/Et2θ=9/l) to obtain intermediate 1121 as an orange amorphous solid (125 mg, 27 % yield).
Preparation of (R)-(methyl-phenyl-amino)-phenyl-acetic acid hydrochloride (174):
(R)-(Methyl-phenyl-amino)-phenyl-acetic acid methyl ester (173) (125 mg, 0.49 mmol) is dissolved in dioxane (2 mL). 37% Hydrogen chloride in water
(3.00 mL, 36.5 mmol) is added and the mixture is stirred at 70 0C for 18h. Then a second portion of 37% hydrogen chloride in water (1.00 mL, 12.2 mmol) is added and the mixture is stirred at 70 0C for additional 36h. The mixture is cooled to RT and the white precipitate is filtered and washed with dioxane and Et2θ to obtain intermediate 1122 as a white solid (97 mg, 71% yield). Preparation of (methyl-phenyl-amino)-phenyl-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yI) ester (C75):
(R)-(Methyl-phenyl-amino)-phenyl-acetic acid hydrochloride (174) (97 mg, 0.35 mmol), HOBT (107 mg, 0.70 mmol), DCC (144 mg, 0.70 mmol) and
(R)-quinuclidin-3-ol (89 mg, 0.70 mmol) are dissolved in dioxane (5 mL) and the mixture is stirred at RT for 15h. The white precipitate is filtered and discarded whereas the clear solution is evaporated to dryness. The residue is dissolved in EtOAc and washed with sat. Na2CO3 and then brine. The organic phase is dried over sodium sulphate, filtered and evaporated to dryness. The resulting crude is purified by flash chromatography on silica gel (DCM/MeOH=97/3 to 95/5) to obtain the title compound as a pale yellow oil (46 mg, 38 % yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.29 - 7.53 (m, 5 H) 7.14 - 7.29 (m, 2 H) 6.86 - 6.99 (m, 2 H) 6.67 - 6.80 (m, 1 H) 5.84 and 5.83(s, 1 H) 4.73 - 4.88 (m, 1 H) 2.99 - 3.16 (m, 1 H) 2.75 and 2.71(s, 3 H) 2.53 - 2.69 (m, 3 H) 2.29 - 2.47 (m, 2 H) 1.74 - 1.95 (m, 1 H) 1.32 - 1.63 (m, 3 H) 1.12 - 1.30 (m, 1 H); LC-MS (ESI POS): 351.3 (MH+).
EXAMPLE 29
Preparation of (4-methyl-benzylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C77)
Figure imgf000103_0001
Scheme 29
Preparation of amino-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (176):
(R)-Quinuclidin-3-yl 2-amino-2-phenylacetate dihydrochloride (C25) (1.11 g, 3.33 mmol) is dissolved in MeOH (10 mL) and 32% NH4OH (2.0 niL, 16.07 mmol) is added. The solution is stirred at RT for 30 sec. and then is evaporated under vacuum. The residue is dissolved in DCM/MeOH (4.5/0.5 mL) and about Ig of Siθ2 is added. The suspension is evaporated and the residue is loaded on a silica gel column and purified eluting with DCM/MeOH/NH4θH = 9.2/0.8/0.1 to 9/1/0.1 to collect intermediate 1124 as a pale yellow oil (635 mg, 73 % yield).
Preparation of (4-methyl-benzylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C77):
A solution of amino-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3- yl) ester (176) (100 mg, 0.38 mmol) in dry THF (3.84 mL), is added with 4- methylbenzaldehyde (68 mL, 0.57 mmol) and AcOH (0.5 mL, 8.73 mmol). The mixture is stirred at RT and sodium triacetoxyborohydride (163 mg, 0.77 mmol) is added. The reaction is stirred at RT for 1.5 hour then cyclohexane is added and the mixture is evaporated to dryness. The crude is purified by flash chromatography (DCM/MeOH/NH4OH = 95/5/0.5) to obtain the title compound as a colorless oil (76 mg, 54 % yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.25 - 7.51 (m, 5 H), 7.15 - 7.23 (m, 2 H), 7.03 - 7.15 (m, 2 H), 4.51 - 4.81 (m, 1 H), 4.33 (d, 1 H), 3.61 (s, 2 H), 2.85 - 3.19 (m, 1 H), 2.57 - 2.69 (m, 5 H), 2.28 (s, 3 H), 1.68 - 1.92 (m, 1 H), 0.91 - 1.64 (m, 4 H);
LC-MS (ESI POS): 365.2 (MH+).
The compounds listed in Table 12 are prepared as previously described for C77, using 4-fluorobenzaldehyde, 4-methoxybenzaldehyde and benzaldehyde instead of 4-methylbenzaldehyde.
Table 12
Figure imgf000104_0001
(continue)
Figure imgf000105_0001
EXAMPLE 30
Alternative preparation of (4-fluoro-benzylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yI) ester (C82)
Figure imgf000105_0002
Scheme 30
Preparation of (4-fluoro-benzylamino)-phenyl-acetic acid hydrochloride (181):
4-Fluorobenzaldehyde (0.25 mL, 2.38 mmol), 2-amino-2-phenylacetic acid (300 mg, 1.98 mmol) and NaOH (79 mg, 1.98 mmol) are dissolved in MeOH (20 mL) and stirred at RT overnight. The reaction is cooled at 00C and NaBH4 (150 mg, 3.97 mmol) is added. After being stirred at 00C for 30 min, the reaction is judged complete by UPLC-MS analysis. 4M HCl in dioxane is added dropwise till pH 5 and the precipitate is collected by suction filtration, washed with Et2O and dried under vacuum at 400C to obtain intermediate 1129 as a white solid (587 mg, quantitative yield).
Preparation of (4-fluoro-benzylamino)-phenyl-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C82): A mixture of (4-fluoro-benzylamino)-phenyl-acetic acid hydrochloride
(233 mg, 0.79 mmol), (R)-quinuclidin-3-ol (200 mg, 1.57 mmol), 2-(1H- benzo[d] [ 1 ,2,3]triazol- 1 -yl)- 1 , 1 ,3,3-tetramethylisouronium hexafluorophosphate(V) (596 mg, 1.57 mmol), TEA (0.22 mL, 1.57 mmol) and HOBT (241 mg, 1.57 mmol) in acetonitrile (10 mL) is stirred at RT for 48 hours. THF is removed under vacuum and the crude is partitioned between EtOAc and water. The organic phase is dried over sodium sulphate, filtered and evaporated to dryness. The crude is purified by preparative HPLC. The combined fractions are dried and partitioned between EtOAc and 2M K2CO3. The organic phase is dried over sodium sulphate, filtered and evaporated to dryness to afford the title compound as colorless oil (61 mg, 21% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.25 - 7.63 (m, 7 H), 7.00 - 7.24 (m, 2 H), 4.58 - 4.79 (m, 1 H), 4.34 (s, 1 H), 3.64 (s, 2 H), 2.80 and 3.07 (ddd, 1 H), 2.54 - 2.69 (m, 3 H), 2.08 - 2.46 (m, 2 H), 1.69 - 1.79 and 1.83 - 1.90 (m, 1 H), 1.03 - 1.64 (m, 4 H);
LC-MS (ESI POS): 369.1 (MH+).
EXAMPLE 31
Preparation of (4-fluoro-phenyl)-(3-fluoro-phenylamino)-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yI) ester (C84)
Figure imgf000107_0001
183 C84
Scheme 31 Preparation of (4-fluoro-phenyl)-(3-fluoro-phenylamino)-acetic acid
(183):
A mixture of 2-bromo-2-(4-fluorophenyl)acetic acid (500 mg, 2.15 mmol) and 3-fluoroaniline (477 mg, 4.29 mmol) in acetonitrile (8 mL) is heated under microwave irradiation at 1000C for 50 minutes. Then 3-fluoroaniline (238 mg, 2.15 mmol) is added again and reaction is heated at 1200C for 45 minutes in a microwave oven (LC-MS monitoring: complete conversion). The organic solution is diluted with EtOAc and washed with 2N HCl and then with brine. The organic phase is dried over Na2SO4, filtered and the solvent is evaporated to give intermediate 1131 as a white solid (510 mg, 90% yield). Preparation of (4-fluoro-phenyl)-(3-fluoro-phenylamino)-acetic acid
(R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C84):
A mixture of (4-fluoro-phenyl)-(3-fluoro-phenylamino)-acetic acid (183) (510 mg, 1.94 mmol), (R)-quinuclidin-3-ol (246 mg, 1.94 mmol), HOBT (356 mg, 2.32 mmol) and DCC (480 mg, 2.32 mmol) in THF (10 mL) is stirred at RT overnight (UPLC-MS monitoring: complete conversion). The solvent is evaporated, the crude is dissolved in EtOAc and the insoluble is filtered off. The clear solution is washed with IN K2CO3 and then with brine. The organic layer is dried over Na2SO4, filtered and evaporated. The crude is purified by silica gel chromatography (EtOAc/MeOH= 8/2) to give the title compound as a yellow oil (360 mg, 50% yield, mixture of diastereoisomers). 1H NMR (300 MHz, DMSO-d6):
Diastereoisomer 1 of C84: 7.41 - 7.65 (m, 2 H), 7.15 - 7.33 (m, 2 H), 6.96 - 7.14 (m, 1 H), 6.67 (d, 1 H), 6.43 - 6.59 (m, 2 H), 6.20 - 6.42 (m, 1 H), 5.36 (d, 1 H), 4.46 - 4.88 (m, 1 H), 2.97 (ddd, 1 H), 2.53 - 2.72 (m, 3 H), 2.18 - 2.39 (m, 1 H), 2.01 - 2.16 (m, 1 H), 1.80 - 1.96 (m, 1 H), 1.21 - 1.66 (m, 4 H).
Diastereoisomer 2 of C84: 7.41 - 7.65 (m, 2 H), 7.15 - 7.33 (m, 2 H), 6.96 - 7.14 (m, 1 H), 6.67 (d, 1 H), 6.43 - 6.59 (m, 2 H), 6.20 - 6.42 (m, 1 H), 5.35 (d, 1 H), 4.46 - 4.88 (m, 1 H), 3.08 (ddd, 1 H), 2.53 - 2.72 (m, 5 H), 1.66 - 1.76 (m, 1 H), 1.21 - 1.66 (m, 4 H);
LC-MS (ESI POS): 373 (MH+).
C85 listed in Table 13 is prepared as previously described for C84, using 2-fluoroaniline instead of 3-fluoroaniline.
Table 13
Figure imgf000108_0001
EXAMPLE 32
Preparation of (R)-quinucIidin-3-yl 2-(phenylamino)-2-(thiophen-2- yl)acetate hydrochloride (C90)
Figure imgf000109_0001
186 187
NH,
Figure imgf000109_0002
C90 189 188
Scheme 32 Preparation of hydroxy-thiophen-2-yl-acetic acid ethyl ester (186):
A solution of ethyl 2-oxo-2-(thiophen-2-yl)acetate (5.00 g, 27.1 mmol) in ethanol (50 niL) is cooled at 00C with an ice bath. NaBH4 (0.31 g, 8.14 mmol) is added in four portion under stirring. The mixture is stirred at 00C for 10 minutes, then allowed to warm at RT and stirred for additional 30 minutes. Reaction is concentrated under vacuum and the residue is partitioned between Et2O and ice-cooled water. The organic layer is separated, washed with water and brine, dried over Na2SO4, filtered and evaporated to give a colorless liquid (5.05 g, 91% yield).
Preparation of ethyl 2-(methyIsulfonyloxy)-2-(thiophen-2-yl)acetate (187):
Hydroxy-thiophen-2-yl-acetic acid ethyl ester (4.58 g, 24.6 mmol) is dissolved in dry DCM (125 mL) and cooled at 00C. DIPEA (5.15 mL, 29.5 mmol) and methanesulphonyl chloride (2.11 mL, 27.1 mmol) are added and the resulting solution is stirred at RT for Ih. DIPEA (0.859 ml, 4.92 mmol) and methanesulphonyl chloride (0.19 mL, 2.46 mmol) are added again. After being stirred at room temperature for 1 additional hour, a third portion of DIPEA (0.43 mL, 2.46 mmol) and methanesulphonyl chloride (77 ul, 0.98 mmol) is added. After Ih the reaction is completed. The mixture is diluted with DCM, washed with sat. NaHCO3, water and brine, dried (Na2SO4), filtered and evaporated. The resulting yellow oil is used in the next step without any further purification.
Preparation of ethyl 2-(phenylamino)-2-(thiophen-2-yl)acetate (188):
Ethyl 2-(methylsulfonyloxy)-2-(thiophen-2-yl)acetate (187) (5.7 g, 21.6 mmol), aniline (2.16 mL, 23.7 mmol) and DIPEA (4.52 mL, 25.9 mmol) are dissolved in acetonitrile (20 mL) to give a yellow solution which is heated under microwave irradiation in a sealed vial at 1000C for 15 minutes. Conversion complete by UPLC/MS-UV. Solvent is evaporated and the residue is dissolved in
DCM and washed with water and brine, dried (Na2SO4), filtered and evaporated to dryness. The resulting crude is purified by flash chromatography (Petroleum ether/EtOAc = 85/15) to get desired compound as a yellow solid (4.33 g, 77% yield).
Preparation of 2-(phenylamino)-2-(thiophen-2-yl)acetic acid hydrochloride (189): Ethyl 2-(phenylamino)-2-(thiophen-2-yl)acetate (188) (3.86 g, 14.8 mmol) and lithium hydroxide hydrate (1.24 g, 29.5 mmol) are dissolved in THF/water (20 mL/20 mL) and stirred at RT for 4h. THF is evaporated, the mixture is cooled to 00C and 4M HCl in dioxane is added until pH is about 1. The resulting precipitate is collected by suction filtration and washed with water. The white solid is dried under vacuum at 400C for 18h (3.09g, 78% yield).
Preparation of (R)-quinuclidin-3-yl 2-(phenylamino)-2-(thiophen-2- yl)acetate hydrochloride (C90):
2-(Phenylamino)-2-(thiophen-2-yl)acetic acid hydrochloride (189) (359 mg, 1.33 mmol), DCC (330 mg, 1.60 mmol) and HOBT (245 mg, 1.60 mmol) are dissolved in THF (15 mL). (R)-quinuclidin-3-ol (339 mg, 2.66 mmol) is added and the reaction mixture is stirred at RT for 16 hours. HOBT (20.4 mg, 0.13 mmol) and DCC (33.0 mg, 0.16 mmol) are added again and the mixture is stirred for additional 8 hours. HOBT (20.4 mg, 0.13 mmol), DCC (33.0 mg, 0.16 mmol), (R)-quinuclidin-3-ol (16.9 mg, 0.13 mmol) are added and the mixture is stirred for additional 16 hours. THF is evaporated and the resulting crude oil is dissolved in EtOAc and washed with water and brine. The organic phase is recovered, dried over Na2SO4, filtered and evaporated. The crude is first purified by flash chromatography (DCM/MeOH=9/l) and then by preparative HPLC. The pure fractions are collected and evaporated. The resulting TFA salt is dissolved in THF and passed through a PL-HCO3 cartridge (Varian, 200 mg, 1.8 mmol/g
HCO3"). THF is evaporated, the product is dissolved in dioxane (2 mL) and 4M
HCl in dioxane (2 mL) is added. The solvent is evaporated and the residue is dried under vacuum for 24h to obtain the title compound as a brown solid (33 mg, 7% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-Gf6) ppm: 10.01 (br. s., 1 H) 7.47 - 7.56 (m, 1 H) 7.21 - 7.29 (m, 1 H) 6.99 - 7.16 (m, 3 H) 6.71 - 6.82 (m, 2 H) 6.53 - 6.70 (m, 1 H) 5.64 and 5.61 (s, 1 H) 4.99 - 5.13 (m, 1 H) 3.03 - 3.28 (m, 4 H) 2.71 - 2.92 (m, 2 H) 1.42 - 2.28 (m, 5 H);
LC-MS (ESI POS): 343.1 (MH+).
EXAMPLE 33
Preparation of (4-methoxy-phenyl)-phenyIamino-acetic acid (R)-(I- aza-bicydo[2.2.2]oct-3-yI) ester (C93)
Figure imgf000112_0001
LiOH
Figure imgf000112_0002
C93 192
Scheme 33
Preparation of (4-methoxy-phenyl)-phenylamino-acetic acid methyl ester (191):
Methyl 2-bromo-2-(4-methoxyphenyl)acetate (1.10 g, 4.25 mmol), DIPEA (0.89 mL, 5.09 mmol), and aniline (0.43 mL, 4.67 mmol) are dissolved in acetonitrile (12 mL). The reaction is heated for 18 minutes at 1000C under microwave irradiation. Acetonitrile is evaporated and the residue is diluted with DCM and washed with water and brine, dried over Na2SO4, filtered and evaporated to dryness. The crude is purified by flash chromatography (Petroleum Ether/EtOAc = 9/1) to give intermediate 1139 as a yellow oil (745 mg, 65% yield).
Preparation of (4-methoxy-phenyl)-phenylamino-acetic acid hydrochloride (192):
(4-Methoxy-phenyl)-phenylamino-acetic acid methyl ester (953 mg, 3.51 mmol) and lithium hydroxide hydrate (295 mg, 7.03 mmol) are dissolved in THF (5 mL) and water (5 mL) and the resulting reaction is stirred overnight at RT (Conversion complete by UPLC-MS/UV). THF is evaporated, the aqueous phase is cooled at 00C and acidified till pH 1 with 4M HCl in 1 ,4 dioxane. The precipitate is collected by suction filtration and the white solid is dried overnight at 45°C under vacuum (718 mg, 70% yield).
Preparation of (4-methoxy-phenyl)-phenylamino-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C93):
(4-Methoxy-phenyl)-phenylamino-acetic acid hydrochloride (192) (300 mg, 1.02 mmol), DCC (253 mg, 1.23 mmol), and HOBT (188 mg, 1.23 mmol) are dissolved in THF (10 mL). DIPEA (0.36 mL, 2.04 mmol) and (R)- quinuclidin-3-ol (130 mg, 1.02 mmol) are added. The mixture is stirred ad RT for 16h. Then DCC (25.3 mg, 0.12 mmol), HOBT (18.8 mg, 0.12 mmol), DIPEA (36 uL, 0.204 mmol) and (R)-quinuclidin-3-ol (13.0 mg, 0.10 mmol) are added again and reaction is stirred for additional 32 hours. THF is evaporated and the residue is dissolved in EtOAc and washed with sat. NaHCO3, H2O and brine. The organic layer is dried (Na2SO4), filtered and evaporated. The crude residue is purified by flash chromatography (DCM/MeOH= 97/3 to 92/8) to obtain the title compound as a yellow solid (90 mg, 24% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.34 - 7.63 (m, 2 H), 7.01 - 7.15 (m, 2 H), 6.87 - 7.01 (m, 2 H), 6.63 - 6.74 (m, 2 H), 6.52 - 6.62 (m, 1 H), 6.19 (d, 1 H), 5.17 (d, 1 H), 4.55 - 4.85 (m, 1 H), 3.74 (s, 3 H), 2.83 - 3.20 (m, 1 H), 2.03 - 2.69 (m, 5 H), 1.65 - 1.94 (m, 1 H), 0.93 - 1.63 (m, 4 H); LC-MS (ESI POS): 367.3 (MH+). EXAMPLE 34
Preparation of 4-{[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]- phenylamino-methylj-benzoic acid methyl ester (C95)
Figure imgf000114_0001
Scheme 34
Preparation of N-ethyl-N-isopropylpropan-2-amine 2-(4- (methoxycarbonyl)phenyl)-2-(phenylamino)acetate (194):
2-Bromo-2-(4-(methoxycarbonyl)phenyl)acetic acid (700 mg, 2.56 mmol), aniline (0.23 mL, 2.56 mmol), and DIPEA (0.94 mL, 5.38 mmol) are dissolved in acetonitrile (5 mL). The reaction is stirred at 1000C under microwave irradiation for 15 minutes. Acetonitrile is evaporated and the residue is dissolved in DCM and washed with water and brine. The organic layer is dried (Na2SO4), filtered and evaporated. The crude compound is purified by flash chromatography (DCM/MeOH= 9/1) to obtain intermediate 1142 as a white solid (381 mg, 37% yield).
Preparation of 4-{[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]- phenylamino-methylj-benzoic acid methyl ester (C95):
N-Ethyl-N-isopropylpropan-2-amine 2-(4-(methoxycarbonyl)phenyl)-2- (phenylamino)acetate (194) (212 mg, 0.51 mmol), DCC (158 mg, 0.77 mmol), and HOBT (117 mg, 0.77 mmol) are dissolved in dry THF (5 mL).
(R)-Quinuclidin-3-ol (195 mg, 1.53 mmol) is added and the mixture is stirred at RT for 2 days. A second portion of DCC (79 mg, 0.38 mmol), HOBT (58.7 mg, 0.38 mmol) and (R)-quinuclidin-3-ol (98 mg, 0.77 mmol) are added and the mixture is further stirred for 24h. Then THF is evaporated, the residue is dissolved in EtOAc and washed with NaHCO3, water and brine. The organic phase is dried (Na2SO4), filtered and evaporated. The crude is purified by preparative HPLC. The recovered fractions are evaporated, dissolved in EtOAc and washed with sat. NaHCO3 The organic phase is dried (Na2SO4), filtered and evaporated to afford the desired compound as a colorless oil (42 mg, 21% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.88 - 8.05 (m, 2 H), 7.51 - 7.76 (m, 2 H), 6.91 - 7.13 (m, 2 H), 6.71 (dd, 2 H), 6.50 - 6.64 (m, 1 H), 6.38 (d, 1 H), 5.42 (d, 1 H), 4.39 - 4.86 (m, 1 H), 3.85 (s, 3 H), 2.84 - 3.15 (m, 1 H), 2.54 - 2.67 (m, 4 H), 0.76 - 2.16 (m, 6 H);
LC-MS (ESI POS): 395.4 (MH+).
EXAMPLE 35
Preparation of (3-fluoro-phenyl)-phenylamino-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C99)
Figure imgf000115_0001
LiOH
Figure imgf000115_0002
C99 198
Scheme 35 Preparation of bromo-(3-fluoro-phenyl)-acetic acid methyl ester (196):
Methyl 2-(3-fluorophenyl)acetate (1.90 g, 11.3 mmol) and N-bromo succinimide (2.01 g, 11.3 mmol) are dissolved in CCl4 (80 mL). HBr (64 ul, 0.56 mmol) is added and the mixture is stirred under reflux overnight. The mixture is cooled at RT, diluted with DCM and washed with sat. NaHCO3, water and brine.
The organic layer is dried (Na2SO4), filtered and evaporated obtaining intermediate 1144 as a yellow oil (2.68 g, 96% yield).
Preparation of (3-fluoro-phenyl)-phenylamino-acetic acid methyl ester (197):
Bromo-(3-fluoro-phenyl)-acetic acid methyl ester (196) (300 mg, 1.21 mmol), DIPEA (0.32 mL, 1.82 mmol), and aniline (0.17 mL, 1.82 mmol) are dissolved in acetonitrile (4 mL) and heated under MW irradiation at 1000C for Ih. Acetonitrile is evaporated and the residue is purified by flash chromatography (Petroleum ether/EtOAc^S/S) to obtain intermediate 1145 as a colorless oil (229 mg, 73% yield).
Preparation of (3-fluoro-phenyI)-phenylamino-acetic acid (198): (3-Fluoro-phenyl)-phenylamino-acetic acid methyl ester (197) (229 mg, 0.88 mmol) and lithium hydroxide hydrate (74.1 mg, 1.77 mmol) are dissolved in THF/water (6 mL/2mL) and stirred at RT for 2h. THF is evaporated, the resulting basic aqueous solution is acidified till pH 1 with IM HCl. The precipitate is recovered by suction filtration and washed with IM HCl. The compound is dried at 400C under vacuum overnight to get intermediate 1146 as a white solid (186 mg, 75% yield).
Preparation of (3-fluoro-phenyl)-phenylamino-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C99):
PS-DCC (982 mg, 1.31 mmol, loading: 1.33 mmol/g) is suspended in dry THF (15 mL). (3-Fluoro-phenyl)-phenylamino-acetic acid hydrochloride (198) (184 mg, 0.65 mmol), HOBT (200 mg, 1.31 mmol), and (R)-quinuclidin-3-ol (249 mg, 1.96 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off and the filtrate is evaporated. The residue is dissolved in EtOAc and washed with NaHCO3, water and brine. The organic layer is dried over Na2SO4, filtered and evaporated to dryness. The crude compound is purified by filtration through a pad of silica-gel using DCM/MeOH=9/l as the eluent. The title compound is obtained as a colorless oil (129 mg, 56% yield, mixture of diastereoisomers) .
1H NMR (300 MHz, DMSO-d6) ppm: 7.31 - 7.52 (m, 3 H), 7.11 - 7.23 (m, 1 H), 6.98 - 7.11 (m, 2 H), 6.67 - 6.76 (m, 2 H), 6.51 - 6.63 (m, 1 H), 6.35 (d, 1 H), 5.35 and 5.36 (d, 1 H), 4.59 - 4.80 (m, 1 H), 2.97 and 3.07 (ddd, 1 H), 2.55 - 2.67 (m, 5 H), 1.67 - 1.74 and 1.81 - 1.95 (m, 1 H), 1.10 - 1.66 (m, 4 H);
LC-MS (ESI POS): 355.2 (MH+).
ClOO listed in Table 14 is alternatively prepared as previously described for C99, using methyl 2-(4-fluorophenyl)acetate instead of methyl 2-(3-fluorophenyl)acetate.
Table 14
Figure imgf000117_0001
EXAMPLE 36
Preparation of phenylamino-(4-trifluoromethyl-pheny.)-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C105)
Figure imgf000118_0001
C105 1104 1103
Scheme 36
Preparation of hydroxy-(4-trifluoromethyl-phenyl)-acetic acid ethyl ester (1101):
Ethyl 2-oxo-2-(4-(trifluoromethyl)phenyl)acetate (500 mg, 2.03 mmol) is dissolved in absolute EtOH (10 niL) and cooled at 00C under N2. NaBH4
(38.4 mg, 1.02 mmol) is added in two portions and the resulting suspension is allowed to warm to RT and stirred for 45 minutes. The solvent is evaporated, the resulting residue is diluted with Et2θ and cool water is added. The organic layer is separated, washed with water and brine, dried over Na2SO4, filtered and evaporated obtaining intermediate 1149 as a colorless oil (440 mg, 87% yield).
Preparation of methanesulfonyloxy-(4-trifluoromethyl-phenyl)- acetic acid ethyl ester (1102):
Hydroxy-(4-trifluoromethyl-phenyl)-acetic acid ethyl ester (1101) (440 mg, 1.77 mmol) and DIPEA (0.43 mL, 2.48 mmol) are dissolved in dry DCM (17 mL) and cooled at 00C under N2- Methanesulfonyl chloride (0.18 mL,
2.30 mmol) is added dropwise to the solution and the resulting mixture is allowed to warm to RT and stirred for 3h. The mixture is diluted with DCM and washed with sat. NaHCO3, water and brine. The organic layer is dried (Na2SO4), filtered and evaporated to obtain intermediate 1150 as a yellow oil
(578 mg, quantitative yield), which is used in the next step without any further purification.
Preparation of phenylamino-(4-trifluoromethyI-phenyl)-acetic acid ethyl ester (1103): Methanesulfonyloxy-(4-trifluoromethyl-phenyl)-acetic acid ethyl ester
(1102) (594 mg, 1.82 mmol), aniline (0.25 mL, 2.73 mmol), and DIPEA (0.48 mL, 2.73 mmol) are dissolved in acetonitrile (4 mL). The reaction is heated under microwave irradiation at 1000C for 1 hour and 30 minutes. Aniline (0.17 mL, 1.820 mmol) is added again and the reaction is heated under microwave irradiation at 1000C for 3 hours. Acetonitrile is removed under vacuum and the residue is purified by flash chromatography (Petroleum ether/DCM=75/25) to afford intermediate 1151 as a yellow oil (195 mg, 60% yield).
Preparation of phenylamino-(4-trifluoromethyl-phenyl)-acetic acid hydrochloride (1104):
Phenylamino-(4-trifluoromethyl-phenyl)-acetic acid ethyl ester (1103) (195 mg, 0.60 mmol) and lithium hydroxide hydrate (50.6 mg, 1.21 mmol) are dissolved in THF/water (9 mL/3mL) and stirred at RT for 4h and then at 400C for Ih. THF is evaporated and the remaining aqueous solution is acidified with IM HCl till pH 1. The resulting precipitate is recovered by suction filtration, washed with IM HCl and dried under vacuum at 400C overnight to obtain intermediate 1152 as a white solid (200 mg, quantitative yield).
Preparation of phenylamino-(4-trifluoromethyl-phenyl)-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester (C105):
PS-DCC (907 mg, 1.21 mmol, loading: 1.33 mmol/g) is suspended in dry THF (10 mL). Phenylamino-(4-trifluoromethyl-phenyl)-acetic acid hydrochloride (1104) (200 mg, 0.60 mmol), HOBT (185 mg, 1.21 mmol), and (R)-quinuclidin-3-ol (230 mg, 1.81 mmol) are added and the mixture is shaken at RT overnight. PS-DCC is filtered off, the filtrate is evaporated and the residue is dissolved in EtOAc and washed with NaHCO3, water and brine.
The organic layer is dried over Na2SO4, filtered and evaporated to dryness.
The resulting crude compound is purified by filtration through a pad of silica- gel using DCM/MeOH=9/l as the eluent. The title compound is obtained as a colorless oil (110 mg, 45% yield, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.69 - 7.83 (m, 4 H), 7.01 - 7.16 (m, 2 H), 6.65 - 6.79 (m, 2 H), 6.53 - 6.64 (m, 1 H), 6.42 (d, 1 H), 5.46 and 5.47 (d, 1 H), 4.66 - 4.81 (m, 1 H), 2.99 and 3.10 (ddd, 1 H), 2.54 - 2.88 (m, 4 H), 2.04 - 2.41 (m, 1 H), 0.92 - 1.97 (m, 5 H);
LC-MS (ESI POS): 405.2 (MH+).
EXAMPLE 37
Preparation of (S)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)- acetate (C106)
Figure imgf000120_0001
Scheme 37
A solution of 2-phenyl-2-(phenylamino)acetic acid (II) (500 mg, 2.20 mmol), (R)-quinuclidin-3-ol (280 mg, 2.20 mmol) and triphenylphosphine (577 mg, 2.20 mmol) in dry THF (7 mL) cooled at 00C, is added with (E)-diethyl diazene-l,2-dicarboxylate (0.35 mL, 2.20 mmol) and the reaction is stirred 2h at RT. The solvent is removed under vacuum and the residue is taken up with EtOAc, washed with 5% NaHCO3 and brine, dried over Na2SO4 and evaporated to dryness. The resulting yellow oil is purified by flash chromatography (EtOAc/MeOH/NH4OH =90/10/0.1 to 70/30/0.1) to obtain desired product as a white powder (78.0 mg, 10% yield, mixture of diastereoisomer).
1H NMR (300 MHz, DMSO-J6) ppm
Diastereoisomer 1 of C106: 7.48 - 7.62 (m, 2 H), 7.24 - 7.45 (m, 3 H), 6.98 - 7.11 (m, 2 H), 6.66 - 6.75 (m, 2 H), 6.51 - 6.62 (m, 1 H), 6.27 (d, 1 H), 5.25 (d, 1 H), 4.58 - 4.82 (m, 1 H), 3.08 (dd, 1 H), 2.54 - 2.70 (m, 5 H), 1.62 - 1.75 (m, 1 H), 0.97 - 1.60 (m, 4 H);
Diastereoisomer 2 of C106: 7.48 - 7.62 (m, 2 H), 7.24 - 7.45 (m, 3 H), 6.98 - 7.11 (m, 2 H), 6.66 - 6.75 (m, 2 H), 6.51 - 6.62 (m, 1 H), 6.27 (d, 1 H), 5.26 (d, 1 H), 4.58 - 4.82 (m, 1 H), 2.95 (m, 1 H), 2.54 - 2.70 (m, 4 H), 2.02 - 2.14 (m, 1 H), 1.86 - 1.95 (m, 1 H), 0.97 - 1.60 (m, 4 H);
LC-MS (ESI POS): 337.2 (MH+).
EXAMPLE 38
Preparation of phenyl-phenylamino-acetic acid l-methyl-azepan-4- yl ester (C107)
Figure imgf000121_0001
Scheme 38
A mixture of 2-phenyl-2-(phenylamino)acetic acid (II) (175 mg, 0.77 mmol), DCC (192 mg, 0.92 mmol), HOBt (124 mg, 0.92 mmol) and 1-methyl- azepan-4-ol (100 mg, 0.77 mmol) in dry THF (100 mL) is stirred at RT overnight under nitrogen flowstream (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the residue is taken up with aq. HCl and washed with EtOAc. The aqueous phase is basifϊed with NaHCO3 and extracted with DCM (three times). The organic layers are combined, dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is first purified by flash chromatography (DCM to DCM/MeOH=95/5) and then by preparative LC-MS. The purified compound is partitioned between sat. NaHCO3 and DCM, the organic phase is dried over Na2SO4, filtered and evaporated under vacuum to give 53 mg of the title compound as brown oil (20% yield, mixture of diastereoisomers).
1H NMR (300 MHz, CHLOROFORM-d) ppm: 12.76 (br. s., 1 H), 7.30 - 7.62 (m, 6 H), 7.07 - 7.23 (m, 2 H), 6.50 - 6.84 (m, 3 H), 5.15 - 5.39 (m, 1 H), 5.09 (d, 1 H), 3.21 - 3.79 (m, 2 H), 2.60 (d, 3 H), 1.80 - 3.15 (m, 8 H);
LC-MS (ESI POS): 339.2 (MH+).
EXAMPLE 39
Preparation of (R)-l-(2-phenoxy-ethyl)-3-((R)-2-phenyI-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane (Diastereoisomer 1 of C108)
Figure imgf000122_0001
Scheme 39
A solution of (R)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)acetate (diastereoisomer 1 of C2) (127 mg, 0.38 mmol), α-bromophenethole is added (91.2 mg, 0.45 mmol) and the mixture reacted in a closed vessel under MW irradiation for 1 hr at 1000C (LC-MS monitoring: complete conversion). The resulting crude is purified by preparative LC-MS to obtain the title compound as a pale yellow solid (18.9 mg, 14% yield, trifluoroacetate salt, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6 + Na2CO3) ppm: 7.46 - 7.69 (m, 2H), 7.21 - 7.46 (m, 5H), 6.89 - 7.16 (m, 5H), 6.66 - 6.80 (m, 2H), 6.58 (t, IH), 6.36 (d, IH), 5.34 (d, IH), 4.99 - 5.21 (m, IH), 4.34 (t, 2H), 3.86 - 4.08 (m, IH), 3.39 - 3.72 (m, 5H), 3.1 1 (d, IH), 2.78 - 3.02 (m, IH), 2.20 - 2.39 (m, 1 H), 1.61 - 2.15 (m, 4H);
LC-MS (ESI POS): 457.3 (MH+).
Final compounds listed in Table 15 are prepared as previously described for C 108, by alkylation of suitable compounds (Diastereoisomer 1 of C2, Diastereoisomer 2 of C2, C2, Diastereoisomer 1 of C3, Diastereoisomer 2 of C3, C12, C4, Diastereoisomer 2 of C22, C43 and C30) and the commercially available alkylating agents.
Table 15
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
(continue)
Figure imgf000126_0001
(continue)
Figure imgf000127_0001
(continue)
Figure imgf000128_0001
(continue)
Figure imgf000129_0001
(continue)
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
(continue)
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
(continue)
Figure imgf000137_0001
(continue)
Figure imgf000138_0001
(continue)
Figure imgf000139_0001
The compounds listed in Table 16 are prepared as previously described for C 108 by reaction of an equimolar mixture of diastereoisomer 1 and 2 of C2 with the suitable alkylating reagent.
Table 16
Figure imgf000140_0001
(continue) LC-MS (ESI POS): 419.3 (MH+)
1H NMR (300 MHz, DMSO-d6) ppm:
15% 7.51 - 7.67 (m, 2 H), 7.28 - 7.49 (m, 3 yield H), 6.99 - 7.19 (m, 2 H), 6.67 - 6.85
C139 (m, 2 H), 6.52 - 6.67 (m, 1 H), 5.33 (s,
Pale 1 H), 5.07 - 5.21 (m, 1 H), 4.87 - 5.07
Figure imgf000141_0001
yellow (m, 1 H), 3.66 - 3.94 (m, 1 H), 3.28 -
Mixture of oil 3.55 (m, 3 H), 3.09 - 3.28 (m, 2 H), diastereoisomers 2.82 - 3.08 (m, 2 H), 1.74 - 2.43 (m, 7 H), 1.63 (s, 3 H), 1.69 (s, 3 H)
LC-MS (ESI POS): 523.3 (MH+)
1H NMR (300 MHz, DMSO-d6) ppm:
16% 8.16 - 8.27 (m, 1 H), 7.92 (d, 2 H), yield 7.53 - 7.66 (m, 2 H), 7.27 - 7.49 (m, 3 H), 7.00 - 7.16 (m, 2 H), 6.68 - 6.81
C140 (m, 2 H), 6.52 - 6.66 (m, 1 H), 5.37 (s,
Pale 1 H), 5.17 - 5.27 (m, 1 H), 4.94 - 5.17
Figure imgf000141_0002
yellow (m, 2 H), 3.92 - 4.25 (m, 1 H), 3.65 -
Mixture of oil 3.81 (m, 1 H), 3.54 - 3.69 (m, 3 H), diastereoisomers 3.30 - 3.54 (m, 1 H), 1.38 - 2.45 (m, 5 H)
EXAMPLE 40
Preparation of (R)-l-(2-oxo-2-phenyI-ethyI)-3-((R)-2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane (Diastereoisomer 1 of C141)
Figure imgf000141_0003
diastereoisomer 1 of C2 diastereoisomer 1 of C 141
Scheme 40
A solution of (R)-phenyl-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (153 mg, 0.45 mmol), is added with α-chloroacetophenone (107 mg, 0.54 mmol) and the mixture reacted in a closed vessel under MW irradiation for lhr at 1000C (LC-MS monitoring: complete conversion). The resulting crude is purified by flash chromatography (DCM/MeOH=9/l) to obtain the title compound as a white solid (108.9 mg, 50% yield, chloride salt, single diastereoisomer).
1H NMR (400 MHz, DMSO-d6) ppm: 7.96 (d, 2H) 7.70 - 7.81 (m, IH) 7.58 (d, 2H) 7.62 (d, 2H) 7.29 - 7.47 (m, 3H) 7.09 (t, 2H) 6.74 (d, 2H) 6.59 (t, IH) 6.41 (d, IH) 5.39 (d, IH) 5.16 - 5.26 (m, IH) 5.13 (s, 2H) 4.08 (ddd, IH) 3.47 - 3.71 (m, 4 H) 3.35 - 3.47 (m, IH) 2.36 (br. s., IH) 1.84 - 2.13 (m, 4H);
LC-MS (ESI POS): 455.27 (MH+).
The compounds listed in Table 17 are prepared as previously described for C33 by reaction of C12, diastereoisomer 1 of C2 or C24 with the commercially available alkylating agents
Table 17
Figure imgf000142_0001
LC-MS (ESI POS): 394.2 (MH+)
1H NMR (300 MHz, DMSO- d6) ppm: 7.88 (br. s., 1 H), 7.68 (br. s., 1 H), 7.48 - 7.61
78% (m, 2 H), 7.26 - 7.48 (m, 3 H), yield 6.98 - 7.20 (m, 2 H), 6.67 - 6.81 (m, 2 H), 6.52 - 6.67 (m,
Diastereoisomer 1 H), 6.34 (d, 1 H), 5.35 (d, 1 l of C143
Figure imgf000143_0001
H), 5.03 - 5.25 (m, 1 H), 4.02
Yellow (ddd, 1 H), 3.93 (d, 1 H), 3.87
Single solid (d, 1 H), 3.37 - 3.69 (m, 4 H), diastereoisomer 3.13 - 3.27 (m, 1 H), 2.21 - 2.40 (m, 1 H), 1.76 - 2.05 (m, 4 H)
[α]D= -41.19° (c=0.27, MeOH)
LC-MS (ESI POS): 470.3 (MH+)
1H NMR (300 MHz, DMSO- d6) ppm: 10.52 (s, 1 H), 7.47
86% - 7.70 (m, 4 H), 7.24 - 7.47 yield (m, 5 H), 6.98 - 7.24 (m, 3 H), 6.66 - 6.84 (m, 2 H), 6.51 -
Diastereoisomer 6.66 (m, 1 H), 6.35 (d, 1 H), l of C144
Figure imgf000143_0002
5.37 (d, 1 H), 5.06 - 5.27 (m,
Yellow 1 H), 4.17 (d, 1 H), 4.11 (d, 1
Single solid H), 3.99 - 4.09 (m, 1 H), 3.46 diastereoisomer - 3.74 (m, 4 H), 3.20 - 3.36 (m, 1 H), 2.30 - 2.43 (m, 1 H), 1.80 - 2.13 (m, 4 H)
[<X]D= -55.2° (c=0.25, MeOH)
(continue)
Figure imgf000144_0001
EXAMPLE 41
Preparation of (R)-l-(2-oxo-2-phenyl-ethyI)-3-((R)-2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo [2.2.2] octane bromide
(Diastereoisomer 1 of C147)
Figure imgf000144_0002
EtOAc
diastereoisomer 1 of C2
Figure imgf000144_0003
Scheme 41 (R)-Quinuclidin-3-yl 2-phenyl-2-(phenylamino)acetate (Diastereoisomer 1 of C2) (20.3 mg, 0.06 mmol) is dissolved in EtOAc (0.60 mL) and 2-bromo- 1-phenylethanone (12.0 mg, 0.06 mmol) is added. The reaction is stirred at room temperature for 2 hours (UPLC-MS: complete and clean conversion). Et2O (0.20 mL) is added and the product is triturated to obtain a white solid which is isolated by filtration and dried under vacuum overnight (31 mg, 96% yield, bromide salt, single diastereoisomer).
1U NMR (300 MHz, DMSO-d6) ppm: 7.89 - 8.08 (m, 2 H), 7.69 - 7.84
(m, 1 H), 7.52 - 7.69 (m, 4 H), 7.31 - 7.48 (m, 3 H), 6.99 - 7.17 (m, 2 H), 6.68 - 6.83 (m, 2 H), 6.51 - 6.66 (m, 1 H), 6.37 (d, 1 H), 5.39 (d, 1 H), 5.17 - 5.26
(m, 1 H), 5.13 (s, 2 H), 4.04 - 4.17 (m, 1 H), 3.34 - 3.79 (m, 5 H), 2.32 - 2.40
(m, 1 H), 1.83 - 2.16 (m, 4 H);
LC-MS (ESI POS): 455.3 (MH+). EXAMPLE 42 Preparation of (R)-3-((S)-2-amino-phenylpropanoyIoxy)-l-(2- phenoxyethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate trifluoroacetate anion (Diastereoisomer 1 of C149)
Figure imgf000145_0001
Scheme 42 Preparation of (R)-3-((S)-2-tertbutoxycarbonylamino- phenylpropanoy!oxy)-l-(2-phenoxyethyl)-l-azonia-bicycIo[2.2.2]octane bromide (1148)
A solution of (S)-((R)-quinuclidin-3-yl)-2-(tert-butoxycarbonylamino)- 3-phenylpropanoate (119) (200 mg, 0.53 mmol), is added with α- bromophenethole (130 mg, 0.64 mmol) and the mixture reacted in a closed vessel under MW irradiation for lhr at 1000C (LC-MS monitoring: complete conversion). The solvent is evaporated under reduced pressure and the resulting crude is used without further purification. Preparation of (R)-3-((S)-2-amino-phenylpropanoyloxy)-l-(2- phenoxyethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate trifluoroacetate anion (Diastereoisomer 1 of C149)
A solution of (R)-3-((S)-2-tertbutoxycarbonylamino- phenylpropanoyloxy)- l-(2-phenoxyethyl)- l-azonia-bicyclo[2.2.2]octane bromide (1148) (0.53 mmol) in DCM (5 mL), is added with trifluoroacetic acid (0.50 mL, 4.41 mmol) and the mixture stirred at RT overnight. The solvent is evaporated and the resulting crude is purified by preparative LC-MS to obtain the title compound as a brown gummy solid (112 mg, 43% overall yield, trifluoroacetate salt and trifluoroacetate anion, single diastereoisomer). 1H NMR (300 MHz, DMSO-d6) ppm: 8.60 (br. s., 3H), 7.19 - 7.45 (m,
7H), 6.82 - 7.13 (m, 3H), 5.03 - 5.25 (m, IH), 4.39 - 4.48 (m, 2H), 4.25 - 4.38 (m, IH), 3.90 - 4.09 (m, IH), 3.28 - 3.52 (m, 7 H), 3.19 (dd, IH), 3.10 (dd, IH), 2.09 (br. s., IH), 1.81 - 2.04 (m, 2H), 1.66 - 1.79 (m, 2H); LC-MS (ESI POS): 395.4 (MH+). The compounds listed in Table 18 are prepared as previously described for C149, by reaction of 119 with 2-chloroacetylthiophene, 3-phenoxypropyl bromide and α-bromoacetophenone. Table 18
Figure imgf000147_0001
Figure imgf000148_0001
EXAMPLE 43
Preparation of (R)-l-(2-oxo-2-phenylethyl)-3-((R)-3-phenyl-2- (phenylamino)propanoyloxy)-l-azoniabicyclo|2.2.2]octane bromide
(Diastereoisomer 1 of C153)
Figure imgf000148_0002
diasteroisomer 1 of C22
Figure imgf000148_0003
Scheme 43
A solution of (R)-((R)-quinuclidin-3-yl) 3-phenyl-2-(phenylamino)- propanoate (Diastereoisomer 1 of C22) (50.0 mg, 0.14 mmol), is added with 2- bromo- 1 -phenylethanone (28.4 mg, 0.14 mmol) and the mixture reacted in a closed vessel under MW irradiation for Ih at 1000C (LC-MS monitoring: complete conversion). Solvent is removed under reduced pressure and residue is triturated with EtOAc to obtain the title compound as a white solid (75.5 mg, 98% yield, bromide salt, single diastereoisomer). 1H NMR (300 MHz5 DMSO-d6) ppm: 7.92 - 8.10 (m, 2 H), 7.71 - 7.85 (m, 1 H), 7.51 - 7.71 (m, 2 H), 7.27 - 7.44 (m, 4 H), 7.17 - 7.26 (m, 1 H), 6.95 - 7.16 (m, 2 H), 6.45 - 6.77 (m, 3 H), 6.1 1 (d, 1 H), 5.05 - 5.21 (m, 3 H), 4.23 - 4.50 (m, 1 H), 3.94 - 4.20 (m, 1 H), 3.49 - 3.81 (m, 3 H), 3.35 - 3.49 (m, 2 H), 3.15 (dd, 1 H), 3.08 (dd, 1 H), 2.17 - 2.37 (m, 1 H), 1.94 - 2.17 (m, 2 H), 1.70 - 1.94 (m, 2 H);
LC-MS (ESI POS): 469.3 (MH+);
[α]D= -8.19° (c=0.53, MeOH).
Diastereoisomer 2 of C 154 listed in Table 19 is prepared as previously described for C 153, by reaction of 170 with 2-chloroacetylthiophene
Table 19
Figure imgf000149_0001
Preparation of (R)-l-[2-(4-methoxy-phenyl)-2-oxo-ethyl]-3-((R)-2- phenyl-2-phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (diastereoisomer 1 of C155)
Figure imgf000150_0001
Diasteroisomer 1 of C2 Diasteroisomer 1 of C 155
Scheme 44 A solution of (R)-phenyl-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (120 mg, 0.35 mmol) in acetonitrile (5 mL), is added with 2-bromo- l-(4-methoxy-phenyl)-ethanone (99 mg, 0.43 mmol) and the mixture is heated under MW irradiation for lhr at 1000C (UPLC-MS monitoring: complete conversion). Solvent was evaporated and the resulting crude is first purified by flash chromatography (DCM/MeOH=99/l to 9/1) and then purified by preparative LC-MS to obtain the title compound as a white solid (70.2 mg, 33% yield, trifluoroacetate salt, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6) ppm: 7.84 - 8.06 (m, 2 H), 7.51 - 7.71 (m, 2 H), 7.25 - 7.51 (m, 3 H), 6.95 - 7.22 (m, 4 H), 6.67 - 6.80 (m, 2 H), 6.53 - 6.67 (m, 1 H), 6.35 (br. s., 1 H), 5.38 (s, 1 H), 5.13 - 5.30 (m, 1 H), 5.01 (s, 2 H), 3.97 - 4.17 (m, 1 H), 3.88 (s, 3 H), 3.19 - 3.50 (m, 5 H), 2.31 - 2.42 (m, 1 H), 1.68 - 2.20 (m, 4 H);
LC-MS (ESI POS): 485.2 (MH+); [α]D=-48.32° (c=0.25, MeOH).
Final compounds listed in Table 20 are prepared as previously described for C155, by alkylation of suitable intermediate (Diastereoisomer 1 of C2, Diastereoisomer 2 of C2, Diastereoisomer 1 of C37, C29, C 105, C 13, C 14) and the commercially available alkylating agents. Table 20
Figure imgf000151_0001
(continue)
Figure imgf000152_0001
(continue)
Figure imgf000153_0001
(continue)
Figure imgf000154_0001
(continue)
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
(continue)
Figure imgf000158_0001
(continue)
Figure imgf000159_0001
(continue)
Figure imgf000160_0001
Figure imgf000161_0001
EXAMPLE 45
Preparation of (R)-l-[2-(2,4-difluoro-phenyl)-2-oxo-ethyl]-3-(2- phenyl-2-phenylamino-acetoxy)-l-azonia-bicyclo [2.2.2] octane bromide(diastereoisomer 1 of C174)
Figure imgf000162_0001
Diastereoismer 1 of C2 Diastereoismer 1 of C174
Scheme 45
A solution of (R)-phenyl-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (50 mg, 0.15 mmol) in acetonitrile (1 mL), is added with 2-bromo-l-(2,4-difluoro-phenyl)-ethanone
(35 mg, 0.15 mmol) and the mixture reacted in a closed vessel under MW irradiation for lhr at 1000C (UPLC-MS monitoring: complete conversion).
The solvent is evaporated and the resulting crude is purified by flash chromatography (DCM/MeOH=95/5) to obtain the title compound as a white solid (37.3 mg, 44% yield, bromide salt, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6) ppm: 7.97 - 8.07 (m, 1 H), 7.52 - 7.72 (m, 3 H), 7.39 - 7.52 (m, 2 H), 7.25 - 7.39 (m, 2 H), 6.92 - 7.21 (m, 2 H), 6.67 - 6.84 (m, 2 H), 6.51 - 6.67 (m, 1 H), 6.36 (d, 1 H), 5.38 (d, 1 H), 5.00 - 5.30 (m, 1 H), 4.88 (br. s., 2 H), 3.91 - 4.20 (m, 1 H), 3.51 - 3.74 (m, 3 H), 3.41 - 3.51 (m, 1 H), 3.31 - 3.41 (m, 1 H), 2.31 - 2.43 (m, 1 H), 1.86 - 2.09 (m, 4 H); LC-MS (ESI POS): 491.1 (MH+); [α]D=-45.42° (c=0.24, MeOH).
Final compounds listed in Table 21 are prepared as previously described for C 174, by alkylation of suitable intermediate (Diastereoisomer 1 of C2, C2, C80, C83, C85, C89, C87, C95, ClOl, C94, C95 ClOO, C132, C133, C143, C27, C138) and the commercially available alkylating agents. Table 21
Figure imgf000163_0001
(continue)
Figure imgf000164_0001
(continue)
Figure imgf000165_0001
(continue)
Figure imgf000166_0001
(continue)
Figure imgf000167_0001
(continue)
Figure imgf000168_0001
(continue)
Figure imgf000169_0001
(continue)
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
(continue)
Figure imgf000173_0001
(continue)
Figure imgf000174_0001
(continue)
Figure imgf000175_0001
(continue)
Figure imgf000176_0001
(continue)
Figure imgf000177_0001
(continue)
Figure imgf000178_0001
(continue) :
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
(continue)
Figure imgf000182_0001
(continue) :
Figure imgf000183_0001
EXAMPLE 46
Preparation of (R)-3-[2-(3-fluoro-4-methyl-phenyIamino)-2-phenyl- acetoxy]-l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide
Figure imgf000184_0001
Scheme 46
(R)-Quinuclidin-3-yl 2-(3-fluoro-4-methylphenylamino)-2-phenylacetate (C97) (80 mg, 0.22 mmol) and 2-bromo-l-phenylethanone (45.4 mg, 0.23 mmol) are dissolved in acetonitrile (3 mL) and stirred at RT overnight (Conversion complete by UPLC/MS). Acetonitrile is evaporated and the residue is purified by flash chromatography (DCM/MeOH=97/3) affording the title compound as a white solid (29 mg, 23% yield, bromide salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 7.92 - 8.05 (m, 2 H), 7.71 - 7.86 (m, 1 H), 7.50 - 7.71 (m, 4 H), 7.28 - 7.50 (m, 3 H)5 6.95 and 6.97 (d, 1 H), 6.38 - 6.62 (m, 3 H), 5.37 and 5.41 (d, 1 H), 5.19 - 5.27 (m, 1 H), 5.15 (s, 2 H), 4.00 - 4.27 (m, 1 H), 3.79 (d, 1 H), 3.40 - 3.72 (m, 4 H), 2.10 - 2.20 and 2.33 - 2.42 (m, 1 H), 2.04 (s, 3 H), 1.85 - 2.02 (m, 2 H), 1.65 - 1.85 (m, 1 H), 1.42 - 1.65 (m, I H);
LC-MS (ESI POS): 487.1 (MH+). Final compounds listed in Table 22 are prepared as previously described for C209, by alkylation of suitable intermediate (C103, C106, C107, C 109, Cl 12, C l 15, Cl 17, C147, C148) and the commercially available alkylating agents. Table 22
Figure imgf000185_0001
(continue)
Figure imgf000186_0001
(continue)
Figure imgf000187_0001
(continue)
Figure imgf000188_0001
Figure imgf000189_0001
(continue)
Figure imgf000190_0001
Figure imgf000191_0001
(continue)
Figure imgf000192_0002
EXAMPLE 47
Preparation of (R)-l-(2-oxo-2-phenylethyl)-3-((R)-2-phenyI-2- (phenylamino)acetoxy)-l-azoniabicyclo[2.2.2]octane chloride
(Diastereoisomer 1 of C113)
Figure imgf000192_0001
Diastereoisomer 1 of C2 Diastereoisomer 1 of C113
Scheme 47 A mixture of 2-chloroacetophenone (6.20 g, 40.3 mmol) and (R)-((R)- quinuclidin-3-yl) 2-phenyl-2-(phenylamino)acetate) (Diastereoisomer 1 of C2) (12.3 g, 36.6mmol) in EtOAc (100ml) is stirred at RT for 2 days (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the crude is purified by flash chromatography eluting with DCM/MeOH=95/5 to get 10. Ig of the title compound as a white solid (56% yield, chloride salt, single diastereoisomer).
1H NMR (400 MHz, DMSO-d6): ppm 7.96 (d, 2H) 7.70 - 7.81 (m, IH) 7.58 (d, 2H) 7.62 (d, 2H) 7.29 - 7.47 (m, 3H) 7.09 (t, 2H) 6.74 (d, 2H) 6.59 (t, IH) 6.41 (d, IH) 5.39 (d, IH) 5.16 - 5.26 (m, IH) 5.13 (s, 2H) 4.08 (ddd, IH) 3.47 - 3.71 (m, 4 H) 3.35 - 3.47 (m, IH) 2.36 (br. s., IH) 1.84 - 2.13 (m, 4H);
LC-MS (ESI POS): 455.3 (MH+).
Diastereoisomer 1 of C220 and C221 listed in Table 23 are obtained as previously described for diastereoisomer 1 of Cl 13, using bromo-acetonitrile and bromo-acetic acid tert-butyl ester instead of 2-chloroacetophenone.
Table 23
Figure imgf000194_0001
EXAMPLE 48
Preparation of (S)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane chloride (C222)
Figure imgf000195_0001
Scheme 48
A solution of (S)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)acetate (50.0 mg, 0.15 mmol) in EtOAc (2 mL), is added with 2-chloro-l-phenylethanone (23.0 mg, 0.15 mmol) and the reaction is stirred first at RT for 15h, then at 700C for 7h and finally at RT for 3 days. The solvent is removed and the resulting crude is triturated with i-Pr2O/Et2O (3/1) and then with i-Pr2O to afford the title compound as a beige solid (47.7 mg, 65% yield, chloride salt, mixture of diastereoisomers). 1H NMR (300 MHz, DMSO-J6) Ppm: 7.92 - 8.03 (m, 2 H) 7.71 - 7.81 (m, 1
H) 7.52 - 7.67 (m, 4 H) 7.30 - 7.47 (m, 3 H) 7.04 - 7.15 (m, 2 H) 6.69 - 6.79 (m, 2 H) 6.55 - 6.64 (m, 1 H) 6.38 (d, 1 H) 5.39 (d, 1 H) 5.18 - 5.28 (m, 1 H) 5.13 (s, 2 H) 4.00 - 4.19 (m, 1 H) 3.48 - 3.78 (m, 4 H) 3.34 - 3.48 (m, 1 H) 2.31 - 2.42 (m, 1 H) 1.84 - 2.16 (m, 4 H); LC-MS (ESI POS): 455.2 (MH+). EXAMPLE 49
Preparation of (R)-3-[2-(3-acetyl-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane formate (C223)
Figure imgf000196_0001
Scheme 49
(R)-Quinuclidin-3-yl 2-(3-acetylphenylamino)-2-phenylacetate (C53) (134 mg, 0.35 mmol) and 2-bromo-l-phenylethanone (85.0 mg, 0.42 mmol) are dissolved in ethyl acetate (5 mL) and stirred at RT for 2h. EtOAc is evaporated and the resulting crude oil is first purified by flash chromatography (DCM/MeOH=95/5) and then by preparative HPLC. The fractions containing the product are combined and concentrated under vacuum to remove the organic solvent. The resulting aqueous solution is freeze-dried obtaining the title compound as a white-foam (77.7 mg, 40% yield, formate salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-Uf6) ppm: 8.44 (s, 1 H, formiate), 7.92 - 8.05 (m, 2 H), 7.69 - 7.80 (m, 1 H), 7.51 - 7.66 (m, 4 H), 7.15 - 7.49 (m, 6 H), 6.97 - 7.07 (m, 1 H), 6.76 and 6.78 (d, 1 H), 5.46 and 5.49 (d, 1 H), 5.23 - 5.28 (m, 1 H), 5.17 and 5.22 (s, 2 H), 4.01 - 4.26 (m, 1 H), 3.36 - 3.87 (m, 5 H), 2.48 (s, 3 H), 2.12 - 2.20 and 2.33 - 2.40 (m, 1 H), 1.48 - 2.11 (m, 4 H); LC-MS (ESI POS): 497.1 (MH+). EXAMPLE 50
Preparation of (R)-l-[2-(4-acetylamino-phenyl)-2-oxo-ethyl]-3-((R)- 2-phenyl-2-phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide (C224)
Figure imgf000197_0001
Diastereoisomer 1 of C2 Diastereoisomer 1 of C224
Scheme 50
A mixture (R)-((R)-quinuclidin-3-yl) 2-phenyl-2-(phenylamino)acetate (Diastereoisomer 1 of C2) (80.0 mg, 0.24 mmol) and N-(4-(2- bromoacetyl)phenyl)acetamide (60.9 mg, 0.24 mmol) in acetonitrile (2 mL) is heated in a microwave oven at 1000C for 1 hour (UPLC-MS monitoring: complete conversion). The title compound is isolated by suction filtration and washed with Et2O (98.2 mg, 81% yield, off-white solid, bromide salt, single diastereoisomers). 1H NMR (300 MHz, DMSO-d6) ppm: 10.44 (s, 1 H), 7.85 - 7.97 (m, 2
H), 7.69 - 7.84 (m, 2 H), 7.52 - 7.63 (m, 2 H), 7.25 - 7.49 (m, 3 H), 6.97 - 7.19 (m, 2 H), 6.70 - 6.79 (m, 2 H), 6.52 - 6.64 (m, 1 H), 6.37 (d, 1 H), 5.38 (d, 1 H), 5.14 - 5.27 (m, 1 H), 5.04 (s, 2 H), 3.88 - 4.20 (m, 1 H), 3.33 - 3.78 (m, 5 H), 2.31 - 2.43 (m, 1 H), 2.1 1 (s, 3 H), 1.84 - 2.05 (m, 4 H); LC-MS (ESI POS): 512.2 (MH+).
C225 listed in Table 24 is obtained as previously described for C224, using 4-(2-bromo-acetyl)-benzoic acid methyl ester instead of N-[4-(2-bromo- acetyl)-phenyl]-acetamide. Table 24
Figure imgf000198_0001
EXAMPLE 51
Preparation of (R)-3-((R)-2-phenyl-2-phenylamino-acetoxy)-l- pyridin^-ylmethyl-l-azonia-bicycloβ^^Joctane trifluoroacetate trifluoroacetate anion (Diastereoisomer 1 of C226)
Figure imgf000198_0002
Diastereoisomer 1 of C2 Diastereoisomer 1 of C226
Scheme 51
A solution of (R)-phenyl-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (100 mg, 0.30 mmol) and DIPEA (61 uL, 0.36 mmol) in acetonitrile (4 mL), is added with 2- bromomethyl-pyridine hydrobromide (91.0 mg, 0.36 mmol) and the mixture is heated under MW irradiation for lhr at 1000C (UPLC-MS monitoring: complete conversion). Solvent is evaporated and the resulting crude is first purified by flash chromatography (DCM/MeOH=98/2 to 9/1) and then by preparative LC-MS to obtain the title compound as a brown viscous oil (58 mg, 36% yield, trifluoroacetate trifluoroacetate anion, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6) ppm: 8.68 (ddd, 1 H), 7.96 (td, 1 H), 7.41 - 7.71 (m, 4 H), 7.23 - 7.41 (m, 3 H), 6.93 - 7.16 (m, 2 H), 6.70 (m, 2 H),
6.58 (m, 1 H), 5.32 (s, 1 H), 5.02 - 5.18 (m, 1 H), 4.46 (d, 1 H), 4.41 (d, 1 H),
3.90 (ddd, 1 H), 3.39 - 3.60 (m, 3 H), 3.17 (d, 1 H), 2.74 - 2.92 (m, 1 H), 2.20
- 2.35 (m, 1 H), 1.74 - 2.04 (m, 4 H);
LC-MS (ESI POS): 428.2 (MH+); [α]D=-40.80° (c=0.25, MeOH).
Diastereoisomer 1 of C227 listed in Table 25 is obtained as previously described for diastereoisomer 1 of C226, using 2-bromo- l-pyridin-2-yl- ethanone hydrobromide instead of 2-bromomethyl-pyridine hydrobromide.
Figure imgf000200_0001
EXAMPLE 52
Preparation of (R)-l-(2-(2-methylthiazol-4-yl)-2-oxoethyl)-3-((R)-2- phenyl-2-(phenylamino)acetoxy)-l-azoniabicyclo[2.2.2]octane bromide (C229)
Figure imgf000201_0001
Scheme 52
Preparation of 2-bromo-l-(2-methyl-thiazol-5-yl)-ethanone (1228): A solution of 2-methylthiazole-4-carbonyl chloride (0.34 g, 2.10 mmol) in dry MeCN (8 mL) cooled at 00C, under nitrogen atmosphere, is slowly added with (diazomethyl)trimethylsilane (3.14 ml, 6.29 mmol, 2.0M in hexane). The reaction is stirred at RT for 15h (UPLC-MS monitoring: complete conversion). The reaction is cooled at 00C and 48% hydrobromic acid (1.23 mL, 7.34 mmol) is added dropwise. The reaction is stirred at RT for 3h. Then EtOAc and water are added, the organic layer is separated and the aqueous phase is neutralized with IM NaOH and extracted with EtOAc. The combined organic layers are dried over Na2SO4, filtered and evaporated to dryness to obtain compound 1228 as a dark brown gummy solid (400 mg, 87% yield).
Preparation of (R)-l-(2-(2-methyIthiazol-4-yl)-2-oxoethyl)-3-((R)-2- phenyl-2-(phenylamino)acetoxy)-l-azoniabicyclo[2.2.2]octane bromide (C229):
(R)-Phenyl-phenylamino-acetic acid (R)-(I -aza-bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (75.0 mg, 0.22 mmol) and 2-bromo- l-(2- methylthiazol-4-yl)ethanone (1228) (49.1 mg, 0.22 mmol) in acetonitrile (5 mL) is heated at 100°C for 75 minutes under microwave irradiation (UPLC- MS monitoring: complete conversion). The solvent is removed and the resulting brown solid is triturated with iPr2O/Et2O (1/1) and then with iPrOH to obtain the title compound as a grey powder (43.3 mg, 35% yield, bromide salt, single diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 8.59 (s, 1 H) 7.53 - 7.66 (m, 2 H) 7.29
- 7.51 (m, 3 H) 7.01 - 7.15 (m, 2 H) 6.69 - 6.82 (m, 2 H) 6.56 - 6.66 (m, 1 H) 6.36 (d, 1 H) 5.37 (d, 1 H) 5.10 - 5.25 (m, 1 H) 5.02 (s, 2 H) 4.00 - 4.17 (m, 1 H) 3.45 -
3.75 (m, 4 H) 3.35 - 3.45 (m, 1 H) 2.75 (s, 3 H) 2.31 - 2.40 (m, 1 H) 1.80 - 2.10
(m, 4 H);
LC-MS (ESI POS): 476.2 (MH+).
EXAMPLE 53
Preparation of (R)-l-(6-amino-pyridin-2-ylmethyl)-3-((R)-2-phenyl- 2-phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate trifluoroacetate anion (Diastereoisomers 1 of C233)
Figure imgf000203_0001
diasteroisomers 1 of C2
Figure imgf000203_0002
Diastereoisomer 1 of C233 I232
Scheme 53
Preparation of N,N-(bis-tert-butoxycarbonyl)-6-methylpyridin-2- amine (1230): A mixture of 6-methylpyridin-2-amine (5.00 g, 46.3 mmol), di-tert- butyl dicarbonate (24.2 g, 111 mmol) and DIPEA (9.4 mL, 55.5 mmol) in DCM (40 mL) is stirred at RT for 3 days. The organic phase is washed with 5% citric acid and then with sat. NaHCO3. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The crude is purified by flash chromatography (Petroleum ether/EtOAc=9/l) to obtain intermediate 1230 as a white solid (3.0 g, 21% yield).
Preparation of N,N-(bis tert-butoxycarbonyl)- 6- (bromomethyl)pyridin-2-amine (1231):
A catalytic amount of azobisisobutyronitrile (5% w/w) is added to a solution of N,N-(bis-tert-butoxycarbonyl)- 6-methylpyridin-2-amine (1230) (308 mg, 1.00 mmol) and N-bromo-succinimide (284 mg; 1.6 mmol) in carbon tetrachloride (8 mL). The reaction is refluxed for two hours, diluted with DCM and washed with water. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The crude is purified by flash chromatography (DCM) to obtain intermediate 1231 as a yellow solid (240 mg, 83% yield).
Preparation of (R)-l-(N,N-(bis tert-butoxycarbonyl)-6-amino- pyridin-2-yImethyl)-3-(2-phenyI-2-phenylamino-acetoxy)-l-azonia- bicyclo[2.2.2]octane bromide (1232):
A solution of (R)-phenyl-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (Diastereoisomer 1 of C2) (100 mg, 0.54 mmol) in acetonitrile (5 mL), is added with N,N-(bis tert-butoxycarbonyl)-6- (bromomethyl)pyridin-2-amine (240 mg, 1.15 mmol) and the mixture is heated under MW irradiation for 30 minutes at 1000C (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the resulting crude is purified by flash chromatography (DCM to DCM/MeOH=9/l) to obtain intermediate 1232 as a colorless oil (125 mg, 32% yield). Preparation of (R)-l-(6-amino-pyridin-2-ylmethyl)-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate trifluoroacetate anion (diastereoisomers 1 of C233):
Trifluoroacetic acid (0.5 mL) is added to a solution of (R)-I -(N,N-(bis tert-butoxycarbonyl)-6-amino-pyridin-2-ylmethyl)-3-(2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide (1232) (125 mg, 0.19 mmol) in DCM (5 mL). The reaction is stirred at RT for 2 days. Solvent is removed under vacuum and the crude is purified by preparative LC-MS to obtain the title compound as a brown oil (21 mg, 16% yield, trifluoroacetate trifluoroacetate anion, single diastereoisomer).
1H NMR (300 MHz, DMSO-d6) ppm: 7.42 - 7.59 (m, 3 H), 7.22 - 7.42 (m, 3 H), 6.97 - 7.17 (m, 2 H), 6.66 - 6.82 (m, 2 H), 6.44 - 6.66 (m, 3 H), 5.33 (s, 1 H), 5.03 - 5.21 (m, 1 H), 4.13 (s, 2 H), 3.75 - 3.95 (m, 1 H), 3.29 - 3.61 (m, 3 H), 3.14 (d, 1 H), 2.75 - 2.96 (m, 1 H), 2.18 - 2.35 (m, 1 H), 1.54 - 2.14 (m, 4 H);
LC-MS (ESI POS): 443.1 (MH+).
EXAMPLE 54
Preparation of (R)-3-{2-[(4-fluoro-phenyl)-methyl-amino]-2-phenyl- acetoxy}-l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride (C234)
Figure imgf000205_0001
Scheme 54
A solution of [(4-fluoro-phenyl)-methyl-amino]-phenyl-acetic acid (R)- (l-aza-bicyclo[2.2.2]oct-3-yl) ester (C120) (100 mg, 0.27 mmol) in ethyl acetate (2.7 mL), is added with 2-chloro-l-(thiophen-2-yl)ethanone (48.0 mg,
0.30 mmol). The reaction is stirred at RT for 3.5 days. The suspension is evaporated and the residue is triturated with Et2θ (8 mL). The solid is filtered on a buckner funnel and the sticky solid is dissolved in DCM. The solution is evaporated giving the title compound as a pale yellow solid (120 mg, 84 % yield, chloride salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-</6) ppm: 8.21 (dd, 1 H), 8.11 (d, 1 H), 7.26 - 7.52 (m, 6 H), 7.02 - 7.15 (m, 2 H), 6.88 - 7.02 (m, 2 H), 5.91 and 5.92 (s, 1 H), 5.23 - 5.44 (m, 1 H), 5.19 (d, 1 H), 5.11 (d, 1 H), 4.07 - 4.34 (m, 1 H), 3.36 - 3.92 (m, 5 H), 2.73 (s, 3 H), 2.20 - 2.33 (m, 1 H), 1.47 - 2.12 (m, 4 H);
LC-MS (ESI POS): 493.1 (MH+).
EXAMPLE 55
Preparation of (R)-3-[2-(methyl-phenyl-amino)-2-phenyl-acetoxy]- l-(2-oxo-2-thiazol-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide
(C235)
Figure imgf000206_0001
Scheme 55 2-Bromo-l-(l,3-thiazol-2-yl)ethanone (54.2 mg, 0.26 mmol) is added to a solution of (R)-quinuclidin-3-yl 2-(methyl(phenyl)amino)-2-phenylacetate (C75)
(92.2 mg, 0.26 mmol) in EtOAc (5 mL). The mixture is stirred at RT overnight. The solvent is evaporated to dryness and the crude is triturated with Et2θ. The yellow solid is collected by filtration (120 mg, 82% yield, bromide salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 8.39 (d, 1 H), 8.25 (d, 1 H), 7.32 - 7.50 (m, 5 H), 7.19 - 7.30 (m, 2 H), 6.84 - 7.00 (m, 2 H), 6.67 - 6.85 (m, 1 H), 5.97 (s, 1 H), 5.23 - 5.38 (m, 1 H), 5.19 and 5.20 (s, 2 H), 4.04 - 4.29 (m, 1 H), 3.44 - 3.82 (m, 5 H), 2.76 and 2.77 (s, 3 H), 2.24 - 2.36 (m, 1 H), 1.45 - 2.13 (m, 4 H); LC-MS (ESI POS): 476.0 (MH+).
C236 listed in Table 26 is obtained as previously described for C235, using 2-bromo- l-thiophen-3-yl-ethanone instead of 2-bromo-l-(l,3-thiazol-2- yl)ethanone. Table 26
Figure imgf000207_0001
EXAMPLE 56
Preparation of (R)-3-(2-benzyIamino-2-phenyl-acetoxy)-l-[2-(3- ethoxycarbonyl-isoxazol-5-yl)-2-oxo-ethyl]-l-azonia-bicyclo[2.2.2]octane bromide (C237)
Figure imgf000208_0001
Scheme 56
Benzylamino-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl)ester (C80) (100 mg, 0.28 mmol) is dissolved in ethyl acetate (1.90 mL) and acetonitrile (0.95 mL) and ethyl 5-(2-bromoacetyl)isoxazole-3-carboxylate (82.0 mg, 0.31 mmol) is added. The orange solution is stirred at RT overnight. The suspension is evaporated and the crude is purified by flash chromatography (DCM/EtOH= 93/7) to obtain the title compound as a pale brown solid (61 mg, 35 % yield, bromide salt, mixture of diastereoisomers).
1U NMR (300 MHz, DMSO-d6) ppm: 7.86 and 7.89 (s, 1 H), 6.97 - 7.60 (m, 10 H), 5.10 - 5.24 (m, 1 H), 5.00 and 5.04 (s, 2 H), 4.33 - 4.53 (m, 3 H), 4.10 (dd, 1 H), 3.40 - 3.82 (m, 7 H), 2.15 - 2.24 and 2.29 - 2.38 (m, 1 H), 1.50 - 2.1 1 (m, 4 H), 1.35 (t, 3 H);
LC-MS (ESI POS): 532.3 (MH+). EXAMPLE 57
Preparation of (R)-3-(2-benzylamino-2-phenyl-acetoxy)-l-(2-oxo-2- thiazol-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate trifluoroacetate anion (C238)
Figure imgf000209_0001
Scheme 57
Benzylamino-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl)ester
(C80) (100 mg, 0.28 mmol) is dissolved in ethyl acetate (1.90 mL) and acetonitrile (0.95 mL) and 2-bromo-l-(thiazol-2-yl)ethanone (64.7 mg,
0.314 mmol) is added. The pale yellow solution is stirred at RT overnight. The suspension is evaporated and the crude is purified by flash chromatography
(DCM/MeOH = 93/7). The resulting compound is further purified by preparative LC/MS. The collected fractions are first concentrated with rotary evaporator to remove organic solvent and then with freeze-drier overnight to get the title compound as a pale yellow oil (31 mg, 15 % yield, trifluoroacetate trifluoroacetate anion, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm 8.40 (d, 1 H), 8.24 (d, 1 H), 7.36 - 7.71 (m, 10 H), 5.25 - 5.40 (m, 2 H), 5.17 and 5.21 (s, 2 H), 3.99 - 4.24 (m, 3 H), 3.46 - 3.84 (m, 5 H), 2.15 - 2.25 and 2.32 - 2.44 (m, 1 H), 1.35 - 2.14 (m, 4 H);
LC-MS (ESI POS): 475.9 (MH+).
EXAMPLE 58
Preparation of (R)-3-(2-benzylamino-2-phenyl-acetoxy)-l-(2-oxo-2- thiophen-S-yl-ethy^-l-azonia-bicycloβ.l.lJoctane bromide (C239)
Figure imgf000210_0001
Scheme 58 A solution of (R)-quinuclidin-3-yl 2-(benzylamino)-2-phenylacetate (C80)
(116 mg, 0.33 mmol) in ethyl acetate (3.31 mL) and acetonitrile (3.31 mL), is added with 2-bromo-l-(thiophen-3-yl)ethanone (66.5 mg, 0.32 mmol). The mixture is stirred at RT overnight. The insoluble precipitate is filtered on a buckner funnel and washed with acetonitrile. The clear solution is evaporated and purified by flash chromatography (DCM/EtOH = 9/1) to obtain the title compound as a white solid (26 mg, 14% yield, bromide salt, mixture of diastereoisomers).
1U NMR (300 MHz, DMSO-^6) ppm: 8.63 (br. s., 1 H), 7.68 - 7.84 (m, 1 H), 7.10 - 7.63 (m, 11 H), 5.11 - 5.25 (m, 1 H), 5.03 and 5.06 (s, 2 H), 4.43 (br. s., 1 H), 3.99 - 4.24 (m, 1 H), 3.42 - 3.87 (m, 7 H), 2.18 and 2.23 (br. s., 1 H), 1.44 - 2.14 (m, 4 H);
LC-MS (ESI POS): 475.3 (MH+).
EXAMPLE 59
Preparation of (R)-3-[2-(4-methyl-benzyIamino)-2-phenyl-acetoxy]- l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane formate formate anion (C240)
Figure imgf000211_0001
Scheme 59
(R)-Quinuclidin-3-yl 2-(4-methylbenzylamino)-2-phenylacetate (C77)
(73 mg, 0.20 mmol) is dissolved in ethyl acetate (2.00 mL) and 2-chloro- l- (thiophen-2-yl)ethanone (35.4 mg, 0.22 mmol) is added. The colorless solution is stirred at RT overnight. Solvent is evaporated and the residue is first purified by flash chromatography (DCM/MeOH = 9/1 to 85/15) and then by preparative LC/MS. Organic solvent is evaporated and then the aqueous solution is freeze-dried overnight to afford the title compound as a pale yellow oil (42 mg, 36% yield, formate formate anion, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6) ppm: 8.43 (s, 2 H) 8.16 - 8.24 (m, 1 H) 8.03 - 8.12 (m, 1 H) 7.28 - 7.51 (m, 6 H) 7.04 - 7.25 (m, 4 H) 4.94 - 5.26 (m, 3 H) 4.40 (s, 1 H) 4.00 - 4.18 (m, 1 H) 3.48 - 3.76 (m, 7 H) 2.29 (s, 3 H) 2.11 - 2.22 (m, 1 H) 1.39 - 2.12 (m, 5 H); LC-MS (ESI POS): 489.1 (MH+).
EXAMPLE 60
Preparation of (R)-3-[2-(4-methoxy-benzylamino)-2-phenyI- acetoxy]-l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicycIo[2.2.2]octane formate formate anion (C241)
Figure imgf000212_0001
Scheme 60 A solution of (R)-quinuclidin-3-yl 2-(4-methoxybenzylamino)-2- phenylacetate (C79) (78 mg, 0.21 mmol) in ethyl acetate (2.05 mL), is added with 2-chloro-l-(thiophen-2-yl)ethanone (36.2 mg, 0.23 mmol). The colorless solution is stirred at RT overnight. The residue is first purified by flash chromatography (DCM/MeOH = 90/10 to 85/15) and then by preparative LC/MS. MeOH is evaporated from the fractions collected and then the aqueous solution is freeze-dried overnight to obtain the title compound as a pale pink oil (44 mg, 36 % yield, formate formate anion, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 8.42 (s, 2 H) 8.17 - 8.25 (m, 1 H) 8.03 - 8.13 (m, 1 H) 7.15 - 7.50 (m, 8 H) 6.81 - 6.94 (m, 2 H) 4.97 - 5.23 (m, 3 H) 4.40 (s, 1 H) 3.88 - 4.22 (m, 1 H) 3.74 (s, 3 H) 3.46 - 3.71 (m, 6 H) 2.12 - 2.35 (m, 1 H) 1.70 - 2.10 (m, 3 H) 1.44 - 1.66 (m, 1 H); LC-MS (ESI POS): 505.1 (MH+). EXAMPLE 61
Preparation of (R)-3-[2-(4-fluoro-benzylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride
(C242)
Figure imgf000213_0001
Scheme 61
(R)-Quinuclidin-3-yl 2-(4-fluorobenzylamino)-2-phenylacetate (C78) (85 mg, 0.23 mmol) is dissolved in ethyl acetate (2.31 mL) and 2-chloro-l- (thiophen-2-yl)ethanone (40.8 mg, 0.25 mmol) is added. The solution is stirred at RT overnight. The suspension is evaporated and the white residue is first purified by flash chromatography (DCM/MeOH = 9/1 to 8/2) and then by trituration with Et2θ to afford the title compound as an off-white powder (83 mg, 68% yield, chloride salt, mixture of diastereoisomers).
1H NMR (SOO MHz, DMSO-J6) ppm: 8.18 - 8.25 (m, 1 H), 8.04 - 8.18 (m, 1 H), 7.43 - 7.52 (m, 2 H), 7.26 - 7.43 (m, 6 H), 7.09 - 7.21 (m, 2 H), 5.16 - 5.24 (m, 1 H), 5.12 and 5.15 (s, 2 H), 4.42 (s, 1 H), 4.01 - 4.22 (m, 1 H), 3.67 (s, 2 H), 3.54 - 3.85 (m, 5 H), 2.13 - 2.23 and 2.29 - 2.33 (m, 1 H), 1.48 - 2.10 (m, 4 H);
LC-MS (ESI POS): 492.9 (MH+). EXAMPLE 62
Preparation of (R)-3-[2-(4-fluoro-benzyIainino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl-ethyI)-l-azonia-bicycIo[2.2.2]octane bromide (C243)
Figure imgf000214_0001
Scheme 62
A mixture of (R)-quinuclidin-3-yl 2-(4-fluorobenzylamino)-2- phenylacetate (C78) (61 mg, 0.17 mmol) and 2-bromo-l-phenylethanone (33.0 mg, 0.17 mmol) in ethyl acetate (3 mL) is stirred at RT overnight. The solid is collected by suction filtration and washed with Et2O. The product is further purified by flash chromatography (DCM/MeOH=95/5 to 92/8) to obtain the title compound as a white solid (35 mg, 37% yield, bromide salt, mixture of diastereoisomers).
1H NMR (300 MHz, METHANOL-^) ppm: 7.91 - 8.07 (m, 2 H) 7.67 - 7.80 (m, 1 H) 7.53 - 7.64 (m, 2 H) 7.26 - 7.53 (m, 7 H) 6.97 - 7.13 (m, 2 H) 5.17 - 5.33 (m, 1 H) 4.50 (s, 1 H) 4.04 - 4.28 (m, 1 H) 3.49 - 3.89 (m, 8 H) 3.36 (s, 2 H) 2.40 - 2.52 (m, 1 H) 1.94 - 2.25 (m, 4 H);
LC-MS (ESI POS): 487.1 (MH+). EXAMPLE 63
Preparation of (R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2-p- methylphenyl-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide (C246)
Figure imgf000215_0001
1244
Figure imgf000215_0002
C246 C245
Scheme 63 Preparation of 4-methyl-phenyI-amino-phenyl-acetic acid (1244):
A solution of α-bromophenylacetic acid (1.00 g, 4.65 mmol) in acetonitrile (20 mL), is added with 4-methyl-phenylamine (0.96 g, 9.30 mmol) and the mixture reacted in a closed vessel under MW irradiation at 1000C for 1 h (UPLC-MS monitoring: complete conversion). Solvent is evaporated and residue is partitioned between EtOAc and 2N HCl. The organic phase is dried over Na2SO4, filtered and evaporated to dryness to get desired compound as a yellow solid (0.88 g, 78% yield). Preparation of 4-methyl-phenyI-amino-phenyI-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C245):
A solution of 4-methyl-phenyl-amino-phenyl-acetic acid (1244) (870 mg, 3.60 mmol) in dry THF (35 mL), is added with DCC (891 mg, 4.32 mmol), HOBt (583 mg, 4.32 mmol) and 3(R)-quinuclidinol (915 mg, 7.20 mmol). The resulting mixture is stirred at RT for 48 hours (UPLC-MS monitoring: complete conversion). The solvent is evaporated and the residue is partitioned between EtOAc and IM K2CO3. The organic phase is dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is dissolved in little DCM and filtered to remove the insoluble. The solution is concentrated under vacuum to obtain the title compound as a yellow solid, which is used in the next step without any further purification.
Preparation of (R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-4-methyl- phenyl-amino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide (C246)
A solution of 4-methyl-phenyl-amino-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (C245) (63.5 mg, 0.18 mmol) in acetonitrile (5 mL), is added with 2-bromo-l -phenyl-ethanone (36 mg, 0.18 mmol) and the mixture was heated at 1000C for 1 h in a MW oven (UPLC-MS monitoring: complete conversion). Solvent is evaporated and the resulting crude is purified by flash chromatography (DCM/MeOH = 95/5) to obtain the title compound as a white solid (58 mg, 32% yield, bromide salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.88 - 8.07 (m, 2 H), 7.71 - 7.83 (m, 1 H), 7.51 - 7.68 (m, 4 H), 7.24 - 7.48 (m, 3 H), 6.91 (m, 2 H), 6.66 (m, 2 H), 6.16 (d, 1 H), 5.34 (d, 1 H), 5.15 - 5.27 (m, 1 H), 5.09 (s, 2 H), 3.92 - 4.19 (m, 1 H), 3.33 - 3.77 (m, 5 H), 2.31 - 2.41 (m, 1 H), 2.12 (s, 3 H), 1.77 - 2.08 (m, 4 H); LC-MS (ESI POS): 469.1 (MH+). EXAMPLE 64
Preparation of (R)-3-[2-(2-fluoro-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C249)
Figure imgf000217_0001
I247 C248
1> If ^*> Br
2) Preparative HPLC
Figure imgf000217_0002
Scheme 64
Preparation of (2-fluoro-phenylamino)-phenyl-acetic acid hydrochloride (1247): 2-Fluoroaniline (347 ul, 3.60 mmol), ethyl 2-bromo-2-phenylacetate (420 ul, 2.40 mmol) and N-ethyl-N-isopropylpropan-2-amine (628 ul, 3.60 mmol) are dissolved in acetonitrile (5 mL) and stirred under MW irradiation at 1000C for 1 h and 30 minutes. Water (3.89 mL) and lithium hydroxide (230 mg, 9.59 mmol) are added to the reaction and the resulting mixture is stirred at RT overnight and then at 500C for 3 h. Acetonitrile is removed and IM HCl is added to the remaining aqueous solution until pH is about 1. The aqueous phase is extracted several time with DCM and the combined organic phases are washed with water and brine, dried (Na2SO4), filtered and evaporated to give intermediate 1247 as a brown solid (464 mg, 69% yield).
Preparation of (2-fluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo [2.2.2] oct-3-yl) ester (C248): A solution of DCC (534 mg, 0.71 mmol), lH-benzo[d][l,2,3]triazol-l-ol hydrate (217 mg, 1.42 mmol), (2-fluoro-phenylamino)-phenyl-acetic acid hydrochloride (1247) (200 mg, 0.71 mmol) and (R)-quinuclidin-3-ol (271 mg,
2.13 mmol) in THF (10 mL) is stirred at RT for 2 days. The solvent is evaporated and the residue is taken up with EtOAc, washed with sat NaHCO3, water and brine. The organic layer is collected, dried over Na2SO4, filtered and evaporated to dryness. The residue is purified by preparative HPLC. The organic solvent is evaporated and the acid aqueous phase is basified with Na2CO3 and extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and evaporated to afford the title compound as yellow oil (41 mg, 16% yield). Preparation of (R)-3-[2-(2-fluoro-phenylamino)-2-phenyl-acetoxy]-l-
(2-oxo-2-phenyl-ethy.)-l-azonia-bicyclo [2.2.2] octane trifluoroacetate (C249):
(2-Fluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-
3-yl) ester (C248) (267 mg, 0.75 mmol) and 2-bromo-l-phenylethanone (157 mg, 0.79 mmol) are dissolved in CH3CN (20 mL). The resulting reaction is stirred at RT for two days. The solvent is evaporated and the crude is purified with preparative HPLC to obtain the title compound as a yellow amorphous solid (178 mg, 40.3 % yield, trifluoroacetate salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.87 - 8.14 (m, 2 H), 7.67 - 7.81 (m, 1 H), 7.50 - 7.68 (m, 4 H), 7.26 - 7.50 (m, 3 H), 7.01 - 7.16 (m, 1 H)5 6.85 - 7.00 (m, 1 H), 6.56 - 6.77 (m, 2 H), 5.75 (br. s., 1 H), 5.46 and 5.49 (s, 1 H), 5.24 (br. s., 1 H), 5.12 and 5.17 (s, 2 H), 4.00 - 4.20 (m, 1 H), 3.29 - 3.83 (m, 5 H), 2.12 - 2.23 and 2.31 - 2.42 (m, 1 H), 1.37 - 2.11 (m, 4 H); LC-MS (ESI POS): 473.2 (MH+). C250 and C251 listed in Table 27 are prepared as previously described for C249, using 3-fluoroaniline instead of 2-fluoroaniline and the suitable commercially available alkylating agents.
Table 27
Figure imgf000219_0001
EXAMPLE 65
Preparation of (R)-3-[(R)-2-(4-fluoro-phenylamino)-2-phenyl- acetoxy]-l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride (C255)
Figure imgf000220_0001
I3 I252 I253
P(Ph)3 DEAD
"0^
THF
Figure imgf000220_0002
Scheme 65
Preparation of (R)-(4-fluoro-phenylamino)-phenyI-acetic acid methyl ester (1252): A solution of (S)-methyl 2-(methylsulfonyloxy)-2-phenylacetate (15) (520 mg, 2.13 mmol) in CH3CN (10 mL), is added with 4-fluoroaniline (473 mg, 4.26 mmol) and the mixture is heated at 12O0C for 5 min under MW irradiation. (UPLC-MS: complete conversion). Acetonitrile was evaporated and the resulting crude is dissolved in IN HCl and extracted several times with EtOAc. The combined organic phase is dried over Na2SO4, filtered and evaporated to dryness to obtain intermediate 1254 as a pale yellow oil (520 mg, 94% yield). Preparation of (R)-(4-fluoro-phenylaraino)-phenyl-acetic acid
(1253):
A solution of (R)-(4-fluoro-phenylamino)-phenyl-acetic acid methyl ester (1252) (510 mg, 1.97 mmol) in dioxane (10 mL), is added with 12N HCl (10 mL) and the mixture is heated at 700C for 12 h. The organic solvent is evaporated, the mixture is cooled to 00C and the resulting solid is collected by filtration to obtain intermediate 1255 as a brownish solid (420 mg, 87% yield).
Preparation of (R)-(4-fluoro-phenylamino)-phenyl-acetic acid (R)- (l-aza-bicyclo[2.2.2]oct-3-yl) ester (C254): A solution of (R)-(4-fluoro-phenylamino)-phenyl-acetic acid (1253)
(420 mg, 1.71 mmol) in dry THF (40 mL), is sequentially added with (S)-quinuclidin-3-ol (218 mg, 1.71 mmol), DEAD (407 ul, 2.57 mmol) and triphenylphosphine (674 mg, 2.57 mmol). The reaction is refluxed for 30 min under N2 flowstream and then the solvent is evaporated. The residue is partitioned between water and EtOAc, the organic layer is separated, dried over Na2SO4, filtered and evaporated to dryness. The resulting crude is purified by flash chromatography (DCM/MeOH=95/5) to obtain the title compound as a pale yellow oil (480 mg, 79% yield).
Preparation of (R)-3-[(R)-2-(4-fluoro-phenylamino)-2-phenyl- acetoxyl-l-(2-oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride (C255):
A solution of (R)-(4-fluoro-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester (C254) (200 mg, 0.56 mmol) in CH3CN (2 mL), is added with 2-chloro-l-(thiophen-2-yl)ethanone (100 mg, 0.62 mmol). The reaction is heated at 1000C for 1 hr under MW irradiation. The solvent is evaporated and the crude is purified by flash chromatography (DCM/MeOH=9/l) recovering the title compound as a white solid (104 mg, 36% yield, chloride salt, single diastereoisomer). 1H NMR (300 MHz, DMSO-^6) ppm: 8.21 (d, 1 H), 8.08 (d, 1 H), 7.50 - 7.65 (m, 2 H), 7.23 - 7.48 (m, 4 H), 6.84 - 6.99 (m, 2 H), 6.61 - 6.84 (m, 2 H), 6.39 (d, 1 H), 5.36 (d, 1 H), 5.15 - 5.26 (m, 1 H), 5.06 (s, 2 H), 3.99 - 4.21 (m, 1 H), 3.38 - 3.85 (m, 5 H), 2.30 - 2.40 (m, 1 H), 1.70 - 2.17 (m, 4 H);
LC-MS (ESI POS): 478.9 (MH+).
EXAMPLE 66
Preparation of (R)-3-[2-(4-chloro-phenyl)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C258)
Figure imgf000222_0001
1256
Figure imgf000222_0002
C258 C257
Scheme 66 Preparation of (4-chloro-phenyl)-phenylamino-acetic acid (1256):
2-Bromo-2-(4-chlorophenyl)acetic acid (1.2 g, 4.67 mmol) and aniline (0.85 niL, 9.33 mmol) are dissolved in acetonitrile (29 mL). The reaction is heated under microwave irradiation at 1000C for 5 minutes. The solvent is evaporated and the residue is dissolved in EtOAc and washed with 3M HCl and then brine. The organic layer is dried over Na2SO4, filtered and evaporated to dryness to give intermediate 1258 as a white solid (1.22 g, quantitative yield).
Preparation of (4-chloro-phenyl)-phenylamino-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C257):
(4-Chloro-phenyl)-phenylamino-acetic acid (1256) (1.22 g, 4.97 mmol), HOBT (0.99 g, 6.46 mmol) and DCC (1.33 g, 6.46 mmol) are dissolved in
THF (250 mL). The reaction is stirred for 15 minutes and then
(R)-quinuclidin-3-ol (1.26 g, 9.93 mmol) is added. The reaction is stirred at
RT for 4 days. The solvent is evaporated and the residue is taken up with
EtOAc. The insoluble is filtered off, the solution is washed with IM K2CO3 and brine. The organic phase is dried (Na2SO4), filtered and evaporated to dryness. The crude is purified by flash chromatography (DCM/MeOH= 98/2 to 90/10) to afford compound C259 as a yellow solid (462 mg, 25 % yield).
Preparation of (R)-3-[2-(4-chloro-phenyl)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyI-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C258):
2-Bromo-l-phenylethanone (54.8 mg, 0.27 mmol) is added to a solution of (4-chloro-phenyl)-phenylamino-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3- yl) ester (C257) (100 mg, 0.27 mmol) in acetonitrile (4 mL). The reaction is heated in a microwave oven at 1000C for 1 hour. The solvent is evaporated and the crude is first purified by flash chromatography (DCM/MeOH=98/2 to 85/15) and then by preparative HPLC to collect the title compound as a brown viscous oil (37 mg, 22.76 % yield, trifluoroacetate salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-^6) ppm: 7.94 - 8.02 (m, 2 H), 7.72 - 7.83 (m, 1 H), 7.54 - 7.68 (m, 4 H), 7.40 - 7.54 (m, 2 H), 6.96 - 7.17 (m, 2 H), 6.68 - 6.78 (m,
2 H), 6.52 - 6.67 (m, 1 H), 5.42 (s, 1 H), 5.19 - 5.28 (m, 1 H), 5.16 (s, 2 H), 4.05 -
4.19 (m, 1 H), 3.44 - 3.86 (m, 5 H), 2.09 - 2.22 (m, 1 H), 1.90 - 2.08 (m, 2 H), 1.75
- 1.88 (m, I H), 1.54 - 1.73 (m, I H); LC-MS (ESI POS): 488.9 (MH+).
EXAMPLE 67
Preparation of (R)-3-[2-(2-fluoro-phenyI)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C263)
Figure imgf000224_0001
Scheme 67
Preparation of bromo-(2-fluoro-phenyl)-acetic acid methyl ester (1259):
A solution of methyl 2-(2-fluorophenyl)acetate (1.0 g, 5.95 mmol) in CCI4 (15 mL), is added with N-bromo succinimide (1.06 g, 5.95 mmol) and
48% hydrogen bromide (33 uL, 0.30 mmol) and the reaction is refluxed for 15h. Reaction is diluted with DCM and washed with Na2CO3 and water. The organic phase is dried over Na2SO4 filtered and evaporated under vacuum to afford intermediate 1261 as a dark brown oil (1.47 g, quantitative yield).
Preparation of (2-fluoro-phenyl)-phenylamino-acetic acid methyl ester (1260):
A solution of bromo-(2-fluoro-phenyl)-acetic acid methyl ester (1259) (1.47 g, 5.95 mmol), aniline (814 ul, 8.93 mmol) and N-ethyl-N- isopropylpropan-2-amine (1.53 mL, 8.93 mmol) in acetonitrile (10 mL) is heated under microwave irradiation at 1000C for Ih. The solvent is evaporated, the residue is taken up with DCM and washed with water and brine, dried over Na2SO4 and evaporated to afford intermediate 1262 as a dark brown oil (1.54 g, quantitative yield).
Preparation of (2-fluoro-phenyl)-phenylamino-acetic acid hydrochloride (1261):
A solution of (2-fluoro-phenyl)-phenylamino-acetic acid methyl ester (1260) (1.54 g, 5.95 mmol) in THF (15 mL), cooled at 00C, is added with
2.0M lithium hydroxide (5.95 mL, 11.9 mmol) and the reaction is stirred at RT for 72 h. The solvent is evaporated, IM HCl is added to the reaction until pH
1. The product is extracted with EtOAc, and the organic phase is washed with water and brine, dried over Na2SO4 and evaporated to provide intermediate 1263 as a dark brown gummy solid (1.34 g, 80% yield).
Preparation of (2-fluoro-phenyl)-phenylamino-acetic acid (R)-(I- aza-bicyclo [2.2.2] oct-3-yl) ester (C262):
A solution of (2-fluoro-phenyl)-phenylamino-acetic acid hydrochloride (1261) (217 mg, 0.77 mmol), (R)-quinuclidin-3-ol (338 mg, 2.66 mmol) and lH-benzo[d][l,2,3]triazol-l-ol (180 mg, 1.332 mmol) in dry THF (15 mL), is added with PS-DCC (1.0 g, 1.33 mmol). The mixture is shaken at RT for 15h. Then (R)-quinuclidin-3-ol (49.0 mg, 0.38 mmol) and PS-DCC (290 mg, 0.38 mmol) are added again and the reaction is shaken for additional 3h at RT. The resin is removed by filtration and washed several time with EtOAc. The solvent is evaporated, the residue is taken up with EtOAc and washed with NaHCO3, water and brine. The organic phase is dried (Na2SO4), filtered and evaporated to afford the title compound as a brown oil (225 mg, 82% yield).
Preparation of (R)-3-[2-(2-fluoro-phenyl)-2-phenyIamino-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C263):
A solution of (2-fluoro-phenyl)-phenylamino-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester (C262) (225 mg, 0.63 mmol) in acetonitrile (8 mL), is added with 2-bromo-l-phenylethanone (126 mg, 0.63 mmol) and the reaction is stirred at RT for 15h. The solvent is evaporated and the resulting crude is purified by preparative HPLC to obtain the title compound as a brown oil (130 mg, 35%yield, trifluoroacetate salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm: 7.92 - 8.07 (m, 2 H), 7.69 - 7.82 (m, 1 H), 7.52 - 7.68 (m, 3 H), 7.35 - 7.49 (m, 1 H), 7.19 - 7.35 (m, 2 H), 7.05 - 7.15 (m,
2 H), 6.68 - 6.81 (m, 2 H), 6.56 - 6.67 (m, 1 H), 6.42 (br. s., 1 H), 5.57 and 5.59 (s,
1 H), 5.21 - 5.34 (m, 1 H), 5.12 and 5.17 (s, 2 H), 4.02 - 4.24 (m, 1 H), 3.27 - 3.83
(m, 5 H), 2.13 - 2.22 and 2.32 - 2.43 (m, 1 H), 1.34 - 2.13 (m, 4 H);
LC-MS (ESI POS): 473.4 (MH+).
EXAMPLE 68
Preparation of (R)-3-[2-(5-methyI-thiophen-2-yI)-2-phenylamino- acetoxy]-l-(2-oxo-2-pheny!-ethyI)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C270)
Figure imgf000227_0001
1264 1265
Figure imgf000227_0002
1268 1267 1266
Figure imgf000227_0003
Scheme 68
Preparation of (5-methyl-thiophen-2-yI)-oxo-acetic acid methyl ester (1264):
A suspension of aluminum trichloride (2.75 g, 20.6 mmol) and methyl 2- chloro-2-oxoacetate (1.90 mL, 20.7 mmol) in dry DCM (25 mL), cooled at 00C and under nitrogen atmosphere, is added with 2-methylthiophene (1.00 mL, 10.33 mmol) dropwise. The reaction is stirred at RT for 15h. Then the mixture is cooled at 00C, ice-water is slowly added and the organic phase is washed with aq. NaHCO3 and brine, dried over Na2SO4 and evaporated to obtain intermediate 1266 as a brown oil (1.9 g, quantitative yield).
Preparation of hydroxy-(5-methyl-thiophen-2-yI)-acetic acid methyl ester (1265):
A solution of methyl (5-methyl-thiophen-2-yl)-oxo-acetic acid methyl ester (1264) (1.90 g, 10.3 mmol) in MeOH (25 mL) cooled at 00C, is added portionwise with sodium boron hydride (0.19 g, 5.17 mmol). The reaction is stirred at 00C for 10 minutes then at RT for Ih. The solvent is evaporated, the residue is taken up with EtOAc and washed with ice-water and brine. The organic phase is dried over Na2SO4, filtered and evaporated to collect intermediate 1267 as a brown oil (1.84 g, 96% yield).
Preparation of methanesuIfonyloxy-(5-methyl-thiophen-2-yl)-acetic acid methyl ester (1266):
A solution of hydroxy-(5-methyl-thiophen-2-yl)-acetic acid methyl ester
(1265) (1.84 g, 9.89 mmol) in dry DCM, cooled at 00C under nitrogen atmosphere, is added with N-ethyl-N-isopropylpropan-2-amine (2.54 mL, 14.8 mmol) and methanesulfonyl chloride (1.16 mL, 14.8 mmol) and the reaction is stirred at RT for 2h. DCM is added and the organic phase is washed with aq. NaHCO3, water and brine, dried over Na2SO4 and evaporated to obtain intermediate 1268 as a dark brown oil (2.1 g, 80% yield). Preparation of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid methyl ester (1267):
A solution of methanesulfonyloxy-(5-methyl-thiophen-2-yl)-acetic acid methyl ester (1266) (2.10 g, 7.94 mmol), aniline (1.09 mL, 11.9 mmol) and N- ethyl-N-isopropylpropan-2-amine (2.04 mL, 11.9 mmol) in MeCN (10 mL) is heated under microwave irradiation at 1000C for Ih. The solvent is removed,
DCM is added and the organic phase is washed with water and brine, dried over Na2SO4 and evaporated. The resulting brown oil is purified by silica gel flash chromatography (Hexane/EtOAc=9575 to 90/10) to obtain intermediate 1269 as a yellow oil (500 mg, 24% yield).
Preparation of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid hydrochloride (1268):
A solution of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid methyl ester (1267) (500 mg, 1.91 mmol) in THF (15 mL), cooled at 00C, is added with
2.0M lithium hydroxide (1.91 mL, 3.83 mmol) and the reaction is stirred at RT for 72 hours. Then the solvent is evaporated, IM HCl is added to the reaction until pH 1 and the product is extracted with EtOAc. The organic phase is washed with water and brine, dried over Na2SO4, filtered and evaporated to obtain intermediate 1270 as a light brown solid (410 mg, 76% yield).
Preparation of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid (R)- (1-aza-bicyclo [2.2.2] oct-3-yl) ester (C269):
A solution of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid hydrochloride (1268) (220 mg, 0.77 mmol), (R)-quinuclidin-3-ol (338 mg, 2.66 mmol) and lH-benzo[d][l,2,3]triazol-l-ol (180 mg, 1.33 mmol) in dry THF (15 mL), is added with PS-DCC (1.0 g, 1.330 mmol) and the mixture is shaken at RT for 15h. Then (R)-quinuclidin-3-ol (49.3 mg, 0.39 mmol) and PS-DCC (291 mg, 0.39 mmol) are added again and the reaction is shaken at RT for other 3h. The resin is filtered off and washed several time with EtOAc. The solvent is concentrated and washed with aq. NaHCO3, water and brine. The organic phase is dried over Na2SO4 and evaporated to obtain the title compound as a brown oil
(175 mg, 63% yield).
Preparation of (R)-3-[2-(5-methyl-thiophen-2-yl)-2-phenylamino- acetoxy]-l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate (C270):
A solution of (5-methyl-thiophen-2-yl)-phenylamino-acetic acid (R)-(I- aza-bicyclo[2.2.2]oct-3-yl) ester (C269) (175 mg, 0.49 mmol) in acetonitrile (8 mL), is added with 2-bromo-l-phenylethanone (98.0 mg, 0.49 mmol) and the reaction is stirred at RT for 15h. The solvent is evaporated and the resulting brown crude is purified by preparative HPLC to obtain the title compound as a brown oil (60 mg, 21% yield, trifluoroacetate salt, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-ύf6) ppm: 7.91 - 8.08 (m, 2 H), 7.69 - 7.88 (m, 1 H), 7.54 - 7.69 (m, 2 H), 7.06 - 7.16 (m, 2 H), 6.99 - 7.07 (m, 1 H), 6.69 - 6.83 (m, 3 H), 6.54 - 6.69 (m, 1 H), 6.33 (br. s., 1 H), 5.52 and 5.56 (d, 1 H), 5.23 - 5.34 (m, 1 H), 5.13 and 5.17 (s, 2 H), 3.98 - 4.21 (m, 1 H), 3.55 - 3.86 (m, 5 H), 2.43 and 2.44 (d, 3 H), 2.19 - 2.25 and 2.33 - 2.40 (m, 1 H), 1.40 - 2.15 (m, 4 H);
LC-MS (ESI POS): 475.3 (MH+).
EXAMPLE 69
Preparation of (R)-l-[2-(4-amino-phenyl)-2-oxo-ethyl]-3-((R)-2- phenyl-2-phenylamino-acetoxy)-l-azonia-bicyclo [2.2.2] octane formate (diastereoisomer 1 of C271)
Figure imgf000230_0001
Diastereoisomer 1 of C 179 Diastereoisomer 1 of C271
Scheme 69
A solution of (R)-l-[2-(4-nitro-phenyl)-2-oxo-ethyl]-3-((R)-2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide
(Diastereoisomer 1 of C 179) (88 mg, 0.152 mmol) in THF (30 mL) is hydrogenated in presence of a catalytic amount Of Pt2O at 15 psi for 2 hr and then at 20 psi for additional 2 hrs. (UPLC-MS monitoring: complete conversion). Catalyst is removed by filtration and the solution evaporated to dryness. The crude is purified by preparative HPLC to give the title compound as a pale yellow solid (31 mg, 37% yield, formate formate anion, single diastereoisomer).
1H NMR (300 MHz, DMSO-J6) ppm: 8.51 (s, 1 HJormiate), 7.63 - 7.77 (m, 2 H), 7.47 - 7.61 (m, 2 H), 7.30 - 7.46 (m, 3 H), 7.02 - 7.18 (m, 3 H), 6.68 - 6.81 (m, 2 H), 6.54 - 6.66 (m, 2 H), 6.41 (br. s., 2 H), 6.36 (d, 1 H), 5.37 (d, 1 H), 4.99 - 5.25 (m, 1 H), 4.82 (s, 2 H), 3.91 - 4.18 (m, 1 H), 3.41 - 3.74 (m, 5 H), 2.30 - 2.43 (m, I H), 1.56 - 2.09 (m, 4 H);
LC-MS (ESI POS): 470.1 (MH+).
EXAMPLE 70
Preparation of (R)-l-(2-hydroxy-2-phenyl-ethyl)-3-((R)-2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate
(C272)
LC-MS
Figure imgf000231_0001
Figure imgf000231_0002
Diastereoisomer 1 of C61 C272
Scheme 70
A solution of (R)-l-(2-oxo-2-phenyl-ethyl)-3-((R)-2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane chloride
(Diastereoisomer 1 of Cl 13) (80 mg, 0.163 mmol) in MeOH, is added with NaBH4 (6.16 mg, 0.163 mmol) and the mixture is stirred at RT for 1 hour (UPLC-MS: complete conversion). The solvent is evaporated and the resulting crude is first purified by flash chromatography (DCM/MeOH =9/1) and then by preparative LC-MS to obtain the title compound as of a brown oil (31.2 mg, 39% yield, trifluoroacetate, mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-J6) ppm 7.51 - 7.64 (m, 2 H), 7.28 - 7.50 (m, 8 H), 6.99 - 7.17 (m, 1 H), 6.66 - 6.86 (m, 2 H), 6.51 - 6.66 (m, 1 H), 5.01 - 5.54 (m, 3 H), 3.02 - 4.07 (m, 9 H), 2.29 - 2.42 (m, 1 H), 1.71 - 2.17 (m, 4 H);
LC-MS (ESI POS): 457.1 (MH+).
Biological characterisation
EXAMPLE 71 Examples of Radioligand Binding Assay for Cloned Human
Muscarinic Receptors and for Human beta Adrenergic Receptors:
CHO-Kl clone cells expressing the human Ml-, M2-, M3- receptors
(Euroscreen, Swissprot P l 1229, P08172, P20309, Genbank: J02960 respectively) were harvested in Ca++/Mg++ free phosphate-buffered saline and collected by centrifugation at 1500 rpm for 10 min, at 4°C min. The pellets were resuspended in ice cold buffer A (15 rnM Tris-HCl pH 7.4, 2 mM MgCl2,
0.3 mM EDTA, 1 mM EGTA). Cloned cells expressing Ml-, M2-, and
M3- receptors were homogenized by a PBI politron (setting 5 for 15 s). The crude membrane fraction was collected by two consecutive centrifugation steps at 40000 g for 20 min at 4°C, separated by a washing step in buffer A.
The pellets obtained from the three cell lines were finally resuspended in buffer C (75 mM Tris HCl pH 7.4, 12.5mM MgCl2, 0.3 mM EDTA, 1 mM EGTA, 250 mM sucrose) and aliquots were stored at - 800C.
The day of experiment, Ml-, M2-, and M3 -receptor frozen membranes were resuspended in buffer D (50 mM Tris-HCl pH 7.4, 2.5 mM MgCl2, 1 mM
EDTA). The non selective muscarinic radioligand [3H]-N-methyl scopolamine
(MoI. Pharmacol. 45 :899-907) was used to label the Ml, M2, and M3 binding sites. Binding experiments were performed in duplicate (ten point concentrations curves) in 96 well plates at radioligand concentration of 0.1-0.3 nM. The non specific binding was determined in the presence of cold
N-methyl scopolamine 10 μM. Samples (final volume 0.75 mL) were incubated at RT for 120 min for Ml, 60 min for M2 and 90 min for M3 binding assay. The reaction was terminated by rapid filtration through GF/B Unifilter plates and two washes (0.75 mL) with cold buffer using a Packard Filtermate Harvester. Radioactivity on the filters was measured by a microplate scintillation counter TopCount NXT (Canberra Packard). In the present assays, Ki values for the tested compounds were determined from the observed IC50 values according to known methods. A lower Ki value indicates that the tested compound has a higher binding affinity for the receptor.
The interaction with M3 muscarinic receptors can be estimated by the results of in vitro studies which evaluated the potency of the test compounds and the offset of the inhibitory activity produced after washout of the antagonists in isolated guinea pig trachea and by the in vivo duration of action against acetylcholine-induced bronchospasm in the guinea pig.
EXAMPLE 72 In vitro interaction with guinea pigs M3 receptors
The potency of the antagonist activity in isolated guinea pig trachea was investigated following a method previously described by Haddad EB et al. in Br J Pharmacol 127, 413-420, 1999, with few modifications.
A cumulative concentration-response curve to test antagonists was constructed on preparations precontracted by carbachol, until a complete inhibition of smooth muscle tone was achieved. The concentration of antagonist producing a 50% reversal of carbachol-induced tonic contraction
(IC50) was taken as a measure of its potency in this bioassay.
In the experiments aiming at assessing the offset of the inhibitory effects produced by test compounds, the minimal concentration of the test compounds known to produce a maximal inhibitory effect was administered to carbachol-precontracted preparations. As soon as the tonic contraction was completely reversed, the organ bath solution was renewed and preparations were thoroughly washed with fresh Krebs solution. Carbachol (0.3 μM) was administered again (at 30 min interval between washout and next administration) during the next 4 hours.
After the administration of carbachol, the inhibitory effects of the compounds of the invention, administered at a concentration of 10 nM, were expressed as percentage of the recovery of the contracting response to carbachol. The percentage of recovery four hours after the washout was lower than 50%.
The compounds of the invention show a remarkable inhibitory M3 activity. In particular, the IC50 values being tested for some representative compounds result to be comprised between 0.03 and 10 nM.
EXAMPLE 73
In vivo studies
The in vivo tests on acetylcholine-induced bronchospasm in guinea pig were performed according to H. Konzett H and Rossler F Arch Exp Path
Pharmacol 195, 71-74, 1940. Aqueous solutions of the test compounds were instilled intratracheally in anaesthetised mechanically ventilated guinea pigs.
Bronchial response to intravenous acetylcholine challenge was determined before and after drug administration and changes in pulmonary resistance at several time-points were expressed as percent of inhibition of bronchospasm.
The bronchodilator activity of the tested compounds persisted unchanged up to 24 hours after the administration.
EXAMPLE 74
Plasma stability In order to demonstrate that the compounds are degraded, stability in human plasma at 1 and 5 hours was tested for the compound of the invention. Briefly lOμl of a stock solution 250 μM of the compound in acetonitrile were added to ImI of human plasma and samples were incubated at 37°C. Plasma (50μL) was taken after 0, 1 and 5 hours of incubation and added to 140μl of acetonitrile with addition of verapamil as internal standard (250ng/ml). Samples were analysed by HPLC-MS/MS analysis.
Plasma stability is calculated as percentage remaining after 1 and 5 hours by dividing the peak area at 1 or 5 hours by the area of the peak at time 0.
After 1 and 5 hours of incubation, plasma stability being tested for some representative compounds of the invention result to be comprised between 0 and 25%, indicating that the compounds of the invention are very unstable in human plasma. Legend
* NMR s = singlet d = doublet t = triplet q = quartet dd = doublet of doublets m = multiplet br = broad

Claims

1. A compound of general formula (I),
Figure imgf000236_0001
(I) wherein:
Rl is selected from the group consisting of H, (C1-C10)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, NHCOR5, COR5, CO2R5, CF3, (C]-C10)-alkoxycarbonyl, (C1-C10)-alkylsulfanyl, (Cj-C10)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (CrC10)-alkyl and (CrCi0)-alkoxyl;
R2 is selected from the group consisting of (C1-C1o)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (-0), SH, NO2, CN, CON(R5)2, COOH, NHCOR5, COR5, CO2R5, CF3, (C1-Cio)-alkoxycarbonyl, (CrCio)-alkylsulfanyl, (C1-C1o)-alkylsulfinyl, (Ci-C10)-alkylsulfonyl. (CrC10)-alkyl and (CrC10)-alkoxyl;
R3 is selected from the group consisting of H, (C1-Ci0)-alkyl, aryl, (C3-C8)-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, CO2R5, CF3, (CrC10)-alkoxycarbonyl, (CrC10)-alkylsulfinyl, (C,-C10)-alkylsulfonyl, (C1- C10)-alkyl and (CrC10)-alkoxyl; R6 represents a group of formula (i) or (ii) or (iii) or (iv)
Figure imgf000237_0001
O) (ϋ)
Figure imgf000237_0002
(iii) (iv) wherein m = 1 , 2 or 3 ; n =1, 2 or 3;
A' is a physiologically acceptable anion; R4 is a group of formula (Y)
-(CH2)P-P- (CH2)q— W
(Y) wherein p is 0 or an integer from 1 to 4; q is 0 or an integer from 1 to 4;
P is absent or is selected from the group consisting of O, S, SO, SO2, CO, NR5 CH-CH, N(R5)SO2, N(R5)COO, N(R5)C(O), SO2N(R5), CO(O)N(R5) and C(O)N(R5); W is selected from the group consisting of H, (C1-C6)-alkyl,
(C3-Cg)-CyClOaIlCyI, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo
(=0), SH, NO2, CN, CON(R5)2, COOH, NH2, NHCOR5, CO2R5, (C1-C10)- alkoxycarbonyl, (CrCio)-alkylsulfanyl, (C1-Ci0)-alkylsulfinyl, (C1-C10)- alkylsulfonyl, (C,-C10)-alkyl and (C,-C10)-alkoxyl;
R5 is selected from the group consisting of H, (CrC10)alkyl, (C,-C6)alkylhalo, (C2-C6)alkynyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(Ci-C6)alkyl, heteroaryl, (Ci-C6)alkyl-heteroaryl and aryl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (-O), SH, NO2, CN, CONH2, COOH, (C1-C1o)-alkoxycarbonyl, (Ci-C1o)-alkylsulfanyl, (C1-C1o)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (C1-Ci0)-alkyl and (CrC10)-alkoxyl; and pharmaceutically acceptable salts thereof, with the proviso that when Rl is H, R2 is phenyl, R3 is H, then R6 is not a group of formula (iii).
2. A compound of claim 1 wherein Rl is H, R2 is arylalkyl or (Cl-ClO)- alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (C1-C10)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R6 is a group of formula (i)
Figure imgf000238_0001
(i) according to the general formula (XIII):
Figure imgf000238_0002
3. A compound of claim 2 wherein Rl is H, R2 and R3 are phenyl.
4. A compound of claim 3 wherein Rl is H, R2 and R3 are phenyl and wherein R4 is a group of formula (Y)
Figure imgf000239_0001
(Y) wherein p is 1, P is CO, q is 0 and W is aryl.
5. A compound of claim 4 wherein R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is phenyl.
6. A compound of claim 4 wherein R4 is a group of formula (Y), wherein p is 1, P is CO, q is 0 and W is thienyl.
7. A compound of claim 4 wherein R4 is a group of formula (Y), wherein p is 2, P is O, q is 0 and W is phenyl.
8. A compound of claim 4 wherein R4 is a group of formula (Y), wherein p is 3, P is O, q is 0 and W is phenyl.
9. A compound of general formula (VI):
Figure imgf000239_0002
(Vl) wherein:
Rl , R2 and R3 are as described in claim 1 ;. R7 represents a group of formula (vi) or (vii) or (viii) or (ix)
Figure imgf000240_0001
(Vi) (vϋ)
Figure imgf000240_0002
(viii) (ix) wherein m and n are as described in claim 1 ; and pharmaceutically acceptable salts thereof, with the provisos that: - when Rl is H or CH3, R2 is phenyl, R3 is H or CH3, then R6 is not a group of formula (viii) and
- the compounds of general formula (VI) are not N-methyl-3- piperidyl-2'-N'dimethylaminoacetate and N-methyl-4-piperidyl-2'-N'- dimethylaminoacetate.
10. A compound of claim 9 wherein Rl is H, R2 is (C]-C1o)-alkyl or aryl or (C3-Cg)-cycloalkyl or arylalkyl or heteroaryl and R3 is (CrC^-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vi)
Figure imgf000240_0003
(vi) according to the general formula (XII):
Figure imgf000241_0001
(XIl)
1 1. A compound of claim 10 wherein Rl is H, R2 is arylalkyl or (C1-CK))- alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is
Figure imgf000241_0002
or aryl or (C3-Cg)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii)
Figure imgf000241_0003
(vii) according to the general formula (XIV)
Figure imgf000241_0004
(XIV)
12. A compound of claim 10 wherein Rl is H, R2 is arylalkyl or (C1-C10)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (C1-C10)- alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii), according to the general formula (XV)
Figure imgf000241_0005
(XV)
13. A compound of claim 10 wherein Rl is H, R2 is arylalkyl or (CrCjo)-alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (Ci-C10)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (vii), according to the general formula (XVI)
Figure imgf000242_0001
14. A compound of claim 10 wherein Rl is H, R2 is arylalkyl or (C1-C10)- alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (CrC10)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (viii)
Figure imgf000242_0002
according to the general formula (XVII)
Figure imgf000242_0003
(XVII)
15. A compound of claim 10 wherein Rl is H, R2 is arylalkyl or (Cl-C lO)- alkyl or aryl or (C3-C8)-cycloalkyl or heteroaryl and R3 is (C1-C10)-alkyl or aryl or (C3-C8)-cycloalkyl or arylalkyl or heteroaryl, preferably substituted with one or more halogen atoms and wherein R7 is a group of formula (ix)
Figure imgf000243_0001
according to the general formula (XVIII)
Figure imgf000243_0002
(XIII)
16. A compound according to any previous claim, selected from (R)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)acetate; (R)-quinuclidin-3-yl 2-(4-fluorophenyl)-2-(4- fluorophenylamino)acetate;
(R)-quinuclidin-3-yl 2-(methyl(phenyl)amino)-2-phenylacetate; (R)-quinuclidin-3-yI 2-(3-fluorophenyl)-2-(3- fluorophenylamino)acetate;
(R)- 1 -methylpiperidin-4-yl-2-phenyl-2-(phenylamino)acetate; (R)- 1 -methy lpyrrolidin-4-yl-2-phenyl-2-(pheny lamino)acetate;
(S)- 1 -methylpyrrolidin-4-yl-2-phenyl-2-(phenylamino)acetate; (R)-I -methy lpiperidin-3-yl 2-phenyl-2-(phenylamino)acetate; 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenyl-2-
(phenylamino)acetate; phenyl-phenylamino-acetic acid 9-methyl-3-oxa-9-aza- tricyclo[3.3.1.0*2,4*]non-7-yl ester;
(R)-quinuclidin-3-yl) 2-amino-3-phenylpropanoate di-trifluoroacetate; 3-phenyl-2-phenylamino-propionic acid (R)-(l-aza-bicyclo[2.2.2]oct-3- yl) ester; (R)-quinuclidin-3-yl 2-(benzylamino)-2-phenylacetate;
(R)-quinuclidin-3-yl 2-amino-2-phenylacetate di-hydrochloride;
(R)-quinuclidin-3-yl 2-(cyclopentylamino)-2-phenylacetate di- trifluoroacetate; (R)-quinuclidin-3-yl 2-(cyclohexylamino)-2-phenylacetate;
(R)- 1 -(2-phenoxyethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- 1 - azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- l-(2-oxo-2-(thiophen-2-yl)ethyl)-3-(2-ρhenyl-2- (phenylamino)acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)- 1 -(3 -phenoxypropy l)-3 -(2-pheny l-2-(pheny lamino)acetoxy)- 1 - azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- 1 -methyl-3-(2-phenyl-2-(phenylamino)acetoxy)- 1 -azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-phenoxyethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-phenylethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)- l-(2-oxo-2-(thiophen-3-yl)ethyl)-3-(2-phenyl-2-(phenylamino)- acetoxy)- 1 -azonia-bicy clo [2.2.2] octane trifluoroacetate; (3R)- l-(2-(4-fluorophenyl)-2-oxoethyl)-3-(2-phenyl-2-(phenylamino)- acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- l-phenethyl-3-(2-phenyl-2-(phenylamino)acetoxy)-l-azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)- l-(2-(benzo[b]thiophen-2-yl)-2-oxoethyl)-3-(2-ρhenyl-2- (phenylamino)acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(4-fluorophenyl)-2-(4-fluorophenylamino)acetoxy)-l-(2-oxo- 2-(thiophen-2-yl)ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(4-fluorophenyl)-2-(4-fluorophenylamino)acetoxy)-l -(2-OXO- 2-phenylethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(4-fluorophenyl)-2-(4-fluorophenylamino)acetoxy)- l-methyl- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(3-fluorophenyl)-2-(3-fluorophenylamino)acetoxy)- l-(2-oxo- 2-phenylethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(methyl(phenyl)amino)-2-phenylacetoxy)- l-(2-oxo-2- (thiophen-2-yl)ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(methyl(phenyl)amino)-2-phenylacetoxy)- l -(2-0X0-2- phenylethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-l-(2-phenoxyethyl)-3-(3-phenyl-2-(phenylamino)propanoyloxy)-l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-(thiophen-2-yl)ethyl)-3-((S)-3-phenyl-2- (phenylamino)propanoyloxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-methyl-3-(3-phenyl-2-(phenylamino)propanoyloxy)-l-azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-phenylethyl)-3-((S)-3-phenyl-2- (phenylamino)propanoyloxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-(benzylamino)-2-phenylacetoxy)- l-(2-oxo-2-phenylethyl)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-l-(2-oxo-2-pyridin-4-yl-ethyl)-3-(2-phenyl-2-phenylamino- acetoxy )- 1 -azonia-bicy clo [2.2.2] octane trifluoroacetate;
(R)- l-[2-(3-chloro-thiophen-2-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(5-methyl-thiophen-2-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(2,4-dimethyl-oxazol-5-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-(2-phenyl-2-phenylamino-acetoxy)- l-(3-phenylsulfanyl-propyl)- l-azonia-bicyclo[2.2.2]octane formate;
(R)-3-[2-(3-ethyl-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane formate;
(R)-3-[2-(4-methoxycarbonyl-phenylamino)-2-phenyl-acetoxy]-l-(2- oxo-2-phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-3-(2-phenyl-2-(phenylamino)acetoxy)- l-(2-(phenylthio)ethyl)-l- azonia-bicyclo[2.2.2]octane trifluoroacetate; (3R)- l-(cyclohexylmethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)-l-(4-methylpent-3-enyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(3R)- l-(2-(3,4-dichloroρhenyl)-2-oxoethyl)-3-(2-phenyl-2- (phenylamino)acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-phenylethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)-l- azonia-bicyclo[2.2.2]octane chloride;
3-(3-(3-fluorophenyl)-3-(3-fluorophenylamino)-2-oxopropyl)-l-(2-oxo- 2-(thiophen-2-yl)ethyl)-l-azonia-bicyclo[2.2.2]octane chloride; (R)-l-(2-amino-2-oxoethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane;
(R)-l-(2-oxo-2-(phenylamino)ethyl)-3-(2-phenyl-2-(phenylamino)- acetoxy)- l-azonia-bicyclo[2.2.2]octane;
(3R)-l-(2-oxo-2-phenylethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)-l- azonia-bicyclo[2.2.2]octane;
(3R)-3-(2-(benzylamino)-2-phenylacetoxy)- l-(2-oxo-2-(thiophen-2- yl)ethyl)- 1 -azonia-bicyclo[2.2.2]octane;
(R)-l-(2-oxo-2-phenylethyl)-3-(2-phenyl-2-(phenylamino)acetoxy)- l- azonia-bicyclo[2.2.2]octane bromide;
(R)-3-((S)-2-amino-phenylpropanoyloxy)- l-(2-phenoxy ethyl)- 1 -azonia- bicyclo[2.2.2]octane;
(R)-3-((S)-2-amino-3-phenylpropanoyloxy)- l-(2-oxo-2-(thiophen-2- yl)ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-((S)-2-amino-3-phenylpropanoyloxy)- l-(3-phenoxypropyl)-l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-((S)-2-amino-3-phenylpropanoyloxy)- l-(2-oxo-2-phenylethyl)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-l-(2-oxo-2-phenylethyl)-3-((R)-3-phenyl-2-(phenylamino)- propanoyloxy)- l-azoniabicyclo[2.2.2]octane bromide;
(R)-l-(2-oxo-2-(thiophen-2-yl)ethyl)-3-((R)-3-phenyl-2-(phenylamino)- propanoyloxy)- 1 -azonia-bicyclo[2.2.2]octane chloride;
((4-chloro-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
4-({ [(R)-(I -aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]-phenyl-methyl}- amino)-benzoic acid methyl ester;
3-({ [(R)-(I -aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]-phenyl-methyl}- amino)-thiophene-2-carboxylic acid methyl ester; (4-fluoro-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(4-fluoro-phenyl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
2-({ [(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]-phenyl-methyl}- amino)-benzoic acid methyl ester;
(2-methoxy-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester; phenyl-o-methyl phenylamino-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester; phenyl-(3-trifluoromethoxy-phenylamino)-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(3-ethyl-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(3-acetylamino-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(3-methylcarbamoyl-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; (3-fluoro-4-methyl-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(3-methylsulfanyl-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(3-acetyl-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(2,5-dimethoxy-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(2,5-difluoro-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; (2,6-dimethyl-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(2-ethyl-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(2-acetyl-phenylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(3,5-difluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester;
3 -({ [(R)-( 1 -aza-bicy clo[2.2.2] oct-3 -y l)oxycarbonyl]-pheny 1-methy 1 } - amino)-benzoic acid ethyl ester;
(3-methoxy-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
[(4-fluoro-phenyl)-methyl-amino]-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(methyl-phenyl-amino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(4-methyl-benzylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester; (4-fluoro-benzylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-
3-yl) ester;
(4-methoxy-benzylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; benzylamino-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct-3-yl) ester;
(4-fluoro-benzylamino)-phenyl-acetic acid (R)-(l-aza-bicyclo[2.2.2]oct- 3-yl) ester;
(4-fluoro-phenyl)-(3-fluoro-phenylamino)-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; (4-fluoro-phenyl)-(2-fluoro-phenylamino)-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-quinuclidin-3-yl 2-(phenylamino)-2-(thiophen-2-yl)acetate hydrochloride;
(4-methoxy-phenyl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
4-{[(R)-(l-aza-bicyclo[2.2.2]oct-3-yl)oxycarbonyl]-phenylamino- methyl} -benzoic acid methyl ester;
(3-fluoro-phenyl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(4-fluoro-phenyl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; phenylamino-(4-trifluoromethyl-phenyl)-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester;
(S)-quinuclidin-3-yl 2-phenyl-2-(phenylamino)-acetate; phenyl-phenylamino-acetic acid l-methyl-azepan-4-yl ester;
(R)-l-[2-(4-methoxy-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-l-(4-oxo-4-phenyl-butyl)-3-(2-phenyl-2-phenylamino-acetoxy)- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- 1 -benzyl-3-(2-phenyl-2-phenylamino-acetoxy)- 1 -azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(5-chloro-thiophen-2-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- 1 -benzyl-3-(2-phenyl-2-phenylamino-acetoxy)- 1 -azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(4-methoxy-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-l-[2-(3-hydroxy-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)- l-dimethylcarbamoylmethyl-3-(2-phenyl-2-phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-propyl)-3-(2-phenyl-2-phenylamino-acetoxy)- l-azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-propyl)-3-(2-phenyl-2-phenylamino-acetoxy)- l-azonia- bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-[2-(2-methoxycarbonyl-thiophen-3-yl)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-[2-(2-methoxycarbonyl-thiophen-3-yl)-2-phenylamino-acetoxy]- l-(2-oxo-2-thiophen-2-yl-ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (R)-3-[2-(4-methoxy-phenyl)-2-phenylamino-acetoxy]- 1 -(2-oxo-2- phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane formate;
(R)-3-[2-(4-chloro-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl- ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-phenyl-ethyl)-3-[2-phenylamino-2-(4-trifluoromethyl- phenyl)-acetoxy]- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-I -methyl- l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2-phenylamino- acetoxy)-pyrrolidinium trifluoroacetate;
1 , 1 -dimethyl-4-(2-phenyl-2-phenylamino-acetoxy)-piperidinium trifluoroacetate; (R)-l-[2-(5-methyl-thiophen-3-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate; v (R)-l-[2-(2,4-difluoro-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-[2-(3,4-difluoro-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-[2-(2-fluoro-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-[2-(3-fluoro-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide; (R)-l-[2-(2,4-dibromo-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)- 1 -azonia-bicyclo[2.2.2]octane chloride;
(R)- l-[2-(4-nitro-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-l-[2-(4-hydroxy-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-[2-oxo-2-(2-oxo-2,3-dihydro- lH-indol-5-yl)-ethyl]-3-(2-phenyl- 2-phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-l-(2-benzo[l,3]dioxol-5-yl-2-oxo-ethyl)-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)- 1 -(2-oxo-2-thiazol-2-y 1-ethy l)-3 -(2-pheny 1-2-phenylamino- acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-[2-(3-ethoxycarbonyl-isoxazol-5-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)- l-[2-(4-methyl-thiophen-2-yl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)- 1 -(2-benzo[b]thiophen-5-yl-2-oxo-ethyl)-3-(2-phenyl-2- phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-3 -(2-pheny l-2-phenylamino-acetoxy)-l-phenylsulfanylmethy 1- 1 - azonia-bicyclo[2.2.2]octane chloride;
(R)- 1 -(2-oxo-2-piperidin- 1 -yl-ethyl)-3 -(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-3-(2-phenyl-2-phenylamino-acetoxy)- l-(thiazol-2- ylcarbamoylmethyl)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-l-(isoxazol-3-ylcarbamoylmethyl)-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2-p-methylphenylamino- acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-[2-(4-fluoro-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(4-fluoro-phenylamino)-2-phenyl-acetoxy]-l -(2-0X0-2- thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride; (R)-3-[2-(2-methoxycarbonyl-phenylamino)-2-phenyl-acetoxy]- l-(2- oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(2-methoxy-phenylamino)-2-phenyl-acetoxy]-l -(2-0X0-2- phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide; (R)-l-(2-oxo-2-phenyl-ethyl)-3-[2-phenyl-2-(3-trifluoromethoxy- phenylamino)-acetoxy]-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2-(phenylamino-acetoxy)- l- azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-acetylamino-phenylamino)-2-phenyl-acetoxy]- l -(2-0X0-2- phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-methylcarbamoyl-phenylamino)-2-phenyl-acetoxy]-l-(2- oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-methylsulfanyl-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo- 2-phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-[2-(4-fluoro-phenyl)-2-(3-fluoro-phenylamino)-acetoxy]- l-(2- oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(4-fluoro-phenyl)-2-(3-fluoro-phenylamino)-acetoxy]- l-(2- oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-3-[2-(4-fluoro-phenyl)-2-(2-fluoro-phenylamino)-acetoxy]-l-(2- oxo-2-phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(4-fluoro-phenyl)-2-(2-fluoro-phenylamino)-acetoxy]-l-(2- oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-3-[2-(4-methoxycarbonyl-phenyl)-2-phenylamino-acetoxy]-l-(2- oxo-2-phenyl-ethyl)- 1 -azonia-bicyclo[2.2.2]octane bromide; (R)-3-(2-cyclohexylamino-2-phenyl-acetoxy)- l-(2-oxo-2-phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-(2-cyclohexylamino-2-phenyl-acetoxy)- l-(2-oxo-2-thiophen-2-yl- ethyl)- l-azonia-bicyclo[2.2.2]octane chloride; (R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenylamino-2-thiophen-2-yl- acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-fluoro-4-methyl-phenylamino)-2-phenyl-acetoxy]- l -(2-OXO- 2-phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-[2-(2,5-dimethoxy-phenylamino)-2-phenyl-acetoxy]- l -(2-0X0-2- phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(2,5-difluoro-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo-2- phenyl-ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(2,6-dimethyl-phenylamino)-2-phenyl-acetoxy]-l -(2-0X0-2- phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(2-ethyl-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(2-acetyl-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-[2-(3-ethoxycarbonyl-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-
2-phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3,5-difluoro-phenylamino)-2-phenyl-acetoxy]- l -(2-0X0-2- phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-methoxy-phenylamino)-2-phenyl-acetoxy]-l -(2-0X0-2- phenyl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-fluoro-phenyl)-2-phenylamino-acetoxy]-l-(2-oxo-2-phenyl- ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(4-fluoro-phenyl)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyl- ethyl)- 1 -azonia-bicyclo[2.2.2]octane bromide; (R)-l-cyanomethyl-3-(2-phenyl-2-phenylamino-acetoxy)- l-azonia- bicyclo[2.2.2]octane bromide;
(R)-l-tert-butoxycarbonylmethyl-3-(2-phenyl-2-phenylamino-acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide; (S)- l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-2-phenylamino-acetoxy)- l- azonia-bicyclo[2.2.2]octane chloride;
(R)-3-[2-(3-acetyl-phenylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl- ethyl)- l-azonia-bicyclo[2.2.2]octane formate; (R)-l-[2-(4-acetylamino-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)- l-[2-(4-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2- phenylamino-acetoxy)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-(2-phenyl-2-phenylamino-acetoxy)- l-pyridin-2-ylmethyl- l- azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-(2-oxo-2-pyridin-2-yl-ethyl)-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane formate;
(R)-l-(2-(2-methylthiazol-4-yl)-2-oxoethyl)-3-((R)-2-phenyl-2- (phenylamino)acetoxy)- l-azoniabicyclo[2.2.2]octane bromide; (R)-l-(6-amino-pyridin-2-ylmethyl)-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-{2-[(4-fluoro-phenyl)-methyl-amino]-2-phenyl-acetoxy}-l-(2- oxo-2-thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-3-[2-(methyl-phenyl-amino)-2-phenyl-acetoxy]-l-(2-oxo-2-thiazol- 2-yl-ethyl)- l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(methyl-phenyl-amino)-2-phenyl-acetoxy]- l -(2-0X0-2- thiophen-3-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane;
(R)-3-(2-benzylamino-2-phenyl-acetoxy)-l-[2-(3-ethoxycarbonyl- isoxazol-5-yl)-2-oxo-ethyl]- l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-(2-benzylamino-2-phenyl-acetoxy)- l-(2-oxo-2-thiazol-2-yl- ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-(2-benzylamino-2-phenyl-acetoxy)- l-(2-oxo-2-thiophen-3-yl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide; (R)-3-[2-(4-methyl-benzylamino)-2-phenyl-acetoxy]- l -(2-0X0-2- thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane formate;
(R)-3-[2-(4-methoxy-benzylamino)-2-phenyl-acetoxy]-l-(2-oxo-2- thiophen-2-yl-ethyl)- l-azonia-bicyclo[2.2.2]octane formate; (R)-3-[2-(4-fluoro-benzylamino)-2-phenyl-acetoxy]- l-(2-oxo-2- thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride;
(R)-3-[2-(4-fluoro-benzylamino)-2-phenyl-acetoxy]- l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
4-methyl-phenyl-amino-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-l-(2-oxo-2-phenyl-ethyl)-3-(2-phenyl-4-methyl-phenyl-amino- acetoxy)- l-azonia-bicyclo[2.2.2]octane bromide;
(2-fluoro-phenylamino)-phenyl-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester; (R)-3-[2-(2-fluoro-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-3-[2-(3-fluoro-phenylamino)-2-phenyl-acetoxy]-l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane bromide;
(R)-3-[2-(3-fluoro-phenylamino)-2-phenyl-acetoxy]-l -(2-0X0-2- thiophen-2-yl-ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-(4-fluoro-phenylamino)-phenyl-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-3-[(R)-2-(4-fluoro-phenylamino)-2-phenyl-acetoxy]- l -(2-0X0-2- thiophen-2-yl-ethyl)-l-azonia-bicyclo[2.2.2]octane chloride; (4-chloro-phenyl)-phenylamino-acetic acid (R)-(l-aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-3-[2-(4-chloro-phenyl)-2-phenylamino-acetoxy]- l-(2-oxo-2-phenyl- ethyl)- l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (2-fluoro-phenyl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-3-[2-(2-fluoro-phenyl)-2-phenylamino-acetoxy]-l-(2-oxo-2-phenyl- ethyl)-l-azonia-bicyclo[2.2.2]octane trifluoroacetate; (5-methyl-thiophen-2-yl)-phenylamino-acetic acid (R)-(I -aza- bicyclo[2.2.2]oct-3-yl) ester;
(R)-3-[2-(5-methyl-thiophen-2-yl)-2-phenylamino-acetoxy]-l-(2-oxo-2- phenyl-ethyl)- 1 -azonia-bicyclo[2.2.2]octane trifluoroacetate;
(R)-l-[2-(4-amino-phenyl)-2-oxo-ethyl]-3-(2-phenyl-2-phenylamino- acetoxy)-l-azonia-bicyclo[2.2.2]octane formate;
(3R)-l-(2-hydroxy-2-phenylethyl)-3-(2-ρhenyl-2- (phenylamino)acetoxy)- 1 -azoniabicyclo[2.2.2]octane trifluoroacetate.
17. A process for the preparation of a compound of formula (I) as defined in claim 1, which comprises the alkylation of compounds of general formula (VI)
by alkylating agents of general formula (XI)
A— R6
(Xl)
in which A is a suitable leaving group selected from the group consisting of halide and sulfonate, wherein Rl, R2, R3, R6 and R7 are defined according to claims 1 and 9.
18. A process for the preparation of a compound of formula (I) as defined in claim 1, which comprises the alkylation of amine compounds of general formula (II)
N H
(H)
with compounds of general formula (III),
Figure imgf000258_0001
in which LG is a suitable leaving group and K may be either a hydroxyl group or a suitably protected hydroxyl group, to yield a compound of formula (IV),
Figure imgf000258_0002
which is condensed with a compound of formula (V)
(V)
to obtain compound (VI), and converting the compound to a further compound of formula (I), according to claim 15 and wherein Rl, R2, R3, R6 and R7 are defined according to claims 1 and 9.
19. A process for the preparation of a compound of formula (I) as defined in claim 1, which comprises coupling amine of general formula (II) R1 , ,R2
N H
(H)
and ketones of formula (VII),
Figure imgf000259_0001
to yield a compound of formula (IV),
Figure imgf000259_0002
which is condensed with a compound of formula (V)
HO.
R7 (V)
to obtain compound (VI)
Figure imgf000259_0003
and converting the compound to a further compound of formula (I), wherein
Rl, R2, R3, R6 and R7 are defined according to claims 1 and 9.
20. A process for the preparation of a compound of formula (I) as reported in scheme 1 , which comprises reacting compound (IX)
Figure imgf000260_0001
with an alkylating agent of general formula (VIII),
R1.
(VlIl)
in which z is a carbonyl group or a suitable leaving group such as a an halide, to yield a compound of formula (IV) in which R2 is hydrogen,
Figure imgf000260_0002
<ιv> which is condensed with a compound of formula (V)
(V)
to obtain compound (VI)
Figure imgf000260_0003
and converting the compound to a further compound of formula (I), wherein Rl , R2, R3, R6 and R7 are defined according to claims 1 and 9.
21. A process for the preparation of a compound of formula (I) as reported in scheme 1 , which comprises coupling compounds of general formula (Ilia)
Figure imgf000261_0001
to compound of general formula (V)
(V)
to yield compound (X),
Figure imgf000261_0002
(X)
which is reacted with an amine of formula (II),
R1. ,R2
" U' H
(H)
to obtain compound (VI)
Figure imgf000261_0003
and converting the compound to a further compound of formula (I), wherein Rl, R2, R3 and R7 are defined according to claims 1 and 9 and wherein W is LG as defined in claim 18 or hydroxy.
22. A pharmaceutical composition comprising a compound of claims 1 to 16 in admixture with one or more pharmaceutically acceptable carriers and/or excipients.
23. The pharmaceutical composition of claim 21 suitable for administration by inhalation.
24. The pharmaceutical composition of claims 21 or 22 wherein said composition further comprises a second component selected from the classes of beta2-agonists and corticosteroids.
25. A compound of claims from 1 to 16 for use as a medicament.
26. The use of any of the compounds of the claims 1 to 16 for the manufacture of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
27. The use as in claim 25 wherein the disease is selected from the group consisting of asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
28. The use of the compounds of general formula (XIX)
Figure imgf000262_0001
(XlX) wherein:
Rl and R2 are independently selected from the group consisting of H,
(Ci-C10)-alkyl, aryl, (C3-C8)-cycloalkyl, arylalkyl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), SH, NO2, CN, CON(R5)2, COOH, NHCOR5,
COR5, CO2R5, CF3, (CrC10)-alkoxycarbonyl, (CrCi0)-alkylsulfanyl,
(CrC10)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (CrCi0)-alkyl and (C1-C10)- alkoxyl; R3 is selected from the group consisting of H, (CrC10)-alkyl, aryl, (C3-Cg)-cycloalkyl, heteroaryl, arylalkyl and heteroarylalkyl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=0), SH, NO2, CN, CON(R5)2, COOH, CO2R5, CF3, (CrC10)-alkoxycarbonyl, (CrCio)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (Ci-Cio)-alkyl and (CrC,0)-alkoxyl;
R8 represents a group of formula (i) or (ii) or (iii) or (iv) or (vi) or (vii) or (viii) or (ix)
Figure imgf000263_0001
(O (ϋ)
Figure imgf000263_0002
(iii) (iv)
Figure imgf000263_0003
(vi) (vii)
Figure imgf000263_0004
(viii) (ix) wherein m = 1 , 2 or 3; n =l, 2 or 3;
A" is a physiologically acceptable anion; R4 is a group of formula (Y)
-(CH2)P-P- (CH2)q— W
(Y) wherein p is 0 or an integer from 1 to 4; q is 0 or an integer from 1 to 4;
P is absent or is selected from the group consisting of O, S, SO, SO2, CO, NR5 CH=CH, N(R5)SO2, N(R5)COO, N(R5)C(O), SO2N(R5), CO(O)N(R5) and C(O)N(R5); W is selected from the group consisting of H, (CrC6)-alkyl, (C3-C8)-cycloalkyl, aryl and heteroaryl, optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), SH, NO2, CN, CON(R5)2, COOH, NH2, NHC0R5, CO2R5, (CrC10)-alkoxycarbonyl, (Ci-Cio)-alkylsulfanyl, (CrC10)-alkylsulfinyl, (CrC10)-alkylsulfonyl, (C1-C, 0)-alkyl and (CrCi0)-alkoxyl;
R5 is selected from the group consisting of H, (C1-C10)alkyl, (CrC6)alkylhalo, (C2-C6)alkynyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(CrC6)alkyl, heteroaryl, (CrC6)alkyl-heteroaryl and aryl optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (-0), SH, NO2, CN, CONH2, COOH, (CrCio)-alkoxycarbonyl, (CrC10)-alkylsulfanyl, (Ci-C10)-alkylsulfinyl, (C1-C, o)-alkylsulfonyl, (CrC10)-alkyl and (C,-C10)-alkoxyl for the preparation of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD).
29. A method for prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably selected from the group consisting of asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD), which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to claims 1 to 16.
30. A method for prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably selected from the group consisting of asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD), which comprises administering to a subject in need thereof a therapeutically effective amount of compound (XIX) as defined in claim 27.
31. A device comprising the pharmaceutical composition of claim 21.
32. The device according to claim 30 which is a single- or multi-dose dry powder inhaler.
33. The device according to claim 31 which is a metered dose inhaler or a soft mist nebulizer.
PCT/EP2009/008870 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof WO2010072338A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
NZ593695A NZ593695A (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
EA201190017A EA020974B1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal compositions thereof
MEP-2011-114A ME01185B (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
CA2748100A CA2748100A1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
MX2011006642A MX2011006642A (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof.
KR1020117014392A KR101414333B1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
BRPI0918206A BRPI0918206A2 (en) 2008-12-23 2009-12-11 animoester derivatives and medicinal composition of these
SG2011045689A SG172316A1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
JP2011542695A JP2012513420A (en) 2008-12-23 2009-12-11 Alkaloid amino ester derivatives and pharmaceutical compositions thereof
CN200980152004.9A CN102264734B (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
MA34030A MA32979B1 (en) 2008-12-23 2009-12-11 Aminostrify derivatives of alkaloids and pharmaceutical compositions
EP20090778904 EP2376489B1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
UAA201106921A UA107334C2 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and their drug compositions
AU2009331945A AU2009331945A1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof
TN2011000282A TN2011000282A1 (en) 2008-12-23 2011-05-31 Alkaloid aminoester derivatives and medicinal composition thereof
IL213712A IL213712A0 (en) 2008-12-23 2011-06-22 Alkaloid aminoester derivatives and medicinal composition thereof
HK12102580.8A HK1162174A1 (en) 2008-12-23 2012-03-14 Alkaloid aminoester derivatives and medicinal composition thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172818.0 2008-12-23
EP08172818A EP2206712A1 (en) 2008-12-23 2008-12-23 "Alkaloid aminoester derivatives and medicinal composition thereof"

Publications (1)

Publication Number Publication Date
WO2010072338A1 true WO2010072338A1 (en) 2010-07-01

Family

ID=40578441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/008870 WO2010072338A1 (en) 2008-12-23 2009-12-11 Alkaloid aminoester derivatives and medicinal composition thereof

Country Status (25)

Country Link
US (2) US8455646B2 (en)
EP (2) EP2206712A1 (en)
JP (1) JP2012513420A (en)
KR (1) KR101414333B1 (en)
CN (1) CN102264734B (en)
AR (1) AR074855A1 (en)
AU (1) AU2009331945A1 (en)
BR (1) BRPI0918206A2 (en)
CA (1) CA2748100A1 (en)
CO (1) CO6400144A2 (en)
EA (1) EA020974B1 (en)
GE (1) GEP20146154B (en)
HK (1) HK1162174A1 (en)
IL (1) IL213712A0 (en)
MA (1) MA32979B1 (en)
ME (1) ME01185B (en)
MX (1) MX2011006642A (en)
MY (1) MY150823A (en)
NZ (1) NZ593695A (en)
PE (1) PE20110829A1 (en)
SG (1) SG172316A1 (en)
TN (1) TN2011000282A1 (en)
TW (1) TW201028412A (en)
UA (1) UA107334C2 (en)
WO (1) WO2010072338A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311461A1 (en) * 2010-06-22 2011-12-22 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
US20110311458A1 (en) * 2010-06-22 2011-12-22 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
WO2011160919A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
WO2012069275A1 (en) 2010-11-26 2012-05-31 Chiesi Farmaceutici S.P.A. Glycine derivatives and their use as muscarinic receptor antagonists
WO2012110462A1 (en) 2011-02-17 2012-08-23 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
CN103502213A (en) * 2011-04-29 2014-01-08 奇斯药制品公司 Alkaloid ester and carbamate derivatives and medicinal compositions thereof
WO2015052169A1 (en) 2013-10-10 2015-04-16 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
US11613548B2 (en) 2021-02-19 2023-03-28 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
US12084458B2 (en) 2021-02-19 2024-09-10 Sudo Biosciences Limited Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12122785B2 (en) 2023-01-27 2024-10-22 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
EP2797910B1 (en) 2011-12-30 2015-09-16 Chiesi Farmaceutici S.p.A. Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
HU230368B1 (en) 2012-11-16 2016-03-29 Magyar Tudományos Akadémia Szegedi Biológiai Kutatóközpont A novel method to load a mammalian artificial chromosome with multiple genes
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
CN104876854B (en) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 Hydroxy acetate derivative and application thereof
WO2018211530A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824106A (en) 1958-02-18 Quaternary tropeine compounds and a process of making same
US2856407A (en) 1956-08-08 1958-10-14 Lakeside Lab Inc Aminoacid esters of n-substituted 3 and 4-piperidinols
EP0424021A1 (en) * 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators
WO1998011063A1 (en) * 1996-09-10 1998-03-19 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
WO1999020612A1 (en) 1997-10-22 1999-04-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2008012290A2 (en) 2006-07-26 2008-01-31 Chiesi Farmaceutici S.P.A. Quinuclidine derivatives as m3 antagonists
WO2008053158A1 (en) 2006-11-02 2008-05-08 Chroma Therapeutics Ltd. Inhibitors of p38 mitogen-activated protein kinase
WO2008059245A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
WO2008075005A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
WO2008075006A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255323B (en) * 1992-07-08 1995-10-31 Fidia Spa COMPOUNDS WITH ANALGESIC AND NOOTROP ACTIVITY
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
BR112012032332A2 (en) 2010-06-22 2016-11-08 Chiesi Farma Spa compound, use of a compound, pharmaceutical composition, combination of a compound and device
CA2803416A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
WO2011160920A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
BR112012031967A2 (en) 2010-06-22 2019-09-24 Chiesi Farm Spa compound, use of a compound, combination of a compound and pharmaceutical composition
KR20130140672A (en) 2010-10-20 2013-12-24 키에시 파르마슈티시 엣스. 피. 에이. Carbonate derivatives for the treatment of cough
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
CN103502213B (en) 2011-04-29 2016-09-28 奇斯药制品公司 Alkaloid ester and carbamate derivatives thereof and medicinal compositions

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824106A (en) 1958-02-18 Quaternary tropeine compounds and a process of making same
US2856407A (en) 1956-08-08 1958-10-14 Lakeside Lab Inc Aminoacid esters of n-substituted 3 and 4-piperidinols
EP0424021A1 (en) * 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators
WO1998011063A1 (en) * 1996-09-10 1998-03-19 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
WO1999020612A1 (en) 1997-10-22 1999-04-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2008012290A2 (en) 2006-07-26 2008-01-31 Chiesi Farmaceutici S.P.A. Quinuclidine derivatives as m3 antagonists
WO2008053158A1 (en) 2006-11-02 2008-05-08 Chroma Therapeutics Ltd. Inhibitors of p38 mitogen-activated protein kinase
WO2008059245A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
WO2008075005A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
WO2008075006A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ANDO, A., TETRAHEDRON, vol. 45/16, 1989, pages 4969
CAREY, F.A.; SUNDEBERG, R.J., ADVANCED ORGANIC CHEMISTRY, 1990, pages 145
CAREY, F.A.; SUNDEBERG, R.J.: "Advanced Organic Chemistry", 1990, PLENUM PRESS, pages: 121
CAREY, F.A.; SUNDEBERG, R.J.: "Advanced Organic Chemistry", 1990, PLENUM PRESS, pages: 219
CAREY, F.A.; SUNDEBERG, R.J.: "Advanced Organic Chemistry", vol. 3, 1990, PLENUM PRESS, pages: 121
CHEMICAL & PHARMACEUTICAL BULLETIN , 19(12), 2603-8 CODEN: CPBTAL; ISSN: 0009-2363, 1971 *
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 19, no. 12, 1971, pages 2603 - 8
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1972, TAKEUCHI, YOSHIO ET AL: "Amino acids and peptides. II. One-step synthesis of atropine and other related alkaloids from dl-phenylalanine 3.alpha.-tropanyl ester", XP002527091, retrieved from STN Database accession no. 1972:46353 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1978, GLUSHKOV, R. G. ET AL: "Synthesis and pharmacological activity of the tropine ester of phenylglyoxylic acid and its derivatives. New method for preparing homatropine", XP002527090, retrieved from STN Database accession no. 1978:15869 *
EPSTEIN, J.W., J.MED.CHEM., vol. 24/5, 1981, pages 481
FACHE, F., TETRAHEDRON, vol. 52/29, 1996, pages 9777
GUALTIERI, FULVIO ET AL: "Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic Drugs. 2. 2-Phenoxy-, 2-(Phenylthio)-, and 2-(Phenylamino)alkanoic Acid Esters", JOURNAL OF MEDICINAL CHEMISTRY , 37(11), 1712-19 CODEN: JMCMAR; ISSN: 0022-2623, 1994, XP002527089 *
H. KONZETT H; ROSSLER F, ARCH EXP PATH PHARMACOL, vol. 195, 1940, pages 71 - 74
HADDAD EB ET AL., BR J PHARMACOL, vol. 127, 1999, pages 413 - 420
HUANG, TETRAHEDRON, vol. 53/37, 1997, pages 12391
J.MED.CHEM., vol. 37, 1994, pages 1712 - 1719
KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 11(7), 30-5 CODEN: KHFZAN; ISSN: 0023-1134, 1977 *
KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 11, no. 7, 1977, pages 30 - 5
KUMARA SWAMY, K.C., CHEM. REV., vol. 109, 2009, pages 2551 - 2651
KUROKAWA, M., HETEROCYCLES, vol. 71/4, 2007, pages 847
LAROCK, L.C.: "Comprehensive Organic Transformation", 1999, JOHN WILEY & SON INC, pages: 689 - 700
LEE, J.B., J.AM.CHEM.SOC., vol. 88, 1966, pages 3440
MA, D., TETRAHEDRON ASYMMETRY, vol. 7/11, 1996, pages 3075
MOL. PHARMACOL., vol. 45, pages 899 - 907
MONTALBETTI, C., TETRAHEDRON, vol. 61, 2005, pages 10827
QUIANG, K., ADV.SYNTH. CATAL., vol. 349, 2007, pages 1657
SUWA T., SYNTHESIS, vol. 6, 2000, pages 789

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629160B2 (en) * 2010-06-22 2014-01-14 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
US20110311458A1 (en) * 2010-06-22 2011-12-22 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
WO2011161018A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
WO2011160919A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
WO2011160918A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
US8492548B2 (en) * 2010-06-22 2013-07-23 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
US20110311461A1 (en) * 2010-06-22 2011-12-22 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
WO2012069275A1 (en) 2010-11-26 2012-05-31 Chiesi Farmaceutici S.P.A. Glycine derivatives and their use as muscarinic receptor antagonists
CN103221390B (en) * 2010-11-26 2015-06-03 奇斯药制品公司 Glycine derivatives and their pharmaceutical composition
CN103221390A (en) * 2010-11-26 2013-07-24 奇斯药制品公司 Glycine derivatives and their use as muscarinic receptor antagonists
US8772314B2 (en) 2010-11-26 2014-07-08 Chiesi Farmaceutici S.P.A. Glycine derivatives and medicinal compositions thereof
WO2012110462A1 (en) 2011-02-17 2012-08-23 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
CN103347518A (en) * 2011-02-17 2013-10-09 奇斯药制品公司 Liquid propellant-free formulation comprising an antimuscarinic drug
CN103502213A (en) * 2011-04-29 2014-01-08 奇斯药制品公司 Alkaloid ester and carbamate derivatives and medicinal compositions thereof
CN103502213B (en) * 2011-04-29 2016-09-28 奇斯药制品公司 Alkaloid ester and carbamate derivatives thereof and medicinal compositions
WO2015052169A1 (en) 2013-10-10 2015-04-16 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
US11613548B2 (en) 2021-02-19 2023-03-28 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
US12084458B2 (en) 2021-02-19 2024-09-10 Sudo Biosciences Limited Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12103937B2 (en) 2021-02-19 2024-10-01 Sudo Biosciences Limited Substituted pyridines and pyridazines as TYK2 inhibitors
US12122785B2 (en) 2023-01-27 2024-10-22 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Also Published As

Publication number Publication date
MX2011006642A (en) 2011-07-29
TN2011000282A1 (en) 2012-12-17
MA32979B1 (en) 2012-01-02
EP2376489A1 (en) 2011-10-19
US20130196978A1 (en) 2013-08-01
US20100173880A1 (en) 2010-07-08
KR101414333B1 (en) 2014-07-02
ME01185B (en) 2013-03-20
GEP20146154B (en) 2014-09-10
KR20110097883A (en) 2011-08-31
HK1162174A1 (en) 2012-08-24
UA107334C2 (en) 2014-12-25
CN102264734B (en) 2015-06-17
MY150823A (en) 2014-02-28
CN102264734A (en) 2011-11-30
CA2748100A1 (en) 2010-07-01
EP2206712A1 (en) 2010-07-14
IL213712A0 (en) 2011-07-31
SG172316A1 (en) 2011-07-28
AU2009331945A1 (en) 2011-07-14
PE20110829A1 (en) 2011-11-19
TW201028412A (en) 2010-08-01
AR074855A1 (en) 2011-02-16
US8455646B2 (en) 2013-06-04
US8835682B2 (en) 2014-09-16
JP2012513420A (en) 2012-06-14
EA020974B1 (en) 2015-03-31
NZ593695A (en) 2014-01-31
EA201190017A1 (en) 2012-02-28
BRPI0918206A2 (en) 2015-12-08
CO6400144A2 (en) 2012-03-15
EP2376489B1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
WO2010072338A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
AU2009278306B2 (en) Quinuclidine carbonate derivatives and medicinal composition thereof
EP2585458B1 (en) Alkaloid aminoester derivatives and medicinal compositions thereof
EP2585459B1 (en) Alkaloid aminoester derivatives and medicinal compositions thereof
US8629160B2 (en) Alkaloid aminoester derivatives and medicinal composition thereof
US8604015B2 (en) Alkaloid ester and carbamate derivatives and medicinal compositions thereof
US8772314B2 (en) Glycine derivatives and medicinal compositions thereof
US8748613B2 (en) Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980152004.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09778904

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12011501082

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 201190017

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/006642

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 001258-2011

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2011542695

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20117014392

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001556

Country of ref document: CL

Ref document number: 12268

Country of ref document: GE

Ref document number: 2009331945

Country of ref document: AU

Ref document number: 2748100

Country of ref document: CA

Ref document number: 593695

Country of ref document: NZ

Ref document number: 11078448

Country of ref document: CO

Ref document number: 2588/KOLNP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009778904

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009331945

Country of ref document: AU

Date of ref document: 20091211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: a201106921

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0918206

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110622